EP2104664A1 - Tetrahydrobenzoisoxazole - and tetrahydroindazole derivatives as modulators of the mitotic motor protein - Google Patents

Tetrahydrobenzoisoxazole - and tetrahydroindazole derivatives as modulators of the mitotic motor protein

Info

Publication number
EP2104664A1
EP2104664A1 EP07856223A EP07856223A EP2104664A1 EP 2104664 A1 EP2104664 A1 EP 2104664A1 EP 07856223 A EP07856223 A EP 07856223A EP 07856223 A EP07856223 A EP 07856223A EP 2104664 A1 EP2104664 A1 EP 2104664A1
Authority
EP
European Patent Office
Prior art keywords
compounds
formula
bis
compound
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07856223A
Other languages
German (de)
French (fr)
Inventor
Kai Schiemann
Dirk Finsinger
Frank Zenke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP2104664A1 publication Critical patent/EP2104664A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the invention was based on the object, new compounds with valuable
  • the present invention relates to compounds of the formula I and their use for the treatment and prophylaxis of diseases in which the inhibition, regulation and / or modulation of mitotic motor proteins, in particular of the mitotic motor protein Eg5 plays a role, and also pharmaceutical compositions which contain these compounds.
  • the present invention relates to compounds of the formula I 1 which preferably inhibit, regulate and / or modulate one or more mitotic motor proteins, compositions containing these compounds and methods for their use in the treatment of diseases and conditions such as angiogenesis, Cancer, tumorigenesis, growth and spread, arteriosclerosis, ocular disorders, choroidal neovascularization and diabetic retinopathy, inflammatory diseases, arthritis, neurodegeneration, restenosis, wound healing or graft rejection.
  • diseases and conditions such as angiogenesis, Cancer, tumorigenesis, growth and spread, arteriosclerosis, ocular disorders, choroidal neovascularization and diabetic retinopathy, inflammatory diseases, arthritis, neurodegeneration, restenosis, wound healing or graft rejection.
  • the compounds according to the invention are suitable for the therapy or prophylaxis of
  • Eg5 regulates exclusively the movement of mitotic microtubules (spindle apparatus) and not those of the cytoskeleton. This is crucial for the side effect profile of the compounds according to the invention, since, for example, neuropathies, as are observed in taxol, do not occur or only weakened. Therefore, the inhibition of Eg5 by the compounds according to the invention is a relevant therapeutic concept for the treatment of malignant tumors.
  • all solid and non-solid tumors can be treated with the compounds of formula I, e.g. monocytic leukemia, brain, urogenital, lymphatic, gastric, laryngeal and lung carcinomas, including lung adenocarcinoma and small cell lung carcinoma.
  • Other examples include prostate, pancreatic and breast carcinoma.
  • the compounds according to the invention bring about a specific inhibition of the mitotic Moter proteins, in particular Eg5.
  • the compounds of the invention preferably exhibit a beneficial biological activity which is readily detectable in the assays described herein, for example.
  • the compounds of the invention preferably exhibit and effect an inhibitory effect, usually documented by IC 50 values in a suitable range, preferably in the micromolar range, and more preferably in the nanomolar range.
  • effects of the compound of the invention are relevant to various diseases. Accordingly, the compounds of the invention are useful in the prophylaxis and / or treatment of diseases that are affected by inhibition of one or more mitotic motor proteins, particularly Eg5.
  • the present invention therefore relates to compounds according to the invention as medicaments and / or active pharmaceutical ingredients in the treatment and / or prophylaxis of said diseases and the use of compounds according to the invention for the preparation of a pharmaceutical for the treatment and / or prophylaxis of said diseases as well as a method of treatment said diseases comprising administering one or more of the compounds of the invention to a patient in need of such administration.
  • the compounds according to the invention have a beneficial effect in a xenograft tumor model.
  • the host or patient may be of any mammalian species, e.g. A primate species, especially humans; Rodents, including mice, rats and hamsters; Rabbits; Horses, cattle, dogs, cats, etc. Animal models are of interest for experimental studies, providing a model for the treatment of human disease.
  • the susceptibility of a particular cell to treatment with the compounds of the invention can be determined by testing in vitro.
  • a culture of the cell is combined with a compound of the invention at various concentrations for a period of time sufficient to allow the drugs to induce cell death or inhibit migration, usually between about one hour and one week.
  • For testing in vitro cultured cells from a biopsy sample can be used.
  • the viable cells remaining after treatment are then counted.
  • the dose will vary depending on the specific compound used, the specific disease, the patient status, etc.
  • a therapeutic dose will be sufficient to substantially reduce the unwanted cell population in the target tissue while maintaining patient viability. Treatment is generally continued until there is a significant reduction, e.g. B. at least about 50% reduction in cell load and can be continued until essentially no more unwanted cells are detected in the body.
  • a i 1, A ⁇ 2 independently of one another N, O or S,
  • X 3 are independently of one another a single bond, NR 3 -NR 3 , NR 3 ,
  • Cy H a carbocyclic or heberocyclic saturated, unsaturated or aromatic radical which is unsubstituted or mono- or polysubstituted by alkyl, Hal, CN, OH; OR, OCF 3 , CF 3 , COOR or may be substituted by a group (CR 1 2) n -YX 1 - (CR 1 2) n -Q,
  • Q is H, alkyl, cycloalkyl, aryl or heteroaryl
  • n O 1, 2, 3, 4, 5, 6, 7, or 8
  • the invention also relates to the optically active forms, the
  • Enantiomers the racemates, the diastereomers and the hydrates and solvates of these compounds.
  • solvates of the compounds will be Associations of inert solvent molecules to the compounds of formula I understood that form due to their mutual attraction.
  • Solvates are, for example, mono- or dihydrate or alcoholates.
  • biodegradable polymer derivatives of the invention include biodegradable polymer derivatives of the invention
  • the term "effective amount” means the amount of a drug or pharmaceutical agent which elicits a biological or medical response in a tissue, system, animal or human, e.g. sought or desired by a researcher or physician.
  • terapéuticaally effective amount means one
  • Amount causing at least one of the following effects in a human or other mammal compared to a subject who has not received this amount: Improvement of the curative treatment, cure, prevention or elimination of a disease, a clinical picture, a disease state, a disease, a disorder or side effects or even the reduction of the progression of a disease, a disease or a disorder.
  • terapéuticaally effective amount also includes those amounts effective to increase or enhance normal physiological function.
  • the invention also provides for the use of mixtures of the compounds of the formula I 1, for example mixtures of two diastereomers, for example in a ratio of 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 10, 1: 100 or 1: 1000. These are particularly preferably mixtures of stereoisomeric compounds.
  • the invention relates to the compounds of the formula I and their salts and to a process for the preparation of compounds of the formula I according to the claims and their pharmaceutically usable derivatives, salts, solvates and stereoisomers, characterized in that a compound of the formula II
  • an activating reagent such as. B. N- (3
  • Dialkylamimoalkyl) -N'-alkylcarbodimid in particular N- (3Dimethylaminopropyl) -N'-ethylcarbodimid.
  • the mixtures of diastereomers optionally obtained by the process described above and
  • the bases and acids of formula I obtained by the process described above are converted into their salts.
  • radicals Hal, R, R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , Y, Q, Cy, m, n and p have the meanings given for the formula I, if not expressly stated otherwise.
  • the radicals independently of one another assume the meanings indicated.
  • Alkyl is preferably unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms.
  • Alkyl is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1, 1, 1, 2 or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methyl-propyl, 1-ethyl-2-methylpropyl, 1, 1, 2 or 1, 2,2-trimethylpropyl, more preferably, for example, trifluoromethyl , Alkyl very particularly preferably denotes alkyl having 1,
  • R, R 1 , R 2 preferably denotes H, alkyl, CF 3 , OCF 3 , SCN, CN, OH, O, alkyl-OCOalkyl, OCOH, Hal, SCF 3 , preferably also t-butyl, -CH (CH 3 ) CH 2 CH 3 , isopropyl, ethyl or methyl.
  • R 1 is 1-butyl, isopropyl, ethyl, CF 3 , methyl, Br, Cl, SCF 3 , CH (CH 3 ) CH 2 CH 3 , n -propyl, OCH 3 , SCH 3 , n-butyl, -SCN 1 CH 2 CN. More preferably R 1 is 1-butyl, isopropyl, ethyl or CF 3 .
  • a 1 , A 2 independently of one another preferably denote O or N.
  • a 1 and A 2 are not identical.
  • R 3 is preferably H, alkyl, hydroxyalkyl, alkoxyalkyl,
  • X 1 , X 2 are preferably NR 3 , O or the following group
  • X is preferably a single bond or (CH 2 ) n
  • Cyclopentyl aryl or heteroaryl.
  • Cy means one of the following groups
  • n -X represents a single bond - compounds of the formula I 1 wherein the group Y, X 2 are preferred.
  • Q is preferably aryl or heteroaryl, u is preferably 0, 1 or 2.
  • m is preferably 1.
  • p is preferably 1.
  • Aryl is preferably unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH 2 , NO 2 , CN, COOH, COOA 1 CONH 2 , NHCOA, NHCONH 2 , NHSO 2 A, CHO, COA, SO 2 NH 2 , SO 2 A, -CH 2 -COOH or -OCH 2 -COOH substituted phenyl, naphthyl or biphenyl.
  • Aryl is preferably phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p- (N-methylamino) -phenyl, o-, m- or p- (N-methylaminocarbonyl) -phenyl, o-, m- or p-acetamidophenyl, o-, m- or p
  • Heteroaryl preferably denotes a mono- or binuclear unsubstituted or mono-, di- or trisubstituted by Hal, A, NO 2 , NHA, NA 2 , OA, COOA or CN substituted aromatic heterocycle having one or more N-, O- and / or S atoms.
  • Heteroaryl particularly preferably denotes a monocyclic saturated or aromatic heterocycle having one N, S or O atom which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA 2 , NO 2 , COOA or benzyl.
  • unsubstituted heteroaryl means, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, A- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or A-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1, 2,3-triazoM-, -A- or -5-yl, 1, 2,4-triazoM-, - 3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4 or -5-yl, 1, 2,4-oxadiazol-3 or -5-yl, 1, 3, 4-thiadiazol-2- or -5-yl, 1, 2,4-thiadiazol-3 or -5-yl, 1,
  • Benzisothiazolyl 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3- , 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo [1,4] oxazinyl, more preferably 1,3-benzodioxole-5 -yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4 or 5-yl or 2,1,3-benzoxadiazol-5-yl.
  • Hal preferably denotes F, Cl or Br, more preferably F or Cl.
  • the compounds of the formula I can possess one or more chiral centers and therefore occur in different stereoisomeric forms.
  • Formula I encompasses all these forms.
  • Particularly preferred compounds of the formula I are those of the subformulae IA to IC:
  • the starting materials may, if desired, also be formed in situ, so that they are not isolated from the reaction mixture, but immediately further reacted to the compounds of formula I.
  • the reaction is generally carried out in an inert solvent, preferably in the presence of an activating reagent, such as N- (3-alkylaminoalkyl) -N'-alkylcarbodiimide, in particular N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide.
  • the reaction time is between a few minutes and 14 days, depending on the conditions used, the reaction temperature between about 0 ° and 180 °, usually between 0 ° and 100 °, more preferably between 0 0 C and 70 ° C.
  • Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane or mixtures of said solvents.
  • Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene
  • chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane or mixtures of said solvents.
  • a functionally modified amino and / or hydroxyl group can be liberated by solvolysis or hydrogenolysis by customary methods. This can e.g. with NaOH or KOH in water, water-THF or water-dioxane at temperatures between 0 and 100 °.
  • the abovementioned compounds according to the invention can be used in their final non-salt form.
  • the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases according to procedures known in the art.
  • Pharmaceutically acceptable salt forms of the compounds of formula I are for the most part prepared conventionally. If the compound of the formula I contains a carboxylic acid group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base addition salt.
  • Such bases include, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide; Alkali metal alcoholates, eg, potassium ethanolate and sodium propanolate; and various organic bases such as piperidine, diethanolamine and N-methylglutamine.
  • alkali metal hydroxides including potassium hydroxide, sodium hydroxide and lithium hydroxide
  • Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide
  • Alkali metal alcoholates eg, potassium ethanolate and sodium propanolate
  • various organic bases such as piperidine, diethanolamine and N-methylglutamine.
  • the aluminum salts of the compounds of formula I are also included.
  • acid addition salts can be formed by reacting these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts, such as sulfate, nitrate or phosphate, and the like. and
  • pharmaceutically acceptable organic and inorganic acids for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts, such as sulfate, nitrate or phosphate, and the like.
  • Monoarylsulfonates such as ethane sulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and their corresponding salts such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like.
  • pharmaceutically acceptable acid addition salts of the compounds of formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate , Cyclopentanepionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfon
  • base salts of the compounds according to the invention include aluminum, ammonium, calcium, copper, iron (III) -,
  • Salts of compounds of formula I derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, e.g. Arginine, betaine, caffeine, chloroprocaine, choline, N.N'-dibenzylethylenediamine (benzathine),
  • Compounds of the present invention containing basic nitrogen-containing groups can be reacted with agents such as (C 1 -C 4 ) alkyl halides, eg, methyl, ethyl, isopropyl, and tert-butyl chloride, bromide, and iodide; Di (Cr C 4 ) alkyl sulfates, eg dimethyl, diethyl and diamylsulfate; (Ci 0 - C 18 ) alkyl halides, eg decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl- (C 1 -C 4 ) alkyl halides, eg benzyl chloride and phenethyl bromide, quaternize.
  • agents such as (C 1 -C 4 ) alkyl halides, eg, methyl, ethy
  • Preferred pharmaceutical salts include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate,
  • the acid addition salts of basic compounds of formula I are prepared by contacting the free base form with a sufficient amount of the desired acid to form the salt in a conventional manner.
  • the free base can be regenerated by contacting the salt form with a base and isolating the free base in a conventional manner.
  • the free base forms in some sense differ from their corresponding salt forms in terms of certain physical properties such as solubility in polar solvents; however, in the context of the invention, the salts otherwise correspond to their respective free base forms.
  • the pharmaceutically acceptable base addition salts of the compounds of formula I are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines.
  • metals are sodium, potassium, magnesium and calcium.
  • Preferred organic amines are N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.
  • the base addition salts of acidic compounds of the invention are prepared by contacting the free acid form with a sufficient amount of the desired base to form the salt in a conventional manner.
  • the free acid can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner.
  • the free acid forms differ in a sense, their corresponding salt forms with respect to certain physical properties such as solubility in polar solvents; However, in the context of the invention, the salts otherwise correspond to their respective free acid forms.
  • a compound according to the invention contains more than one group which can form such pharmaceutically acceptable salts, the invention also encompasses multiple salts.
  • Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to be limiting.
  • the term "pharmaceutically acceptable salt” in the present context means an active ingredient which contains a compound of the formula I in the form of one of its salts, especially if this salt form is the active ingredient in the Imparts improved pharmacokinetic properties to the free form of the active ingredient or any other salt form of the active ingredient which has previously been used.
  • the pharmaceutically acceptable salt form of the active substance may also first impart a desired pharmacokinetic property to this active ingredient which it has not previously possessed, and may even positively influence the pharmacodynamics of this active ingredient in terms of its therapeutic activity in the body.
  • the invention furthermore relates to medicaments comprising at least one compound of the formula I and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and / or adjuvants.
  • compositions may be presented in the form of dosage units containing a predetermined amount of active ingredient per unit dose.
  • a unit may for example be 0.5 mg to 1 g, preferably from 1 mg to 700 mg, more preferably from 5 mg to 100 mg of a compound of the invention, depending on the disease condition being treated, the route of administration and the age, weight and condition of the patient, or pharmaceutical formulations may be in the form of dosage units containing a predetermined amount of active ingredient per
  • Preferred unit dosage formulations are those containing a daily or partial dose as indicated above or a corresponding fraction thereof of an active ingredient. Furthermore, such pharmaceutical formulations can be prepared by any of the methods well known in the pharmaceutical art.
  • compositions may be administered by any suitable route, for example, oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal). Ways, adapt.
  • Such formulations can be prepared by any method known in the pharmaceutical art, for example, by bringing the active ingredient together with the carrier (s) or excipient (s).
  • compositions adapted for oral administration may be administered as separate units, e.g. Capsules or tablets; Powder or granules; Solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • the active ingredient component in the case of oral administration in the form of a tablet or capsule, can be mixed with an oral, non-toxic and pharmaceutically acceptable inert carrier, such as Ethanol, glycerine, water, etc. combine.
  • an oral, non-toxic and pharmaceutically acceptable inert carrier such as Ethanol, glycerine, water, etc. combine.
  • Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate such as starch or mannitol.
  • a flavor, preservative, dispersant and dye may also be present.
  • Capsules are made by preparing a powder mix as described above and filling shaped gelatin casings therewith.
  • Lubricants such as e.g. highly disperse silica, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form can be added to the powder mixture before the filling process.
  • a disintegrants or solubilizers e.g. Agar-agar, calcium carbonate or sodium carbonate may also be added to improve the availability of the drug after ingestion of the capsule.
  • suitable binding, lubricating and disintegrants as well as dyes can also be incorporated into the mixture.
  • suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, etc.
  • Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc.
  • the disintegrating agents include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc.
  • the tablets are formulated by, for example, preparing a powder mixture, granulating or dry pressing , a lubricant and a disintegrant are added and the whole is compressed into tablets.
  • a powder mixture is prepared by treating the appropriately comminuted compound with a diluent or a base as described above, and optionally with a Binders such as carboxymethyl cellulose, an alginate, gelatin or polyvinylpyrrolidone, a Wegsverlangsamer such as paraffin, a absorption accelerator such as a quaternary salt and / or an absorbent, such as bentonite, kaolin or dicalcium phosphate.
  • the powder mixture can be granulated by adding a Binders such as carboxymethyl cellulose, an alginate, gelatin or polyvinylpyrrolidone, a Amsterdamsverlangsamer such as paraffin, a absorption accelerator such as a quaternary salt and / or an absorbent, such as bentonit
  • Binders such as e.g. Syrup, starch paste, Acadia slime or solutions of cellulose or polymer materials wetted and pressed through a sieve.
  • the powder mixture can be run through a tabletting machine to produce non-uniformly shaped lumps which are broken up into granules.
  • the granules may be greased by the addition of stearic acid, a stearate salt, talc or mineral oil to prevent sticking to the tablet molds. The greased mixture is then compressed into tablets.
  • the compounds according to the invention can also be combined with a free-flowing inert carrier and then pressed directly into tablets without carrying out the granulation or dry-pressing steps.
  • a transparent or opaque protective layer consisting of a shellac sealant, a layer of sugar or polymeric material, and a glossy layer of wax may be present. Dyes can be added to these coatings in order to differentiate between different dosage units.
  • Oral fluids such as solution, syrups and elixirs may be prepared in unit dosage form such that a given quantity contains a predetermined amount of the compound.
  • Syrups can be prepared by dissolving the compound in an appropriate taste aqueous solution while preparing elixirs using a non-toxic alcoholic vehicle.
  • Suspensions may be formulated by dispersing the compound in a non-toxic vehicle.
  • Solubilizers and emulsifiers such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavoring additives, such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, among others may also be added.
  • the unit dosage formulations for oral administration may optionally be encapsulated in microcapsules.
  • the formulation may also be prepared to prolong or retard release, such as by coating or embedding particulate material in polymers, wax, and the like.
  • the compounds of formula I as well as salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as e.g. small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • liposomes can be prepared from various phospholipids, such as e.g. Cholesterol, stearylamine or phosphatidylcholines.
  • the compounds of formula I as well as the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds can also be coupled with soluble polymers as targeted drug carriers.
  • Such polymers may include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol or polyethyleneoxidepolylysine substituted with palmitoyl radicals.
  • the compounds may be coupled to a class of biodegradable polymers suitable for controlled release of a drug, eg, polylactic acid, polyepsilone-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates, and crosslinked or amphipathic block copolymers of hydrogels.
  • a drug eg, polylactic acid, polyepsilone-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates, and crosslinked or amphipathic block copolymers of hydrogels.
  • Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches for prolonged, intimate contact with the epidermis of the recipient.
  • the drug may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3 (6), 318 (1986).
  • Pharmaceutical compounds adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the formulations are preferably applied as a topical ointment or cream.
  • the active ingredient may be either paraffinic or water-miscible
  • Cream base can be used.
  • the active ingredient can be formulated into a cream with an oil-in-water cream base or a water-in-oil base.
  • the pharmaceutical formulations adapted for topical application to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
  • Formulations include lozenges, lozenges and mouthwashes.
  • compositions adapted for rectal administration may be presented in the form of suppositories or enemas.
  • compositions adapted for nasal administration in which the carrier substance is a solid contain a coarse powder a particle size, for example, in the range of 20-500 microns, which is administered in the manner in which snuff is taken, ie by rapid inhalation via the nasal passages from a container held close to the nose with the powder.
  • suitable formulations for administration as a nasal spray or nasal drops with a liquid carrier include drug solutions in water or oil.
  • Fine particulate dusts or mists which may be generated by various types of pressurized dosing dispensers with aerosols, nebulizers or insufflators.
  • compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and nonaqueous sterile injection solutions containing antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions which may contain suspending agents and thickeners.
  • the formulations may be administered in single or multiple dose containers, e.g. sealed vials and vials, and stored in the freeze-dried (lyophilized) state so that only the addition of the sterile carrier liquid, e.g. Water for injections, needed immediately before use.
  • Injection solutions and suspensions prepared by formulation can be prepared from sterile powders, granules and tablets.
  • formulations in addition to the above-mentioned particularly mentioned constituents other conventional means with respect to may contain the particular type of formulation; for example, formulations suitable for oral administration may contain flavorings.
  • a therapeutically effective amount of a compound of formula I depends on a number of factors, including e.g. the age and weight of the animal, the exact condition of the disease requiring treatment, as well as its severity, the nature of the formulation and the route of administration, and is ultimately determined by the attending physician or veterinarian.
  • an effective amount of a compound of the invention is useful for the treatment of neoplastic growth, e.g. Colon or breast carcinoma, generally in the range of 0.1 to 100 mg / kg body weight of the recipient (mammal) per day and more typically in the range of 1 to 10 mg / kg body weight per day.
  • the actual amount per day would usually be between 70 and 700 mg, this amount being given as a single dose per day or more commonly in a number of divided doses (such as two, three, four, five or six) per Day can be given so that the total daily dose is the same.
  • An effective amount of a salt or solvate or a physiologically functional derivative thereof can be determined as a proportion of the effective amount of the compound of the invention per se. It can be assumed that similar dosages are suitable for the treatment of the other, above-mentioned disease states.
  • the invention furthermore relates to medicaments comprising at least one compound of the formula I and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further active pharmaceutical ingredient.
  • the invention is also a set (kit), consisting of separate packages of (A) an effective amount of a compound of formula I and / or its pharmaceutically acceptable derivatives, solvates and stereoisomers, including mixtures thereof in all proportions, and
  • the kit contains suitable containers, such as boxes or boxes, individual bottles, bags or ampoules.
  • the set may e.g. containing separate ampoules in each of which an effective amount of a compound of formula I and / or its pharmaceutically acceptable derivatives, solvates and stereoisomers, including mixtures thereof in all proportions, and an effective amount of another drug substance is dissolved or in lyophilized form.
  • the medicaments of Table 1 are combined with the compounds of the formula I.
  • a combination of formula I and drugs of Table 1 can also be combined with compounds of formula V.
  • Mitoxantrone diflomotecan (Beaufourrinotecan (CPT-11) Ipsen)
  • Rhizoxin (Fujisawa) LU 223651 (BASF)
  • Epothilone B Novartis
  • ZD 6126 AstraZeneca
  • Auristatin PE (Teikoku NeuroPharma)
  • Taxoprexin (Protarga) CA-4 (OXiGENE)
  • TNF-alpha-virulizine (Lorus Revimid (Celgene)
  • CapCell TM CYP450-N-acetylcysteine
  • Antagonist kappaB inhibitor, Encore
  • Efaproxiral oxygenator, receptor agonist, Leo
  • PI-88 heparanase antagonist
  • SRL-172 T-cell doranidazole (apoptosis
  • PT-100 growth factor (differentiator, NIH) Agonist, Point MX6 (apoptosis promoter,
  • CDA-II apoptosis-Ro-31-7453 (apoptosis
  • SDX-101 apoptosis-brostallicin (apoptosis)
  • the compounds of the formula I are combined with known anticancer agents.
  • anticancer agents include the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors and other angiogenesis inhibitors.
  • the present compounds are particularly suitable for co-administration with radiotherapy.
  • the synergistic effects of inhibiting VEGF in combination with radiotherapy have been described in the art (see WO 00/61186).
  • Estrogen receptor modulators refers to compounds that interfere with or inhibit the binding of estrogen to the receptor, regardless of how this occurs: Estrogen receptor modulators include, for example, tamoxifen, raloxifene, idoxifen, LY353381, LY 117081, toremifene, fulvestrant , 4- [7- (2,2-Dimethyl-1-oxopropoxy-4-methyl-2- [4- [2- (1-piperidinyl) ethoxy] phenyl] -2H-1-benzopyran-3-yl] phenyl - 2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and SH646, but this is not intended to be limiting.
  • Androgen receptor modulators refers to compounds that interfere with or inhibit the binding of androgens to the receptor, and regardless of how this happens.
  • the androgen receptor modulators include, for example, finasteride and other 5 ⁇ -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.
  • Retinoid receptor modulators refers to compounds that interfere with or inhibit the binding of retinoids to the receptor, regardless of how this occurs
  • retinoid receptor modulators include, for example, bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis Retinoic acid, ⁇ -difluoromethylornithine, ILX23-7553, trans-N- (4'-hydroxyphenyl) -retinamide and N-4-carboxyphenylretinamide.
  • Cytotoxic agents refers to compounds that cause cell death or interfere with cell myosis, primarily through direct action on cell function, including alkylating agents, tumor necrosis factors, intercalators, microtubulin inhibitors, and topoisomerase inhibitors.
  • the cytotoxic agents include, for example, tirapazimine, Sertenef, cachectin, ifosfamide, tasonermine, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcite, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improvisulfan-tosylate, trofosfamide, nimustine, dibrosylamine.
  • microtubulin inhibitors include, for example, paclitaxel, vindesine sulfate, S '''-dideshidro''-deoxy- ⁇ '-norvincaleukoblastin, docetaxol, Rhizoxin, dolastatin, mivobulinisethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N- (3-fluoro-4-methoxyphenyl) benzenesulfonamide, anhydrovinblastine, N 1 N - dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline t-butylamide, TDX258 and BMS188797.
  • paclitaxel vindesine sulfate
  • Topoisomerase inhibitors are, for example, topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3 ', 4'-O-exo-benzylidene-chartreusine, 9-methoxy-N, N-dimethyl-5-nitropyrazolo [3,4, 5-kl] acridine-2- (6H) propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [en] - Lurtotecan, 7- [2- (N-isopropylamino) ethyl] - (20S) camptothecin, BNP1350, BNPM 100, BN80915, BN80942, etoposide-phosphate, teniposide, sobuzoxan, 2'-dimethylamino-2'-deoxy-etoposide, GL331 ,
  • Oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabic sodium hydrate, raltitrexed, paltitrexide, emitefur, tiazo- furin , Decitabine, Nolatrexed, Pemetrexed, Nelzarabin, 2'-Deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N- [5- (2,3-DihydrobenzofuryOsulfonyl) J-N'-CS-dichlorophenyl urea, N6 - [4-deoxy-4- [N2- [2 (
  • antiproliferative agents also include other monoclonal antibodies to growth factors already mentioned among the “angiogenesis inhibitors”, such as trastuzumab, as well as tumor suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see, eg, US Patent No. 6,069,134 ).
  • Particularly preferred is the use of the compound according to the invention for the treatment and prophylaxis of tumor diseases.
  • the tumor is preferably selected from the group of squamous cell tumors, bladder, stomach, kidney, head and neck, esophagus, cervix, thyroid, intestine, liver, brain, prostate, genitourinary tract , the lymphatic system, the stomach, the larynx and / or the lungs.
  • the tumor is furthermore preferably selected from the group
  • Lung adenocarcinoma small cell lung carcinoma, pancreatic cancer, glioblastoma, colon carcinoma and breast carcinoma.
  • a tumor of the blood and immune system preferably for the treatment of a tumor selected from the group of acute myeloid leukemia, the chronic myeloid leukemia, acute lymphoblastic leukemia and / or chronic lymphocytic leukemia.
  • the invention also includes a method of treating a patient having a neoplasm, such as a cancer, by administration
  • Y 'and Z' are each independently O or N
  • R 6 and R 7 are each independently H, OH, halogen, OC 1-10 alkyl, OCF 3 , NO 2 or NH 2
  • S is an integer between 2 and 6, each inclusive
  • R 8 and R 9 are each independently preferably at the meta or para position and selected from the group:
  • first and second compounds are administered simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.
  • pentamidine or its derivatives appear to have pleiotropic effects as it leads to a decrease in DNA, RNA and protein synthesis.
  • Pentamidine has recently been described as a potent inhibitor of PRL1, -2 and 3 phosphatases (Pathak et al., 2002) and tyrosine phosphatases, and its overexpression is associated with human neoplastic malignant tumors.
  • pentamidine is a drug that binds to the small DNA groove (Puckowska et al., 2004) and that can exert its effect via the disruption of gene expression and / or DNA synthesis.
  • Suitable pentamidine analogs include stilbamidine (G-1) and hydroxystilbamidine (G-2) and their indole analogs (e.g., G-3):
  • Each amidine unit can be independently replaced by one of the units defined above for R 8 and R 11 .
  • salts of stilbamidine, hydroxystilbamidine and their indole derivatives are also suitable for the process according to the invention.
  • Preferred salts include, for example, dihydrochloride and methanesulfonate salts.
  • Exemplary analogs include 1, 5-bis (4 '- (N-hydroxyamidino) phenoxy) pentane, 1, 3-bis (4' - (N-hydroxyamidino) phenoxy) propane, 1, 3-bis (2 '-methoxy-4' - (N-hydroxyamidino) phenoxy) propane, 1,4-bis (4 '- (N-hydroxyamidino) phenoxy) butane, 1, 5-bis- (4' - (N-) hydroxyamidino) phenoxy) pentane, 1,4-bis (4 '- (N-hydroxyamidino) phenoxy) butane, 1, 3-bis- (4' - (4-hydroxyamidino) phenoxy) propane, 1, 3-bis - (2 ' methoxy-4 '- (N-hydroxyamidino) phenoxy) propane, 2,5-bis [4-amidinophenyl] furan, 2,5-bis- [4-amidinophenyl] furan-bis-amidoxime, 2,5-bis- [4-amidin
  • Pentamidine metabolites are also useful in the antiproliferative combination of this invention. Pentamidine is rapidly metabolized in the body to at least seven primary metabolites. Some of these metabolites have one or more effects in common with pentamidine. Pentamidine metabolites exhibit antiproliferative activity when combined with a benzimidazole or an analog thereof.
  • the combinations of compounds of the formula I and formula V or their analogues and their metabolites according to the invention are suitable for the treatment of neoplasms.
  • Combination therapy may be performed alone or in conjunction with another therapy (eg surgery, radiation, chemotherapy, biological therapy).
  • another therapy eg surgery, radiation, chemotherapy, biological therapy.
  • a person whose risk of developing a neoplasm is greater eg, someone who is genetically predisposed or someone who previously had a neoplasm
  • the combination of kinesin ATPase Eg5 / KSP with the compounds of formula V, pentamidine, its analogues and / or its metabolites is also an object of the invention.
  • each compound of the combination can be independently controlled. For example, a compound may be administered orally three times a day while the second compound may be administered intramuscularly once a day.
  • the compounds may also be formulated together so that administration will deliver to both compounds.
  • the antiproliferative combinations of the invention may also be provided as components of a pharmaceutical package.
  • the two drugs may be formulated together or separately and in single dosage amounts.
  • the invention includes a treatment of a patient having a neoplasm such as a cancer by administering a compound of the formula (I) and (V) in combination with an antiproliferative agent.
  • Suitable antiproliferative agents include those provided in Table 1.
  • “usual workup” means adding water if necessary, adjusting to pH values between 2 and 10, if necessary, depending on the constitution of the final product, extracted with ethyl acetate or dichloromethane, separating, drying organic phase over sodium sulfate, evaporated and purified by chromatography on silica gel and / or by crystallization Rf values on silica gel, mobile phase: ethyl acetate / methanol 9: 1.
  • the purchased product was 10 (50 mg, 0.28 mmol) with 2-methylbenzylamine (34 L, 0.28 mmol) using ⁇ / -methylmorpholine (1 eq), ⁇ / - (3-dimethylaminopropyl) - ⁇ / '- ethylcarbodiimide hydrochloride (1 eq) and 1-hydroxybenzotriazole (1 eq).
  • the product crystallized cleanly from the reaction solution after addition of water.
  • the amide 11 was obtained as a colorless solid.
  • Example C Injection glasses
  • a solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 2 l of bidistilled water with 2N hydrochloric acid, filtered sterile, filled into injection jars, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg active substance.
  • Soya lecithin and 1400 g cocoa butter pour into molds and let cool.
  • Example E Solution
  • a solution of 1 g of an active ingredient of the formula I 1 9.38 g of NaH 2 PO 4 • 2H 2 O, 28.48 g Na 2 HPO 4 • 12 H 2 O and 0.1 g of benzalkonium chloride in 940 ml of double-one prepares distilled water. Adjust to pH 6.8, make up to 1 liter and sterilize by irradiation. This solution can be used in the form of eye drops.
  • Example F ointment
  • 500 mg of an active compound of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions.
  • a mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed in the usual way into tablets, such that each tablet contains 10 mg of active ingredient.
  • Tablets are pressed analogously to Example E, which are then coated in the usual way with a coating of sucrose, potato starch, talc, tragacanth and dye.
  • Example J Ampoules A solution of 1 kg of active compound of the formula I in 60 l of bidistilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each vial contains 10 mg of active ingredient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of Formula (I), in which A1, A2, R1, X1, X2, X3, Y, R2, Cy, and n have the meanings set forth in claim 1, can be used, among other things, for the treatment of tumors.

Description

TETRAHYDROBENZOISOXAZOLE- UND TETRAHYDROINDAZOLE-DERIVATE ALS MODULATOREN DERTETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF
MITOTISCHE MOTOR-PROTEINMITOTIC ENGINE PROTEIN
HINTERGRUND DER ERFINDUNGBACKGROUND OF THE INVENTION
Der Erfindung lag die Aufgabe zugrunde, neue Verbindungen mit wertvollenThe invention was based on the object, new compounds with valuable
Eigenschaften aufzufinden, insbesondere solche, die zur Herstellung von Arzneimitteln verwendet werden können.Find properties, especially those that can be used for the production of medicines.
Die vorliegende Erfindung betrifft Verbindungen der Formel I und deren Verwendung zur Behandlung und Prophylaxe von Krankheiten, bei denen die Hemmung, Regulierung und/oder Modulation der mitotische Motor- Proteine, insbesondere des mitotischen Motor-Protein Eg5 eine Rolle spielt, ferner pharmazeutische Zusammensetzungen, die diese Verbindungen enthalten.The present invention relates to compounds of the formula I and their use for the treatment and prophylaxis of diseases in which the inhibition, regulation and / or modulation of mitotic motor proteins, in particular of the mitotic motor protein Eg5 plays a role, and also pharmaceutical compositions which contain these compounds.
Im einzelnen betrifft die vorliegende Erfindung Verbindungen der Formel I1 die die bevorzugt eines oder mehrere mitotische Motor-Proteine hemmen, regulieren und/oder modulieren, Zusammensetzungen, die diese Verbindungen enthalten, sowie Verfahren zu ihrer Verwendung zur Behandlung von Krankheiten und Leiden wie Angiogenese, Krebs, Tumorentstehung, -Wachstum und -Verbreitung, Arteriosklerose, Augenerkrankungen, choroidale Neovaskularisierung und diabetische Retinopathie, Entzündungserkrankungen, Arthritis, Neurodegeneration, Restenose, Wundheilung oder Transplantatabstossung. Insbesondere eignen sich die erfindungsgemäßen Verbindungen zur Therapie oder Prophylaxe vonIn particular, the present invention relates to compounds of the formula I 1 which preferably inhibit, regulate and / or modulate one or more mitotic motor proteins, compositions containing these compounds and methods for their use in the treatment of diseases and conditions such as angiogenesis, Cancer, tumorigenesis, growth and spread, arteriosclerosis, ocular disorders, choroidal neovascularization and diabetic retinopathy, inflammatory diseases, arthritis, neurodegeneration, restenosis, wound healing or graft rejection. In particular, the compounds according to the invention are suitable for the therapy or prophylaxis of
Krebserkrankungen.Cancers.
Während der Mitose regulieren verschiedenen Kinesine die Ausbildung und Dynamik des Spindelapparates, der für eine korrekte und koordinierte Ausrichtung und Separation der Chromosomen verantwortlich ist. Es wurde beobachtet, dass eine spezifische Inhibierung eines mitotischen Motor- Proteins - Eg5 - zu einem Kollaps der Spindelfasern führt. Daraus resultiert, dass die Chromosomen nicht mehr korrekt auf die Tochterzellen aufgeteilt werden können. Dies führt zu mitotischem Arrest und kann damit das Absterben der Zelle verursachen. Eine Hochregulierung des Motorproteins Eg5 wurde z.B. in Gewebe von Brust- Lungen- und Colon- Tumoren beschrieben. Da Eg5 eine für die Mitose spezifische Funktion einnimmt, sind hauptsächlich sich schnell teilende Zellen und nicht vollständig ausdifferenzierte Zellen von einer Eg5 Inhibierung betroffen. Darüber hinaus regelt Eg5 ausschließlich die Bewegung mitotischer Mikrotubuli (Spindelapparat) und nicht die des Cytoskeletts. Dies ist entscheidend für das Nebenwirkungsprofil der erfindungsgemäßen Verbindungen, da z.B. Neuropathien, wie sie bei Taxol beobachtet werden, nicht oder nur abgeschwächt auftreten. Daher ist die Inhibierung von Eg5 durch die erfindungsgemäßen Verbindungen ein relevantes Therapiekonzept für die Behandlung von malignen Tumoren.During mitosis, various kinesins regulate the formation and dynamics of the spindle apparatus responsible for correct and coordinated alignment and separation of the chromosomes. It has been observed that specific inhibition of a mitotic motor protein - Eg5 - leads to collapse of the spindle fibers. This results, that the chromosomes can no longer be correctly distributed to the daughter cells. This leads to mitotic arrest and can thus cause cell death. Upregulation of the motor protein Eg5 has been described, for example, in tissues of breast, lung and colon tumors. Since Eg5 occupies a function specific to mitosis, mainly rapidly dividing cells and not fully differentiated cells are affected by Eg5 inhibition. In addition, Eg5 regulates exclusively the movement of mitotic microtubules (spindle apparatus) and not those of the cytoskeleton. This is crucial for the side effect profile of the compounds according to the invention, since, for example, neuropathies, as are observed in taxol, do not occur or only weakened. Therefore, the inhibition of Eg5 by the compounds according to the invention is a relevant therapeutic concept for the treatment of malignant tumors.
Generell können alle soliden und nicht soliden Tumore mit den Verbindungen der Formel I behandelt werden, wie z.B. die Monozytenleukämie, Hirn-, Urogenital-, Lymphsystem-, Magen-, Kehlkopf- und Lungenkarzinom, darunter Lungenadenokarzinom und kleinzelliges Lungenkarzinom. Zu weiteren Beispielen zählen Prostata-, Bauchspeicheldrüsen- und Brustkarzinom.In general, all solid and non-solid tumors can be treated with the compounds of formula I, e.g. monocytic leukemia, brain, urogenital, lymphatic, gastric, laryngeal and lung carcinomas, including lung adenocarcinoma and small cell lung carcinoma. Other examples include prostate, pancreatic and breast carcinoma.
Es wurde überraschend gefunden, daß die erfindungsgemäßen Verbindungen eine spezifische Inhibierung der mitotischen Moter-Proteine, insbesondere Eg5 bewirken. Die erfindungsgemäßen Verbindungen zeigen bevorzugt eine vorteilhafte biologische Aktivität, die in den zum Beispiel hierin beschrieben Assays leicht nachweisbar ist. In derartigen Assays zeigen und bewirken die erfindungsgemäßen Verbindungen bevorzugt einen inhibierenden Effekt, der gewöhnlich durch IC50-Werte in einem geeigneten Bereich, bevorzugt im mikromolaren Bereich und bevorzugter im nanomolaren Bereich dokumentiert wird. Wie hierin besprochen, sind Wirkungen der erfindungsgemäßen Verbindung für verschiedene Erkrankungen relevant. Dementsprechend sind die erfindungsgemäßen Verbindungen nützlich bei der Prophylaxe und/oder Behandlung von Erkrankungen, die durch eine Inhibierung eines oder mehreren mitotischer Motor-Proteine, insbesondere Eg5, beeinflusst werden.It has surprisingly been found that the compounds according to the invention bring about a specific inhibition of the mitotic Moter proteins, in particular Eg5. The compounds of the invention preferably exhibit a beneficial biological activity which is readily detectable in the assays described herein, for example. In such assays, the compounds of the invention preferably exhibit and effect an inhibitory effect, usually documented by IC 50 values in a suitable range, preferably in the micromolar range, and more preferably in the nanomolar range. As discussed herein, effects of the compound of the invention are relevant to various diseases. Accordingly, the compounds of the invention are useful in the prophylaxis and / or treatment of diseases that are affected by inhibition of one or more mitotic motor proteins, particularly Eg5.
Gegenstand der vorliegenden Erfindung sind deshalb erfindungsgemäße Verbindungen als Arzneimittel und/oder Arzneimittelwirkstoffe bei der Behandlung und/oder Prophylaxe der genannten Erkrankungen und die Verwendung von erfindungsgemäßen Verbindungen zur Herstellung eines Pharmazeutikums für die Behandlung und/oder Prophylaxe der genannten Erkrankungen wie auch ein Verfahren zur Behandlung der genannten Erkrankungen umfassend die Verabreichung eines oder mehrerer erfindungsgemäßer Verbindungen an einen Patienten mit Bedarf an einer derartigen Verabreichung.The present invention therefore relates to compounds according to the invention as medicaments and / or active pharmaceutical ingredients in the treatment and / or prophylaxis of said diseases and the use of compounds according to the invention for the preparation of a pharmaceutical for the treatment and / or prophylaxis of said diseases as well as a method of treatment said diseases comprising administering one or more of the compounds of the invention to a patient in need of such administration.
Es kann gezeigt werden, dass die erfindungsgemäßen Verbindungen in einem Xenotransplantat-Tumor-Modell eine vorteilhafte Wirkung aufweisen.It can be shown that the compounds according to the invention have a beneficial effect in a xenograft tumor model.
Der Wirt oder Patient kann jeglicher Säugerspezies angehören, z. B. einer Primatenspezies, besonders Menschen; Nagetieren, einschließlich Mäusen, Ratten und Hamstern; Kaninchen; Pferden, Rindern, Hunden, Katzen usw. Tiermodelle sind für experimentelle Untersuchungen von Interesse, wobei sie ein Modell zur Behandlung einer Krankheit des Menschen zur Verfügung stellen.The host or patient may be of any mammalian species, e.g. A primate species, especially humans; Rodents, including mice, rats and hamsters; Rabbits; Horses, cattle, dogs, cats, etc. Animal models are of interest for experimental studies, providing a model for the treatment of human disease.
Die Suszeptibilität einer bestimmten Zelle gegenüber der Behandlung mit den erfindungsgemäßen Verbindungen kann durch Testen in vitro bestimmt werden. Typischerweise wird eine Kultur der Zelle mit einer erfindungsgemäßen Verbindung bei verschiedenen Konzentrationen für eine Zeitdauer kombiniert, die ausreicht, um den Wirkstoffen zu ermöglichen, Zelltod zu induzieren oder Migration zu inhibieren, gewöhnlich zwischen ungefähr einer Stunde und einer Woche. Zum Testen in vitro können kultivierte Zellen aus einer Biopsieprobe verwendet werden. Die nach der Behandlung zurückbleibenden lebensfähigen Zellen werden dann gezählt. Die Dosis variiert abhängig von der verwendeten spezifischen Verbindung, der spezifischen Erkrankung, dem Patientenstatus usw.. Typischerweise ist eine therapeutische Dosis ausreichend, um die unerwünschte Zellpopulation im Zielgewebe erheblich zu vermindern, während die Lebensfähigkeit des Patienten aufrechterhalten wird. Die Behandlung wird im Allgemeinen fortgesetzt, bis eine erhebliche Reduktion vorliegt, z. B. mindestens ca. 50 % Verminderung der Zelllast und kann fortgesetzt werden, bis im Wesentlichen keine unerwünschten Zellen mehr im Körper nachgewiesen werden.The susceptibility of a particular cell to treatment with the compounds of the invention can be determined by testing in vitro. Typically, a culture of the cell is combined with a compound of the invention at various concentrations for a period of time sufficient to allow the drugs to induce cell death or inhibit migration, usually between about one hour and one week. For testing in vitro cultured cells from a biopsy sample can be used. The viable cells remaining after treatment are then counted. The dose will vary depending on the specific compound used, the specific disease, the patient status, etc. Typically, a therapeutic dose will be sufficient to substantially reduce the unwanted cell population in the target tissue while maintaining patient viability. Treatment is generally continued until there is a significant reduction, e.g. B. at least about 50% reduction in cell load and can be continued until essentially no more unwanted cells are detected in the body.
ZUSAMMENFASSUNG DER ERFINDUNGSUMMARY OF THE INVENTION
Verbindungen der Formel ICompounds of the formula I
worin wherein
A i 1 , A Λ 2 unabhängig voneinander N, O oder S,A i 1, A Λ 2 independently of one another N, O or S,
χ1- χ2. X3 unabhängig voneinander einer Einfachbindung, NR3-NR3, NR3, χ1 - χ2 . X 3 are independently of one another a single bond, NR 3 -NR 3 , NR 3 ,
O, S, oder eine der folgenden Gruppen:O, S, or one of the following groups:
-O i -OP N N oder N CH HC CH-O i -OP N N or N CH HC CH
-(S1 - (S 1
Cy H, ein carbocyclischer oder heberocyclischer gesättigter, ungesättigter oder aromatischer Rest, der unsubstituiert oder ein- oder mehrfach durch Alkyl, HaI, CN, OH; OR, OCF3, CF3, COOR oder durch eine Gruppe (CR12)n-Y-X1-(CR12)n-Q substituiert sein kann,Cy H, a carbocyclic or heberocyclic saturated, unsaturated or aromatic radical which is unsubstituted or mono- or polysubstituted by alkyl, Hal, CN, OH; OR, OCF 3 , CF 3 , COOR or may be substituted by a group (CR 1 2) n -YX 1 - (CR 1 2) n -Q,
1010
Q H, Alkyl, Cycloalkyl, Aryl oder HeteroarylQ is H, alkyl, cycloalkyl, aryl or heteroaryl
R, R1, H, Alkyl, HaI, Alkoxy, OH, Alkenyl, Alkoxyalkyl, Hydroxyakyl, R2, R3 (CH2)n-Q, (CH2)n-Cy oder (CH2)nNR2,R, R 1 , H, alkyl, Hal, alkoxy, OH, alkenyl, alkoxyalkyl, hydroxyalkyl, R 2 , R 3 (CH 2 ) n -Q, (CH 2 ) n -Cy or (CH 2 ) n NR 2 ,
1515
HaI F, Br oder ClHaI F, Br or Cl
n O, 1 , 2, 3, 4, 5, 6, 7, oder 8,n O, 1, 2, 3, 4, 5, 6, 7, or 8,
m 1 oder 2m 1 or 2
20 uunndd p O, 1 oder 220 and p O, 1 or 2
bedeuten,mean,
25 sowie ihre pharmazeutisch verwendbaren Derivate, Solvate, Tautomere,25 and their pharmaceutically usable derivatives, solvates, tautomers,
Salze und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen.Salts and stereoisomers, including mixtures thereof in all proportions.
Gegenstand der Erfindung sind auch die optisch aktiven Formen, dieThe invention also relates to the optically active forms, the
OUOU
Enantiomere, die Racemate, die Diastereomere sowie die Hydrate und Solvate dieser Verbindungen. Unter Solvaten der Verbindungen werden Anlagerungen von inerten Lösungsmittelmolekülen an die Verbindungen der Formel I verstanden, die sich aufgrund ihrer gegenseitigen Anziehungskraft ausbilden. Solvate sind z.B. Mono- oder Dihydrate oder Alkoholate.Enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. Among solvates of the compounds will be Associations of inert solvent molecules to the compounds of formula I understood that form due to their mutual attraction. Solvates are, for example, mono- or dihydrate or alcoholates.
Unter pharmazeutisch verwendbaren Derivaten versteht man z.B. die Salze der erfindungsgemäßen Verbindungen als auch sogenannte Prodrug-Pharmaceutically usable derivatives are understood, for example, as the salts of the compounds according to the invention as well as so-called prodrugs
Verbindungen.Links.
Unter Prodrug-Derivaten versteht man mit z. B. Alkyl- oder Acylgruppen,Under prodrug derivatives is understood with z. B. alkyl or acyl groups,
Zuckern oder Oligopeptiden abgewandelte Verbindungen der Formel I, die im Organismus rasch zu den wirksamen erfindungsgemäßen Verbindungen gespalten werden.Sugars or oligopeptides modified compounds of formula I, which are rapidly cleaved in the organism to the active compounds of the invention.
Hierzu gehören auch bioabbaubare Polymerderivate der erfindungsgemäßenThese include biodegradable polymer derivatives of the invention
Verbindungen, wie dies z. B. in Int. J. Pharm. 115, 61-67 (1995) beschrieben ist.Connections, as z. In Int. J. Pharm. 115, 61-67 (1995).
Ähnliche Verbindungen sind z.B. in Tetrahedron Lett. 1988, 29, 5855-5858,Similar compounds are e.g. in Tetrahedron Lett. 1988, 29, 5855-5858,
Tetrahedron Lett. 2003, 44, 217-219, J. Org. Chem. 1997, 62, 4880-4882, J.Tetrahedron Lett. 2003, 44, 217-219, J. Org. Chem. 1997, 62, 4880-4882, J.
Org. Chem. 1999, 64, 6462-6467, Chem. Lett. 1995, 423-424, J. Org. Chem.Org. Chem. 1999, 64, 6462-6467, Chem. Lett. 1995, 423-424, J. Org. Chem.
2000, 65, 5009-5013, Chem. Lett. 2003, 32, 222-223, US2003149069A1 beschrieben, sind aber nicht im Zusammenhang mit Krebsbehandlungen genannt und/oder enthalten nicht die erfindungswesentlichen Merkmale.2000, 65, 5009-5013, Chem. Lett. 2003, 32, 222-223, US2003149069A1, but are not mentioned in connection with cancer treatments and / or do not contain the features essential to the invention.
Der Ausdruck "wirksame Menge" bedeutet die Menge eines Arzneimittels oder eines pharmazeutischen Wirkstoffes, die eine biologische oder medizinische Antwort in einem Gewebe, System, Tier oder Menschen hervorruft, die z.B. von einem Forscher oder Mediziner gesucht oder erstrebt wird.The term "effective amount" means the amount of a drug or pharmaceutical agent which elicits a biological or medical response in a tissue, system, animal or human, e.g. sought or desired by a researcher or physician.
Darüberhinaus bedeutet der Ausdruck "therapeutisch wirksame Menge" eineIn addition, the term "therapeutically effective amount" means one
Menge, die in einem Menschen oder einem anderen Säuger mindestens eine der folgenden Wirkungen hervorruft (im Vergleich zu einem Subjekt, das diese Menge nicht erhalten hat): Verbesserung der Heilbehandlung, Heilung, Prävention oder Beseitigung einer Krankheit, eines Krankheitsbildes, eines Krankheitszustandes, eines Leidens, einer Störung oder von Nebenwirkungen oder auch die Verminderung des Fortschreitens einer Krankheit, eines Leidens oder einer Störung.Amount causing at least one of the following effects in a human or other mammal (compared to a subject who has not received this amount): Improvement of the curative treatment, cure, prevention or elimination of a disease, a clinical picture, a disease state, a disease, a disorder or side effects or even the reduction of the progression of a disease, a disease or a disorder.
Die Bezeichnung "therapeutisch wirksame Menge" umfaßt auch die Mengen, die wirkungsvoll sind, die normale physiologische Funktion zu erhöhen oder zu verstärken.The term "therapeutically effective amount" also includes those amounts effective to increase or enhance normal physiological function.
Gegenstand der Erfindung ist auch die Verwendung von Mischungen der Verbindungen der Formel I1 z.B. Gemische zweier Diastereomerer z.B. im Verhältnis 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 1 :10, 1 :100 oder 1 :1000. Besonders bevorzugt handelt es sich dabei um Mischungen stereoisomerer Verbindungen.The invention also provides for the use of mixtures of the compounds of the formula I 1, for example mixtures of two diastereomers, for example in a ratio of 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 10, 1: 100 or 1: 1000. These are particularly preferably mixtures of stereoisomeric compounds.
Gegenstand der Erfindung sind die Verbindungen der Formel I und ihre Salze sowie ein Verfahren zur Herstellung von Verbindungen der Formel I nach den Patentansprüchen sowie ihrer pharmazeutisch verwendbaren Derivate, Salze, Solvate und Stereoisomere, dadurch gekennzeichnet, daß man eine Verbindung der Formel IlThe invention relates to the compounds of the formula I and their salts and to a process for the preparation of compounds of the formula I according to the claims and their pharmaceutically usable derivatives, salts, solvates and stereoisomers, characterized in that a compound of the formula II
worin A1, A2, R1, und X1 die oben angegebenen Bedeutungen haben,wherein A 1 , A 2 , R 1 , and X 1 have the meanings given above,
mit einer Verbindung der Formel IIIwith a compound of formula III
H-Y-X2-(CR2 2)n-X3-Cy worinHYX 2 - (CR 2 2 ) n X 3 -Cy wherein
Y, X2, R2, X3 und Cy die oben angegebene Bedeutung aufweisen,Y, X 2 , R 2 , X 3 and Cy have the abovementioned meaning,
bevorzugt in Gegenwart eines aktivierenden Reagenz', wie z. B. N-(3-preferably in the presence of an activating reagent, such as. B. N- (3
Dialkylamimoalkyl)-N'-alkylcarbodimid, insbesondere N- (3Dimethylaminopropyl)-N'-ethylcarbodimid umsetzt.Dialkylamimoalkyl) -N'-alkylcarbodimid, in particular N- (3Dimethylaminopropyl) -N'-ethylcarbodimid.
Vorzugsweise werden die nach dem oben beschriebenen Verfahren gegebenenfalls erhaltenen Gemische von Diastereomeren undPreferably, the mixtures of diastereomers optionally obtained by the process described above and
Enantiomeren der Verbindungen der Formel I durch Chromatographie oder Kristallisation aufgetrennt.Enantiomers of the compounds of formula I separated by chromatography or crystallization.
Gegebenenfalls werden die nach dem oben beschriebenen Verfahren erhaltenen Basen und Säuren der Formel I in ihre Salze umgewandelt.Optionally, the bases and acids of formula I obtained by the process described above are converted into their salts.
Vor- und nachstehend haben die Reste HaI, R, R1, R2, R3, X1, X2, X3, Y, Q, Cy, m, n und p die bei der Formel I angegebenen Bedeutungen, sofern nicht ausdrücklich etwas anderes angegeben ist. Bei mehrfachem Auftreten einzelner Reste innerhalb einer Verbindung nehmen die Reste unabhängig voneinander die angegebenen Bedeutungen an.Above and below, the radicals Hal, R, R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , Y, Q, Cy, m, n and p have the meanings given for the formula I, if not expressly stated otherwise. When multiple occurrences of individual radicals within a compound, the radicals independently of one another assume the meanings indicated.
Alkyl ist bevorzugt unverzweigt (linear) oder verzweigt, und hat 1 , 2, 3, 4, 5, 6, 7, 8, 9 oder 10 C-Atome. Alkyl bedeutet vorzugsweise Methyl, weiterhin Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, sek.-Butyl oder tert.-Butyl, ferner auch Pentyl, 1-, 2- oder 3-Methylbutyl, 1 ,1- , 1 ,2- oder 2,2-Dimethylpropyl, 1- Ethylpropyl, Hexyl, 1-, 2-, 3- oder 4-Methylpentyl, 1,1-, 1 ,2-, 1 ,3-, 2,2- , 2,3- oder 3,3-Dimethylbutyl, 1- oder 2-Ethylbutyl, 1-Ethyl-1-methyl- propyl, 1-Ethyl-2-methylpropyl, 1 ,1 ,2- oder 1 ,2,2-Trimethylpropyl, weiter bevorzugt z.B. Trifluormethyl. Alkyl bedeutet ganz besonders bevorzugt Alkyl mit 1 , 2, 3, 4, 5 oder 6 C- Atomen, vorzugsweise Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, sek.- Butyl, tert.-Butyl, Pentyl, Hexyl, Trifluormethyl, Pentafluorethyl oder 1 ,1 ,1- Trifluorethyl. Alkyl bedeutet auch Cycloalkyl. Cycloalkyl bedeutet vorzugsweise Cyclopropyl, Cyclobutyl, Cylopentyl,Alkyl is preferably unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. Alkyl is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1, 1, 1, 2 or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methyl-propyl, 1-ethyl-2-methylpropyl, 1, 1, 2 or 1, 2,2-trimethylpropyl, more preferably, for example, trifluoromethyl , Alkyl very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl , Pentafluoroethyl or 1,1,1-trifluoroethyl. Alkyl also means cycloalkyl. Cycloalkyl is preferably cyclopropyl, cyclobutyl, cyclopentyl,
Cyclohexyl oder Cycloheptyl, insbesondere aber Cyclopentyl.Cyclohexyl or cycloheptyl, but especially cyclopentyl.
R, R1 , R2, bedeutet vorzugsweise H, Alkyl, CF3, OCF3, SCN, CN, OH, O Alkyl -OCOAlkyl, OCOH, HaI, SCF3, bevorzugt auch t-Butyl, - CH(CH3)CH2CH3, Isopropyl, Ethyl oder Methyl. Insbesondere bedeutet R1 1- Butyl, Isopropyl, Ethyl, CF3, Methyl, Br, Cl, SCF3, CH(CH3)CH2CH3, n-Propyl, OCH3, SCH3, n-Butyl, -SCN1 CH2CN. Besonders bevorzugt bedeutet R1 1- Butyl, Isopropyl, Ethyl oder CF3.R, R 1 , R 2 , preferably denotes H, alkyl, CF 3 , OCF 3 , SCN, CN, OH, O, alkyl-OCOalkyl, OCOH, Hal, SCF 3 , preferably also t-butyl, -CH (CH 3 ) CH 2 CH 3 , isopropyl, ethyl or methyl. In particular, R 1 is 1-butyl, isopropyl, ethyl, CF 3 , methyl, Br, Cl, SCF 3 , CH (CH 3 ) CH 2 CH 3 , n -propyl, OCH 3 , SCH 3 , n-butyl, -SCN 1 CH 2 CN. More preferably R 1 is 1-butyl, isopropyl, ethyl or CF 3 .
A1 , A2 bedeuten unabhängig voneinander bevorzugt O oder N.A 1 , A 2 independently of one another preferably denote O or N.
Besonders bevorzugt sind A1 und A2 nicht identisch.Particularly preferably, A 1 and A 2 are not identical.
R3 bedeuten vorzugsweise H, Alkyl, Hydroxyalkyl, Alkoxyalkyl,R 3 is preferably H, alkyl, hydroxyalkyl, alkoxyalkyl,
(CH2)n Q oder (CH2)nN(R1)2.(CH 2 ) n Q or (CH 2 ) n N (R 1 ) 2 .
X1, X2 bedeuten vorzugsweise NR3, O oder die der folgenden GruppeX 1 , X 2 are preferably NR 3 , O or the following group
X bedeutet vorzugsweise eine Einfachbindung oder (CH2)n X is preferably a single bond or (CH 2 ) n
Y bedeutet vorzugsweise C=O oder -i N- J"l\ Cy bdeutet vorzugsweise substituiertes oder unsubstituiertesY is preferably C = O or -i N- Cy preferably denotes substituted or unsubstituted
Cyclopentyl, Aryl oder Heteroaryl. Insbesondere bedeutet Cy eine der folgenden GruppenCyclopentyl, aryl or heteroaryl. In particular, Cy means one of the following groups
worin q 1 oder 2 bedeutetwherein q is 1 or 2
Bevorzugt sind Verbindungen der Formel I1 worin die Gruppe Y- X2-(CR2 2)n-X eine Einfachbindung darstellt.(CR 2 2) n -X represents a single bond - compounds of the formula I 1 wherein the group Y, X 2 are preferred.
Q bedeutet vorzugsweise Aryl oder Heteroaryl u bedeutet vorzugsweise 0, 1 oder 2. m bedeuetet vorzugsweise 1. p bedeutet vorzugsweise 1.Q is preferably aryl or heteroaryl, u is preferably 0, 1 or 2. m is preferably 1. p is preferably 1.
Aryl bedeutet vorzugsweise unsubstituiertes oder ein-, zwei- oder dreifach durch HaI, A, OH, OA, NH2, NO2, CN, COOH, COOA1 CONH2, NHCOA, NHCONH2, NHSO2A, CHO, COA, SO2NH2, SO2A, -CH2-COOH oder -OCH2-COOH substituiertes Phenyl, Naphthyl oder Biphenyl. Aryl bedeutet bevorzugt Phenyl, o-, m- oder p-Tolyl, o-, m- oder p-Ethyl- phenyl, o-, m- oder p-Propylphenyl, o-, m- oder p-lsopropylphenyl, o-, m- oder p-tert.-Butylphenyl, o-, m- oder p-Hydroxyphenyl, o-, m- oder p-Methoxyphenyl, o-, m- oder p-Nitrophenyl, o-, m- oder p-Aminophenyl, o-, m- oder p-(N-Methylamino)-phenyl, o-, m- oder p-(N-Methylaminocarbonyl)- phenyl, o-, m- oder p-Acetamidophenyl, o-, m- oder p-Methoxyphenyl, o-, m- oder p-Ethoxyphenyl, o-, m- oder p-Ethoxycarbonylphenyl, o-, m- oder p-Aryl is preferably unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH 2 , NO 2 , CN, COOH, COOA 1 CONH 2 , NHCOA, NHCONH 2 , NHSO 2 A, CHO, COA, SO 2 NH 2 , SO 2 A, -CH 2 -COOH or -OCH 2 -COOH substituted phenyl, naphthyl or biphenyl. Aryl is preferably phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p- (N-methylamino) -phenyl, o-, m- or p- (N-methylaminocarbonyl) -phenyl, o-, m- or p-acetamidophenyl, o-, m- or p- Methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p-
(N,N-Dimethylamino)-phenyl, o-, m- oder p-(N,N-Dimethylaminocarbonyl)- phenyl, o-, m- oder p-(N-Ethylamino)-phenyl, o-, m- oder p-(N,N- Diethylamino)-phenyl, o-, m- oder p-Fluorphenyl, o-, m- oder p-Bromphenyl, o-, m- oder p- Chlorphenyl, o-, m- oder p-(Methylsulfonamido)-phenyl, o-, m- oder p-(Methylsulfonyl)-phenyl, weiter bevorzugt 2,3-, 2,4-, 2,5-, 2,6-, 3,4- oder 3,5-Difluorphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- oder 3,5-Dichlorphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- oder 3,5-Dibromphenyl, 2,4- oder 2,5-Dinitrophenyl, 2,5- oder 3,4-Dimethoxyphenyl, 3-Nitro-4-chlorphenyl, 3-Amino-4-chlor-, 2-Amino- 3-chlor-, 2-Amino-4-chlor-, 2-Amino-5-chlor- oder 2-Amino-6-chlorphenyl, 2- Nitro-4-N,N-dimethylamino- oder 3-Nitro-4-N,N-dimethylaminophenyl, 2,3- Diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- oder 3,4,5-Trichlorphenyl, 2,4,6- Trimethoxyphenyl, 2-Hydroxy-3,5-dichlorphenyl, p-lodphenyl, 3,6-Dichlor-4- aminophenyl, 4-Fluor-3-chlorphenyl, 2-Fluor-4-bromphenyl, 2,5-Difluor-4- bromphenyl, 3-Brom-6-methoxyphenyl, 3-Chlor-6-methoxyphenyl, 3-Chlor-4- acetamidophenyl, 3-Fluor-4-methoxyphenyl, 3-Amino-6-methylphenyl, 3- Chlor-4-acetamidophenyl oder 2,5-Dimethyl-4-chlorphenyl.(N, N-dimethylamino) -phenyl, o-, m- or p- (N, N-dimethylaminocarbonyl) -phenyl, o-, m- or p- (N-ethylamino) -phenyl, o-, m- or p- (N, N- Diethylamino) -phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p- (methylsulfonamido) -phenyl, o -, m- or p- (methylsulfonyl) -phenyl, more preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3- , 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4 - or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro, 2-amino 3-chloro, 2-amino-4-chloro, 2-amino-5-chloro or 2-amino-6-chlorophenyl, 2-nitro-4-N, N-dimethylamino or 3-nitro-4 -N, N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2 , 4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2.5 Difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3-chloro -4-acetamide idophenyl or 2,5-dimethyl-4-chlorophenyl.
Heteroaryl bedeutet vorzugsweise einen ein- oder zweikernigen unsubstituierten oder ein-, zwei- oder dreifach durch HaI, A, NO2, NHA, NA2, OA, COOA oder CN substituierten aromatischen Heterocyclus mit einem oder mehreren N-, O- und/oder S-Atomen.Heteroaryl preferably denotes a mono- or binuclear unsubstituted or mono-, di- or trisubstituted by Hal, A, NO 2 , NHA, NA 2 , OA, COOA or CN substituted aromatic heterocycle having one or more N-, O- and / or S atoms.
Heteroaryl bedeutet besonders bevorzugt einen einkernigen gesättigten oder aromatischen Heterocyclus mit einem N, S oder O-Atom, der unsubstituiert oder ein-, zwei- oder dreifach durch HaI, A, NHA, NA2, NO2, COOA oder Benzyl substituiert sein kann.Heteroaryl particularly preferably denotes a monocyclic saturated or aromatic heterocycle having one N, S or O atom which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA 2 , NO 2 , COOA or benzyl.
Ungeachtet weiterer Substitutionen, bedeutet unsubstituiertes Heteroaryl z.B. 2- oder 3-Furyl, 2- oder 3-Thienyl, 1-, 2- oder 3-Pyrrolyl, 1-, 2, A- oder 5- Imidazolyl, 1-, 3-, 4- oder 5-Pyrazolyl, 2-, 4- oder 5-Oxazolyl, 3-, 4- oder 5- Isoxazolyl, 2-, 4- oder 5-Thiazolyl, 3-, 4- oder 5-lsothiazolyl, 2-, 3- oder A- Pyridyl, 2-, 4-, 5- oder 6-Pyrimidinyl, weiterhin bevorzugt 1 ,2,3-TriazoM-, -A- oder -5-yl, 1 ,2,4-TriazoM-, -3- oder 5-yl, 1- oder 5-Tetrazolyl, 1 ,2,3- Oxadiazol-4- oder -5-yl, 1 ,2,4-Oxadiazol-3- oder -5-yl, 1 ,3,4-Thiadiazol-2- oder -5-yl, 1 ,2,4-Thiadiazol-3- oder -5-yl, 1 ,2,3-Thiadiazol-4- oder -5-yl, 3- oder 4-Pyridazinyl, Pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- oder 7-lndolyl, 4- oder 5- Isoindolyl, 1-, 2-, 4- oder 5-Benzimidazolyl, 1-, 3-, 4-, 5-, 6- oder 7- Benzopyrazolyl, 2-, 4-, 5-, 6- oder 7-Benzoxazolyl, 3-, 4-, 5-, 6- oder 7- Benzisoxazolyl, 2-, 4-, 5-, 6- oder 7-Benzothiazolyl, 2-, 4-, 5-, 6- oder 7-Regardless of further substitutions, unsubstituted heteroaryl means, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, A- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or A-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1, 2,3-triazoM-, -A- or -5-yl, 1, 2,4-triazoM-, - 3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4 or -5-yl, 1, 2,4-oxadiazol-3 or -5-yl, 1, 3, 4-thiadiazol-2- or -5-yl, 1, 2,4-thiadiazol-3 or -5-yl, 1, 2,3-thiadiazol-4 or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5- , 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6 or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-
Benzisothiazolyl, 4-, 5-, 6- oder 7-Benz-2,1 ,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- oder 8-Chinolyl, 1-, 3-, 4-, 5-, 6-, 7- oder 8-lsochinolyl, 3-, 4-, 5-, 6-, 7- oder 8-Cinnolinyl, 2-, 4-, 5-, 6-, 7- oder 8-Chinazolinyl, 5- oder 6-Chinoxalinyl, 2-, 3-, 5-, 6-, 7- oder 8-2H-Benzo[1 ,4]oxazinyl, weiter bevorzugt 1 ,3-Benzo- dioxol-5-yl, 1 ,4-Benzodioxan-6-yl, 2,1 ,3-Benzothiadiazol-4- oder -5-yl oder 2,1 ,3-Benzoxadiazol-5-yl.Benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3- , 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo [1,4] oxazinyl, more preferably 1,3-benzodioxole-5 -yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4 or 5-yl or 2,1,3-benzoxadiazol-5-yl.
HaI bedeutet vorzugsweise F, Cl oder Br besonders bevorzugt F oder Cl.Hal preferably denotes F, Cl or Br, more preferably F or Cl.
Für die gesamte Erfindung gilt, daß sämtliche Reste, die mehrfach auftreten, gleich oder verschieden sein können, d.h. unabhängig voneinander sind.For the entire invention, all residues that occur multiple times may be the same or different, i. are independent of each other.
Die Verbindungen der Formel I können ein oder mehrere chirale Zentren besitzen und daher in verschiedenen stereoisomeren Formen vorkommen. Die Formel I umschließt alle diese Formen.The compounds of the formula I can possess one or more chiral centers and therefore occur in different stereoisomeric forms. Formula I encompasses all these forms.
Besonders bevorzugte Verbindungen der Formel I sind die der Teilformeln IA bis IC: Particularly preferred compounds of the formula I are those of the subformulae IA to IC:
IA -X2-(CR2 2)n-X3-Cy IA -X 2 - (CR 2 2 ) n -X 3 -Cy
IBIB
ICIC
worinwherein
R1, X1, X2, X3, Y1 R2 und Cy die oben angegebenen Bedeutungen aufweisenR 1 , X 1 , X 2 , X 3 , Y 1 R 2 and Cy have the meanings given above
Die Verbindungen der Formel I und auch die Ausgangsstoffe zu ihrer Herstellung werden im übrigen nach an sich bekannten Methoden hergestellt, wie sie in der Literatur (z.B. in den Standardwerken wie Houben-Weyl, Methoden der organischen Chemie, Georg-Thieme-Verlag, Stuttgart) beschrieben sind, und zwar unter Reaktionsbedingungen, die für die genannten Umsetzungen bekannt und geeignet sind. Dabei kann man auch von an sich bekannten, hier nicht näher erwähnten Varianten Gebrauch machen.The compounds of formula I and also the starting materials for their preparation are otherwise prepared by methods known per se, as described in the literature (eg in the standard works such as Houben-Weyl, Methods of Organic Chemistry, Georg-Thieme-Verlag, Stuttgart) are described, under reaction conditions which are known and suitable for the said reactions. One can also make use of known per se, not mentioned here variants.
Die Ausgangsstoffe können, falls erwünscht, auch in situ gebildet werden, so daß man sie aus dem Reaktionsgemisch nicht isoliert, sondern sofort weiter zu den Verbindungen der Formel I umsetzt. Die Umsetzung erfolgt in der Regel in einem inerten Lösungsmittel, bevorzugt in Gegenwart eines Aktivierungsreagenz' wie N-(3- Alkylaminoalkyl)-N'-alkylcarbodiimid, insbesondere N-(3- Dimethylaminopropyl)-N'-ethylcarbodiimid. Die Reaktionszeit liegt je nach den angewendeten Bedingungen zwischen einigen Minuten und 14 Tagen, die Reaktionstemperatur zwischen etwa 0° und 180°, normalerweise zwischen 0° und 100°, besonders bevorzugt zwischen 00C und 70°C.The starting materials may, if desired, also be formed in situ, so that they are not isolated from the reaction mixture, but immediately further reacted to the compounds of formula I. The reaction is generally carried out in an inert solvent, preferably in the presence of an activating reagent, such as N- (3-alkylaminoalkyl) -N'-alkylcarbodiimide, in particular N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide. The reaction time is between a few minutes and 14 days, depending on the conditions used, the reaction temperature between about 0 ° and 180 °, usually between 0 ° and 100 °, more preferably between 0 0 C and 70 ° C.
Als inerte Lösungsmittel eignen sich z.B. Kohlenwasserstoffe wie Hexan, Petrolether, Benzol, Toluol oder XyIoI; chlorierte Kohlenwasserstoffe wie Trichlorethylen, 1 ,2-Dichlorethan,Tetrachlorkohlenstoff, Chloroform oder Dichlormethan oder Gemische der genannten Lösungsmittel.Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane or mixtures of said solvents.
Gewünschtenfalls kann in einer Verbindung der Formel I eine funktionell abgewandelte Amino- und /oder Hydroxygruppe durch Solvolyse oder Hydrogenolyse nach üblichen Methoden in Freiheit gesetzt werden. Dies kann z.B. mit NaOH oder KOH in Wasser, Wasser-THF oder Wasser-Dioxan bei Temperaturen zwischen 0 und 100° erfolgen.If desired, in a compound of the formula I, a functionally modified amino and / or hydroxyl group can be liberated by solvolysis or hydrogenolysis by customary methods. This can e.g. with NaOH or KOH in water, water-THF or water-dioxane at temperatures between 0 and 100 °.
Die Reduktion eines Esters zum Aldehyd oder zum Alkohol, oder die Reduktion eines Nitrils zum Aldehyd oder Amin erfolgt nach Methoden wie sie dem Fachmann bekannt sind und in Standardwerken der organischen Chemie beschrieben sind.The reduction of an ester to the aldehyde or to the alcohol, or the reduction of a nitrile to the aldehyde or amine by methods known in the art and are described in standard works of organic chemistry.
Die genannten erfindungsgemäßen Verbindungen lassen sich in ihrer endgültigen Nichtsalzform verwenden. Andererseits umfaßt die vorliegende Erfindung auch die Verwendung dieser Verbindungen in Form ihrer pharmazeutisch unbedenklichen Salze, die von verschiedenen organischen und anorganischen Säuren und Basen nach fachbekannten Vorgehensweisen abgeleitet werden können. Pharmazeutisch unbedenkliche Salzformen der Verbindungen der Formel I werden größtenteils konventionell hergestellt. Sofern die Verbindung der Formel I eine Carbonsäuregruppe enthält, läßt sich eines ihrer geeigneten Salze dadurch bilden, daß man die Verbindung mit einer geeigneten Base zum entsprechenden Basenadditionssalz umsetzt. Solche Basen sind zum Beispiel Alkalimetallhydroxide, darunter Kaliumhydroxid, Natriumhydroxid und Lithiumhydroxid; Erdalkalimetallhydroxide wie Bariumhydroxid und Calciumhydroxid; Alkalimetallalkoholate, z.B. Kaliumethanolat und Natriumpropanolat; sowie verschiedene organische Basen wie Piperidin, Diethanolamin und N-Methylglutamin. Die Aluminiumsalze der Verbindungen der Formel I zählen ebenfalls dazu. Bei bestimmten Verbindungen der Formel I lassen sich Säureadditionssalze dadurch bilden, daß man diese Verbindungen mit pharmazeutisch unbedenklichen organischen und anorganischen Säuren, z.B. Halogenwasserstoffen wie Chlorwasserstoff, Bromwasserstoff oder Jodwasserstoff, anderen Mineralsäuren und ihren entsprechenden Salzen wie Sulfat, Nitrat oder Phosphat und dergleichen sowie Alkyl- undThe abovementioned compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases according to procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of formula I are for the most part prepared conventionally. If the compound of the formula I contains a carboxylic acid group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base addition salt. Such bases include, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide; Alkali metal alcoholates, eg, potassium ethanolate and sodium propanolate; and various organic bases such as piperidine, diethanolamine and N-methylglutamine. The aluminum salts of the compounds of formula I are also included. In certain compounds of the formula I, acid addition salts can be formed by reacting these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts, such as sulfate, nitrate or phosphate, and the like. and
Monoarylsulfonaten wie Ethansulfonat, Toluolsulfonat und Benzolsulfonat, sowie anderen organischen Säuren und ihren entsprechenden Salzen wie Acetat, Trifluoracetat, Tartrat, Maleat, Succinat, Citrat, Benzoat, Salicylat, Ascorbat und dergleichen behandelt. Dementsprechend zählen zu pharmazeutisch unbedenklichen Säureadditionssalzen der Verbindungen der Formel I die folgenden: Acetat, Adipat, Alginat, Arginat, Aspartat, Benzoat, Benzolsulfonat (Besylat), Bisulfat, Bisulfit, Bromid, Butyrat, Kampferat, Kampfersulfonat, Caprylat, Chlorid, Chlorbenzoat, Citrat, Cyclopentanpropionat, Digluconat, Dihydrogenphosphat, Dinitrobenzoat, Dodecylsulfat, Ethansulfonat, Fumarat, Galacterat (aus Schleimsäure), Galacturonat, Glucoheptanoat, Gluconat, Glutamat, Glycerophosphat, Hemisuccinat, Hemisulfat, Heptanoat, Hexanoat, Hippurat, Hydrochlorid, Hydrobromid, Hydroiodid, 2-Hydroxyethansulfonat, lodid, Isethionat, Isobutyrat, Lactat, Lactobionat, Malat, Maleat, Malonat, Mandelat, Metaphosphat, Methansulfonat, Methylbenzoat, Monohydrogenphosphat, 2- Naphthalinsulfonat, Nicotinat, Nitrat, Oxalat, Oleat, Pamoat, Pectinat, Persulfat, Phenylacetat, 3-Phenylpropionat, Phosphat, Phosphonat, Phthalat, was jedoch keine Einschränkung darstellt.Monoarylsulfonates such as ethane sulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and their corresponding salts such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid addition salts of the compounds of formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate , Cyclopentanepionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate , iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methyl benzoate, monohydrogen phosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, Persulfate, phenyl acetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this is not limiting.
Weiterhin zählen zu den Basensalzen der erfindungsgemäßen Verbindungen Aluminium-, Ammonium-, Calcium-, Kupfer-, Eisen(lll)-,Furthermore, the base salts of the compounds according to the invention include aluminum, ammonium, calcium, copper, iron (III) -,
Eisen(ll)-, Lithium-, Magnesium-, Mangan(lll)-, Mangan(ll), Kalium-, Natrium- und Zinksalze, was jedoch keine Einschränkung darstellen soll. Bevorzugt unter den oben genannten Salzen sind Ammonium; die Alkalimetallsalze Natrium und Kalium, sowie die Erdalkalimetalsalze Calcium und Magnesium. Zu Salzen der Verbindungen der Formel I, die sich von pharmazeutisch unbedenklichen organischen nicht-toxischen Basen ableiten, zählen Salze primärer, sekundärer und tertiärer Amine, substituierter Amine, darunter auch natürlich vorkommender substituierter Amine, cyclischer Amine sowie basischer lonenaustauscherharze, z.B. Arginin, Betain, Koffein, Chlorprocain, Cholin, N.N'-Dibenzylethylendiamin (Benzathin),Iron (II), lithium, magnesium, manganese (III), manganese (II), potassium, sodium and zinc salts, but this is not intended to be limiting. Preferred among the above salts are ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of compounds of formula I derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, e.g. Arginine, betaine, caffeine, chloroprocaine, choline, N.N'-dibenzylethylenediamine (benzathine),
Dicyclohexylamin, Diethanolamin, Diethylamin, 2-Diethylaminoethanol, 2- Dimethylaminoethanol, Ethanolamin, Ethylendiamin, N-Ethylmorpholin, N- Ethylpiperidin, Glucamin, Glucosamin, Histidin, Hydrabamin, Iso-propylamin, Lidocain, Lysin, Meglumin, N-Methyl-D-glucamin, Morpholin, Piperazin, Piperidin, Polyaminharze, Procain, Purine, Theobromin, Triethanolamin, Triethylamin, Trimethylamin, Tripropylamin sowie Tris-(hydroxymethyl)- methylamin (Tromethamin), was jedoch keine Einschränkung darstellen soll.Dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl-D- glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris (hydroxymethyl) methylamine (tromethamine), but this is not intended to be limiting.
Verbindungen der vorliegenden Erfindung, die basische stickstoffhaltige Gruppen enthalten, lassen sich mit Mitteln wie (C1-C4) Alkylhalogeniden, z.B. Methyl-, Ethyl-, Isopropyl- und tert.-Butylchlorid, -bromid und -iodid; Di(Cr C4)Alkylsulfaten, z.B. Dimethyl-, Diethyl- und Diamylsulfat; (Ci0- C18)Alkylhalogeniden, z.B. Decyl-, Dodecyl-, Lauryl-, Myristyl- und Stearylchlorid, -bromid und -iodid; sowie Aryl-(Ci-C4)Alkylhalogeniden, z.B. Benzylchlorid und Phenethylbromid, quarternisieren. Mit solchen Salzen können sowohl wasser- als auch öllösliche erfindungsgemäße Verbindungen hergestellt werden. Zu den oben genannten pharmazeutischen Salzen, die bevorzugt sind, zählen Acetat, Trifluoracetat, Besylat, Citrat, Fumarat, Gluconat, Hemisuccinat, Hippurat, Hydrochlorid, Hydrobromid, Isethionat, Mandelat, Meglumin, Nitrat, Oleat, Phosphonat, Pivalat, Natriumphosphat, Stearat,Compounds of the present invention containing basic nitrogen-containing groups can be reacted with agents such as (C 1 -C 4 ) alkyl halides, eg, methyl, ethyl, isopropyl, and tert-butyl chloride, bromide, and iodide; Di (Cr C 4 ) alkyl sulfates, eg dimethyl, diethyl and diamylsulfate; (Ci 0 - C 18 ) alkyl halides, eg decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl- (C 1 -C 4 ) alkyl halides, eg benzyl chloride and phenethyl bromide, quaternize. With such salts, both water- and oil-soluble compounds of the invention can be prepared. Preferred pharmaceutical salts include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate,
Sulfat, Sulfosalicylat, Tartrat, Thiomalat, Tosylat und Tromethamin, was jedoch keine Einschränkung darstellen soll.Sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, which is not intended to be limiting.
Die Säureadditionssalze basischer Verbindungen der Formel I werden dadurch hergestellt, daß man die freie Basenform mit einer ausreichenden Menge der gewünschten Säure in Kontakt bringt, wodurch man auf übliche Weise das Salz darstellt. Die freie Base läßt sich durch In-Kontakt-Bringen der Salzform mit einer Base und Isolieren der freien Base auf übliche Weise regenerieren. Die freien Basenformen unterscheiden sich in gewissem Sinn von ihren entsprechenden Salzformen in bezug auf bestimmte physikalische Eigenschaften wie Löslichkeit in polaren Lösungsmitteln; im Rahmen der Erfindung entsprechen die Salze jedoch sonst ihren jeweiligen freien Basenformen.The acid addition salts of basic compounds of formula I are prepared by contacting the free base form with a sufficient amount of the desired acid to form the salt in a conventional manner. The free base can be regenerated by contacting the salt form with a base and isolating the free base in a conventional manner. The free base forms in some sense differ from their corresponding salt forms in terms of certain physical properties such as solubility in polar solvents; however, in the context of the invention, the salts otherwise correspond to their respective free base forms.
Wie erwähnt werden die pharmazeutisch unbedenklichen Basenadditionssalze der Verbindungen der Formel I mit Metallen oder Aminen wie Alkalimetallen und Erdalkalimetallen oder organischen Aminen gebildet. Bevorzugte Metalle sind Natrium, Kalium, Magnesium und Calcium. Bevorzugte organische Amine sind N,N'-Dibenzylethylendiamin, Chlorprocain, Cholin, Diethanolamin, Ethylendiamin, N-Methyl-D-glucamin und Procain.As mentioned, the pharmaceutically acceptable base addition salts of the compounds of formula I are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.
Die Basenadditionssalze von erfindungsgemäßen sauren Verbindungen werden dadurch hergestellt, daß man die freie Säureform mit einer ausreichenden Menge der gewünschten Base in Kontakt bringt, wodurch man das Salz auf übliche Weise darstellt. Die freie Säure läßt sich durch In- Kontakt-Bringen der Salzform mit einer Säure und Isolieren der freien Säure auf übliche Weise regenerieren. Die freien Säure formen unterscheiden sich in gewissem Sinn von ihren entsprechenden Salzformen in bezug auf bestimmte physikalische Eigenschaften wie Löslichkeit in polaren Lösungsmitteln; im Rahmen der Erfindung entsprechen die Salze jedoch sonst ihren jeweiligen freien Säureformen.The base addition salts of acidic compounds of the invention are prepared by contacting the free acid form with a sufficient amount of the desired base to form the salt in a conventional manner. The free acid can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. The free acid forms differ in a sense, their corresponding salt forms with respect to certain physical properties such as solubility in polar solvents; However, in the context of the invention, the salts otherwise correspond to their respective free acid forms.
Enthält eine erfindungsgemäße Verbindung mehr als eine Gruppe, die solche pharmazeutisch unbedenklichen Salze bilden kann, so umfaßt die Erfindung auch mehrfache Salze. Zu typischen mehrfachen Salzformen zählen zum Beispiel Bitartrat, Diacetat, Difumarat, Dimeglumin, Diphosphat, Dinatrium und Trihydrochlorid, was jedoch keine Einschränkung darstellen soll.If a compound according to the invention contains more than one group which can form such pharmaceutically acceptable salts, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to be limiting.
Im Hinblick auf das oben Gesagte sieht man, daß unter dem Ausdruck "pharmazeutisch unbedenkliches Salz" im vorliegenden Zusammenhang ein Wirkstoff zu verstehen ist, der eine Verbindung der Formel I in der Form eines ihrer Salze enthält, insbesondere dann, wenn diese Salzform dem Wirkstoff im Vergleich zu der freien Form des Wirkstoffs oder irgendeiner anderen Salzform des Wirkstoffs, die früher verwendet wurde, verbesserte pharmakokinetische Eigenschaften verleiht. Die pharmazeutisch unbedenkliche Salzform des Wirkstoffs kann auch diesem Wirkstoff erst eine gewünschte pharmakokinetische Eigenschaft verleihen, über die er früher nicht verfügt hat, und kann sogar die Pharmakodynamik dieses Wirkstoffs in bezug auf seine therapeutische Wirksamkeit im Körper positiv beeinflussen.In view of the above, it can be seen that the term "pharmaceutically acceptable salt" in the present context means an active ingredient which contains a compound of the formula I in the form of one of its salts, especially if this salt form is the active ingredient in the Imparts improved pharmacokinetic properties to the free form of the active ingredient or any other salt form of the active ingredient which has previously been used. The pharmaceutically acceptable salt form of the active substance may also first impart a desired pharmacokinetic property to this active ingredient which it has not previously possessed, and may even positively influence the pharmacodynamics of this active ingredient in terms of its therapeutic activity in the body.
Gegenstand der Erfindung sind femer Arzneimittel, enthaltend mindestens eine Verbindung der Formel I und/oder ihre pharmazeutisch verwendbaren Derivate, Solvate und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, sowie gegebenenfalls Träger- und/oder Hilfsstoffe.The invention furthermore relates to medicaments comprising at least one compound of the formula I and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and / or adjuvants.
Pharmazeutische Formulierungen können in Form von Dosiseinheiten, die eine vorbestimmte Menge an Wirkstoff pro Dosiseinheit enthalten, dargereicht werden. Eine solche Einheit kann beispielsweise 0,5 mg bis 1 g, vorzugsweise 1 mg bis 700 mg, besonders bevorzugt 5 mg bis 100 mg einer erfindungsgemäßen Verbindung enthalten, je nach dem behandelten Krankheitszustand, dem Verabreichungsweg und dem Alter, Gewicht und Zustand des Patienten, oder pharmazeutische Formulierungen können in Form von Dosiseinheiten, die eine vorbestimmte Menge an Wirkstoff proPharmaceutical formulations may be presented in the form of dosage units containing a predetermined amount of active ingredient per unit dose. Such a unit may for example be 0.5 mg to 1 g, preferably from 1 mg to 700 mg, more preferably from 5 mg to 100 mg of a compound of the invention, depending on the disease condition being treated, the route of administration and the age, weight and condition of the patient, or pharmaceutical formulations may be in the form of dosage units containing a predetermined amount of active ingredient per
Dosiseinheit enthalten, dargereicht werden. Bevorzugte Dosierungseinheits- formulierungen sind solche, die eine Tagesdosis oder Teildosis, wie oben angegeben, oder einen entsprechenden Bruchteil davon eines Wirkstoffs enthalten. Weiterhin lassen sich solche pharmazeutischen Formulierungen mit einem der im pharmazeutischen Fachgebiet allgemein bekannten Verfahren herstellen.Dose unit included, to be presented. Preferred unit dosage formulations are those containing a daily or partial dose as indicated above or a corresponding fraction thereof of an active ingredient. Furthermore, such pharmaceutical formulations can be prepared by any of the methods well known in the pharmaceutical art.
Pharmazeutische Formulierungen lassen sich zur Verabreichung über einen beliebigen geeigneten Weg, beispielsweise auf oralem (einschließlich buccalem bzw. sublingualem), rektalem, nasalem, topischem (einschließlich buccalem, sublingualem oder transdermalem), vaginalem oder parenteralem (einschließlich subkutanem, intramuskulärem, intravenösem oder intradermalem) Wege, anpassen. Solche Formulierungen können mit allen im pharmazeutischen Fachgebiet bekannten Verfahren hergestellt werden, indem beispielsweise der Wirkstoff mit dem bzw. den Trägerstoff(en) oder Hilfsstoff(en) zusammengebracht wird.Pharmaceutical formulations may be administered by any suitable route, for example, oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal). Ways, adapt. Such formulations can be prepared by any method known in the pharmaceutical art, for example, by bringing the active ingredient together with the carrier (s) or excipient (s).
An die orale Verabreichung angepaßte pharmazeutische Formulierungen können als separate Einheiten, wie z.B. Kapseln oder Tabletten; Pulver oder Granulate; Lösungen oder Suspensionen in wäßrigen oder nichtwäßrigen Flüssigkeiten; eßbare Schäume oder Schaumspeisen; oder Öl-in-Wasser- Flüssigemulsionen oder Wasser-in-Ö!-Flüssigemulsionen dargereicht werden.Pharmaceutical formulations adapted for oral administration may be administered as separate units, e.g. Capsules or tablets; Powder or granules; Solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
So läßt sich beispielsweise bei der oralen Verabreichung in Form einer Tablette oder Kapsel die Wirkstoffkomponente mit einem oralen, nichttoxischen und pharmazeutisch unbedenklichen inerten Trägerstoff, wie z.B. Ethanol, Glyzerin, Wasser u.a. kombinieren. Pulver werden hergestellt, indem die Verbindung auf eine geeignete feine Größe zerkleinert und mit einem in ähnlicher Weise zerkleinerten pharmazeutischen Trägerstoff, wie z.B. einem eßbaren Kohlenhydrat wie beispielsweise Stärke oder Mannit vermischt wird. Ein Geschmacksstoff, Konservierungsmittel, Dispersionsmittel und Farbstoff können ebenfalls vorhanden sein.Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active ingredient component can be mixed with an oral, non-toxic and pharmaceutically acceptable inert carrier, such as Ethanol, glycerine, water, etc. combine. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate such as starch or mannitol. A flavor, preservative, dispersant and dye may also be present.
Kapseln werden hergestellt, indem ein Pulvergemisch wie oben beschrieben hergestellt und geformte Gelatinehüllen damit gefüllt werden. Gleit- und Schmiermittel wie z.B. hochdisperse Kieselsäure, Talkum, Magnesium- stearat, Kalziumstearat oder Polyethylenglykol in Festform können dem Pulvergemisch vor dem Füllvorgang zugesetzt werden. Ein Sprengmittel oder Lösungsvermittler, wie z.B. Agar-Agar, Kalziumcarbonat oder Natriumcarbonat, kann ebenfalls zugesetzt werden, um die Verfügbarkeit des Medikaments nach Einnahme der Kapsel zu verbessern.Capsules are made by preparing a powder mix as described above and filling shaped gelatin casings therewith. Lubricants such as e.g. highly disperse silica, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form can be added to the powder mixture before the filling process. A disintegrants or solubilizers, e.g. Agar-agar, calcium carbonate or sodium carbonate may also be added to improve the availability of the drug after ingestion of the capsule.
Außerdem können, falls gewünscht oder notwendig, geeignete Bindungs-, Schmier- und Sprengmittel sowie Farbstoffe ebenfalls in das Gemisch eingearbeitet werden. Zu den geeigneten Bindemitteln gehören Stärke, Gelatine, natürliche Zucker, wie z.B. Glukose oder Beta-Lactose, Süßstoffe aus Mais, natürliche und synthetische Gummi, wie z.B. Akazia, Traganth oder Natriumalginat, Carboxymethylzellulose, Polyethylenglykol, Wachse, u.a. Zu den in diesen Dosierungsformen verwendeten Schmiermitteln gehören Natriumoleat, Natriumstearat, Magnesiumstearat, Natriumbenzoat, Natriumacetat, Natriumchlorid u.a. Zu den Sprengmitteln gehören, ohne darauf beschränkt zu sein, Stärke, Methylzellulose, Agar, Bentonit, Xanthangummi u.a. Die Tabletten werden formuliert, indem beispielsweise ein Pulvergemisch hergestellt, granuliert oder trockenverpreßt wird, ein Schmiermittel und ein Sprengmittel zugegeben werden und das Ganze zu Tabletten verpreßt wird. Ein Pulvergemisch wird hergestellt, indem die in geeigneter Weise zerkleinerte Verbindung mit einem Verdünnungsmittel oder einer Base, wie oben beschrieben, und gegebenenfalls mit einem Bindemittel, wie z.B. Carboxymethylzellulose, einem Alginat, Gelatine oder Polyvinylpyrrolidon, einem Lösungsverlangsamer, wie z.B. Paraffin, einem Resorptionsbeschleuniger, wie z.B. einem quatemären Salz und/oder einem Absorptionsmittel, wie z.B. Bentonit, Kaolin oder Dikalziumphosphat, vermischt wird. Das Pulvergemisch läßt sich granulieren, indem es mit einemIn addition, if desired or necessary, suitable binding, lubricating and disintegrants as well as dyes can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, etc. Among those used in these dosage forms Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. The disintegrating agents include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry pressing , a lubricant and a disintegrant are added and the whole is compressed into tablets. A powder mixture is prepared by treating the appropriately comminuted compound with a diluent or a base as described above, and optionally with a Binders such as carboxymethyl cellulose, an alginate, gelatin or polyvinylpyrrolidone, a Lösungsverlangsamer such as paraffin, a absorption accelerator such as a quaternary salt and / or an absorbent, such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by adding a
Bindemittel, wie z.B. Sirup, Stärkepaste, Acadia-Schleim oder Lösungen aus Zellulose- oder Polymermaterialen benetzt und durch ein Sieb gepreßt wird. Als Alternative zur Granulierung kann man das Pulvergemisch durch eine Tablettiermaschine laufen lassen, wobei ungleichmäßig geformte Klumpen entstehen, die in Granulate aufgebrochen werden. Die Granulate können mittels Zugabe von Stearinsäure, einem Stearatsalz, Talkum oder Mineralöl gefettet werden, um ein Kleben an den Tablettengußformen zu verhindern. Das gefettete Gemisch wird dann zu Tabletten verpreßt. Die erfindungsgemäßen Verbindungen können auch mit einem freifließenden inerten Trägerstoff kombiniert und dann ohne Durchführung der Granulierungs- oder Trockenverpressungsschritte direkt zu Tabletten verpreßt werden. Eine durchsichtige oder undurchsichtige Schutzschicht, bestehend aus einer Versiegelung aus Schellack, einer Schicht aus Zucker oder Polymermaterial und einer Glanzschicht aus Wachs, kann vorhanden sein. Diesen Beschichtungen können Farbstoffe zugesetzt werden, um zwischen unterschiedlichen Dosierungseinheiten unterscheiden zu können.Binders, such as e.g. Syrup, starch paste, Acadia slime or solutions of cellulose or polymer materials wetted and pressed through a sieve. As an alternative to granulation, the powder mixture can be run through a tabletting machine to produce non-uniformly shaped lumps which are broken up into granules. The granules may be greased by the addition of stearic acid, a stearate salt, talc or mineral oil to prevent sticking to the tablet molds. The greased mixture is then compressed into tablets. The compounds according to the invention can also be combined with a free-flowing inert carrier and then pressed directly into tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealant, a layer of sugar or polymeric material, and a glossy layer of wax may be present. Dyes can be added to these coatings in order to differentiate between different dosage units.
Orale Flüssigkeiten, wie z.B. Lösung, Sirupe und Elixiere, können in Form von Dosierungseinheiten hergestellt werden, so daß eine gegebene Quantität eine vorgegebene Menge der Verbindung enthält. Sirupe lassen sich herstellen, indem die Verbindung in einer wäßrigen Lösung mit geeignetem Geschmack gelöst wird, während Elixiere unter Verwendung eines nichttoxischen alkoholischen Vehikels hergestellt werden. Suspensionen können durch Dispersion der Verbindung in einem nicht- toxischen Vehikel formuliert werden. Lösungsvermittler und Emulgiermittel, wie z.B. ethoxylierte Isostearylalkohole und Polyoxyethylensorbitolether, Konservierungsmittel, Geschmackszusätze, wie z.B. Pfefferminzöl oder natürliche Süßstoffe oder Saccharin oder andere künstliche Süßstoffe, u.a. können ebenfalls zugegeben werden.Oral fluids such as solution, syrups and elixirs may be prepared in unit dosage form such that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in an appropriate taste aqueous solution while preparing elixirs using a non-toxic alcoholic vehicle. Suspensions may be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavoring additives, such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, among others may also be added.
Die Dosierungseinheitsformulierungen für die orale Verabreichung können gegebenenfalls in Mikrokapseln eingeschlossen werden. Die Formulierung läßt sich auch so herstellen, daß die Freisetzung verlängert oder retardiert wird, wie beispielsweise durch Beschichtung oder Einbettung von partikulärem Material in Polymere, Wachs u.a.The unit dosage formulations for oral administration may optionally be encapsulated in microcapsules. The formulation may also be prepared to prolong or retard release, such as by coating or embedding particulate material in polymers, wax, and the like.
Die Verbindungen der Formel I sowie Salze, Solvate und physiologisch funktionelle Derivate davon lassen sich auch in Form von Liposomen- zuführsystemen, wie z.B. kleinen unilamellaren Vesikeln, großen unilamellaren Vesikeln und multilamellaren Vesikeln, verabreichen. Liposomen können aus verschiedenen Phospholipiden, wie z.B. Cholesterin, Stearylamin oder Phosphatidylcholinen, gebildet werden.The compounds of formula I as well as salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as e.g. small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be prepared from various phospholipids, such as e.g. Cholesterol, stearylamine or phosphatidylcholines.
Die Verbindungen der Formel I sowie die Salze, Solvate und physiologisch funktionellen Derivate davon können auch unter Verwendung monoklonaler Antikörper als individuelle Träger, an die die Verbindungsmoleküle gekoppelt werden, zugeführt werden. Die Verbindungen können auch mit löslichen Polymeren als zielgerichtete Arzneistoffträger gekoppelt werden. Solche Polymere können Polyvinylpyrrolidon, Pyran-Copolymer, Polyhydroxypropyl- methacrylamidphenol, Polyhydroxyethylaspartamidphenol oder Polyethylenoxidpolylysin, substituiert mit Palmitoylresten, umfassen. Weiterhin können die Verbindungen an eine Klasse von biologisch abbaubaren Polymeren, die zur Erzielung einer kontrollierten Freisetzung eines Arzneistoffs geeignet sind, z.B. Polymilchsäure, Polyepsilon-Caprolacton, Polyhydroxybuttersäure, Polyorthoester, Polyacetale, Polydihydroxypyrane, Polycyanoacrylate und quervernetzte oder amphipatische Blockcopolymere von Hydrogelen, gekoppelt sein. An die transdermale Verabreichung angepaßte pharmazeutische Formulierungen können als eigenständige Pflaster für längeren, engen Kontakt mit der Epidermis des Empfängers dargereicht werden. So kann beispielsweise der Wirkstoff aus dem Pflaster mittels lontophorese zugeführt werden, wie in Pharmaceutical Research, 3(6), 318 (1986) allgemein beschrieben.The compounds of formula I as well as the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled with soluble polymers as targeted drug carriers. Such polymers may include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol or polyethyleneoxidepolylysine substituted with palmitoyl radicals. Further, the compounds may be coupled to a class of biodegradable polymers suitable for controlled release of a drug, eg, polylactic acid, polyepsilone-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates, and crosslinked or amphipathic block copolymers of hydrogels. Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches for prolonged, intimate contact with the epidermis of the recipient. For example, the drug may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3 (6), 318 (1986).
An die topische Verabreichung angepaßte pharmazeutische Verbindungen können als Salben, Cremes, Suspensionen, Lotionen, Pulver, Lösungen, Pasten, Gele, Sprays, Aerosole oder Öle formuliert sein.Pharmaceutical compounds adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
Für Behandlungen des Auges oder anderer äußerer Gewebe, z.B. Mund und Haut, werden die Formulierungen vorzugsweise als topische Salbe oder Creme appliziert. Bei Formulierung zu einer Salbe kann der Wirkstoff entweder mit einer paraffinischen oder einer mit Wasser mischbarenFor treatments of the eye or other external tissues, e.g. Mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated into an ointment, the active ingredient may be either paraffinic or water-miscible
Cremebasis eingesetzt werden. Alternativ kann der Wirkstoff zu einer Creme mit einer Öl-in-Wasser-Cremebasis oder einer Wasser-in-ÖI-Basis formuliert werden.Cream base can be used. Alternatively, the active ingredient can be formulated into a cream with an oil-in-water cream base or a water-in-oil base.
Zu den an die topische Applikation am Auge angepaßten pharmazeutischen Formulierungen gehören Augentropfen, wobei der Wirkstoff in einem geeigneten Träger, insbesondere einem wäßrigen Lösungsmittel, gelöst oder suspendiert ist.The pharmaceutical formulations adapted for topical application to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
An die topische Applikation im Mund angepaßte pharmazeutischeTo the topical application in the mouth adapted pharmaceutical
Formulierungen umfassen Lutschtabletten, Pastillen und Mundspülmittel.Formulations include lozenges, lozenges and mouthwashes.
An die rektale Verabreichung angepaßte pharmazeutische Formulierungen können in Form von Zäpfchen oder Einlaufen dargereicht werden.Pharmaceutical formulations adapted for rectal administration may be presented in the form of suppositories or enemas.
An die nasale Verabreichung angepaßte pharmazeutische Formulierungen, in denen die Trägersubstanz ein Feststoff ist, enthalten ein grobes Pulver mit einer Teilchengröße beispielsweise im Bereich von 20-500 Mikrometern, das in der Art und Weise, wie Schnupftabak aufgenommen wird, verabreicht wird, d.h. durch Schnellinhalation über die Nasenwege aus einem dicht an die Nase gehaltenen Behälter mit dem Pulver. Geeignete Formulierungen zur Verabreichung als Nasenspray oder Nasentropfen mit einer Flüssigkeit als Trägersubstanz umfassen Wirkstofflösungen in Wasser oder Öl.Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid contain a coarse powder a particle size, for example, in the range of 20-500 microns, which is administered in the manner in which snuff is taken, ie by rapid inhalation via the nasal passages from a container held close to the nose with the powder. Suitable formulations for administration as a nasal spray or nasal drops with a liquid carrier include drug solutions in water or oil.
An die Verabreichung durch Inhalation angepaßte pharmazeutische Formulierungen umfassen feinpartikuläre Stäube oder Nebel, die mittels verschiedener Arten von unter Druck stehenden Dosierspendern mit Aerosolen, Verneblern oder Insufflatoren erzeugt werden können.Pharmaceutical formulations adapted for administration by inhalation include fine particulate dusts or mists which may be generated by various types of pressurized dosing dispensers with aerosols, nebulizers or insufflators.
An die vaginale Verabreichung angepaßte pharmazeutische Formulierungen können als Pessare, Tampons, Cremes, Gele, Pasten, Schäume oder Sprayformulierungen dargereicht werden.Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
Zu den an die parenterale Verabreichung angepaßten pharmazeutischen Formulierungen gehören wäßrige und nichtwäßrige sterile Injektionslösungen, die Antioxidantien, Puffer, Bakteriostatika und Solute, durch die die Formulierung isotonisch mit dem Blut des zu behandelnden Empfängers gemacht wird, enthalten; sowie wäßrige und nichtwäßrige sterile Suspensionen, die Suspensionsmittel und Verdicker enthalten können. Die Formulierungen können in Einzeldosis- oder Mehrfachdosisbehältern, z.B. versiegelten Ampullen und Fläschchen, dargereicht und in gefriergetrocknetem (lyophilisiertem) Zustand gelagert werden, so daß nur die Zugabe der sterilen Trägerflüssigkeit, z.B. Wasser für Injektionszwecke, unmittelbar vor Gebrauch erforderlich ist. Rezepturmäßig hergestellte Injektionslösungen und Suspensionen können aus sterilen Pulvern, Granulaten und Tabletten hergestellt werden.Pharmaceutical formulations adapted for parenteral administration include aqueous and nonaqueous sterile injection solutions containing antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions which may contain suspending agents and thickeners. The formulations may be administered in single or multiple dose containers, e.g. sealed vials and vials, and stored in the freeze-dried (lyophilized) state so that only the addition of the sterile carrier liquid, e.g. Water for injections, needed immediately before use. Injection solutions and suspensions prepared by formulation can be prepared from sterile powders, granules and tablets.
Es versteht sich, daß die Formulierungen neben den obigen besonders erwähnten Bestandteilen andere im Fachgebiet übliche Mittel mit Bezug auf die jeweilige Art der Formulierung enthalten können; so können beispielsweise für die orale Verabreichung geeignete Formulierungen Geschmacksstoffe enthalten.It is understood that the formulations in addition to the above-mentioned particularly mentioned constituents other conventional means with respect to may contain the particular type of formulation; for example, formulations suitable for oral administration may contain flavorings.
Eine therapeutisch wirksame Menge einer Verbindung der Formel I hängt von einer Reihe von Faktoren ab, einschließlich z.B. dem Alter und Gewicht des Tiers, dem exakten Krankheitszustand, der der Behandlung bedarf, sowie seines Schweregrads, der Beschaffenheit der Formulierung sowie dem Verabreichungsweg, und wird letztendlich von dem behandelnden Arzt bzw. Tierarzt festgelegt. Jedoch liegt eine wirksame Menge einer erfindungsgemäßen Verbindung für die Behandlung von neoplastischem Wachstum, z.B. Dickdarm- oder Brustkarzinom, im allgemeinen im Bereich von 0,1 bis 100 mg/kg Körpergewicht des Empfängers (Säugers) pro Tag und besonders typisch im Bereich von 1 bis 10 mg/kg Körpergewicht pro Tag. Somit läge für einen 70 kg schweren erwachsenen Säuger die tatsächliche Menge pro Tag für gewöhnlich zwischen 70 und 700 mg, wobei diese Menge als Einzeldosis pro Tag oder üblicher in einer Reihe von Teildosen (wie z.B. zwei, drei, vier, fünf oder sechs) pro Tag gegeben werden kann, so daß die Gesamttagesdosis die gleiche ist. Eine wirksame Menge eines Salzes oder Solvats oder eines physiologisch funktionellen Derivats davon kann als Anteil der wirksamen Menge der erfindungsgemäßen Verbindung perse bestimmt werden. Es läßt sich annehmen, daß ähnliche Dosierungen für die Behandlung der anderen, obenerwähnten Krankheitszustände geeignet sind.A therapeutically effective amount of a compound of formula I depends on a number of factors, including e.g. the age and weight of the animal, the exact condition of the disease requiring treatment, as well as its severity, the nature of the formulation and the route of administration, and is ultimately determined by the attending physician or veterinarian. However, an effective amount of a compound of the invention is useful for the treatment of neoplastic growth, e.g. Colon or breast carcinoma, generally in the range of 0.1 to 100 mg / kg body weight of the recipient (mammal) per day and more typically in the range of 1 to 10 mg / kg body weight per day. Thus, for a 70 kg adult mammal, the actual amount per day would usually be between 70 and 700 mg, this amount being given as a single dose per day or more commonly in a number of divided doses (such as two, three, four, five or six) per Day can be given so that the total daily dose is the same. An effective amount of a salt or solvate or a physiologically functional derivative thereof can be determined as a proportion of the effective amount of the compound of the invention per se. It can be assumed that similar dosages are suitable for the treatment of the other, above-mentioned disease states.
Gegenstand der Erfindung sind ferner Arzneimittel enthaltend mindestens eine Verbindung der Formel I und/oder ihre pharmazeutisch verwendbaren Derivate, Solvate und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, und mindestens einen weiteren Arzneimittelwirkstoff.The invention furthermore relates to medicaments comprising at least one compound of the formula I and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further active pharmaceutical ingredient.
Gegenstand der Erfindung ist auch ein Set (Kit), bestehend aus getrennten Packungen von (a) einer wirksamen Menge an einer Verbindung der Formel I und/oder ihrer pharmazeutisch verwendbaren Derivate, Solvate und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, undThe invention is also a set (kit), consisting of separate packages of (A) an effective amount of a compound of formula I and / or its pharmaceutically acceptable derivatives, solvates and stereoisomers, including mixtures thereof in all proportions, and
(b) einer wirksamen Menge eines weiteren Arzneimittelwirkstoffs.(b) an effective amount of another drug.
Das Set enthält geeignete Behälter, wie Schachteln oder Kartons, individuelle Flaschen, Beutel oder Ampullen. Das Set kann z.B. separate Ampullen enthalten, in denen jeweils eine wirksame Menge an einer Verbindung der Formel I und/oder ihrer pharmazeutisch verwendbaren Derivate, Solvate und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen, und einer wirksamen Menge eines weiteren Arzneimittelwirkstoffs gelöst oder in lyophilisierter Form vorliegt.The kit contains suitable containers, such as boxes or boxes, individual bottles, bags or ampoules. The set may e.g. containing separate ampoules in each of which an effective amount of a compound of formula I and / or its pharmaceutically acceptable derivatives, solvates and stereoisomers, including mixtures thereof in all proportions, and an effective amount of another drug substance is dissolved or in lyophilized form.
Bevorzugt aber nicht ausschliesslich werden die Arzneimittel der Tabelle 1 mit den Verbindungen der Formel I kombiniert. Eine Kombination der Formel I und Arzneimitteln der Tabelle 1 kann auch mit Verbindungen der Formel V kombiniert werden.Preferably, but not exclusively, the medicaments of Table 1 are combined with the compounds of the formula I. A combination of formula I and drugs of Table 1 can also be combined with compounds of formula V.
Tabelle 1.Table 1.
Alkylierungsmittel Cyclophosphamid LomustinAlkylating agent Cyclophosphamide Lomustine
Busulfan ProcarbazinBusulfan procarbazine
Ifosfamid AltretaminIfosfamide altretamine
Melphalan EstramustinphosphatMelphalan estramustin phosphate
Hexamethylmelamin MechlorethaminHexamethylmelamine mechlorethamine
Thiotepa StreptozocinThiotepa streptozocin
Chlorambucil TemozolomidChlorambucil Temozolomide
Dacarbazin SemustinDacarbazine Semustin
Carmustincarmustine
Platinmittel Cisplatin CarboplatinPlatinum agent cisplatin carboplatin
Oxaliplatin ZD-0473 (AnorMED)Oxaliplatin ZD-0473 (AnorMED)
Spiroplatin Lobaplatin (Aetema)Spiroplatin Lobaplatin (Aetema)
Carboxyphthalatoplatinum Satraplatin (JohnsonCarboxyphthalatoplatinum Satraplatin (Johnson
Tetraplatin Matthey)Tetraplatinum Matthey)
Ormiplatin BBR-3464 (Hoffrnann-LaOrmiplatin BBR-3464 (Hoffrnann-La
Iproplatin Roche) SM-11355 (Sumitomo)Iproplatin Roche) SM-11355 (Sumitomo)
AP-5280 (Access)AP-5280 (Access)
Antimetabolite Azacytidin TomudexAntimetabolite azacytidine Tomudex
Gemcitabin TrimetrexateGemcitabine trimetrexate
Capecitabin DeoxycoformycinCapecitabine deoxycoformycin
5-Fluoruracil Fludarabin5-fluorouracil fludarabine
Floxuridin PentostatinFloxuridine pentostatin
2-Chlordesoxyadenosin Raltitrexed2-chlorodeoxyadenosine Raltitrexed
6-Mercaptopurin Hydroxyharnstoff6-mercaptopurine hydroxyurea
6-Thioguanin Decitabin (SuperGen)6-thioguanine decitabine (SuperGen)
Cytarabin Clofarabin (Bioenvision)Cytarabine Clofarabine (Bioenvision)
2-Fluordesoxycytidin Irofulven (MGI Pharma)2-Fluorodeoxycytidine Irofulvene (MGI Pharma)
Methotrexat DMDC (Hoffmann-LaMethotrexate DMDC (Hoffmann-La
Idatrexate Roche)Idatrexate Roche)
Ethinylcytidin (Taiho )Ethinylcytidine (Taiho)
Topoisomerase- Amsacrin Rubitecan (SuperGen)Topoisomerase Amsacrine Rubitecane (SuperGen)
Inhibitoren Epirubicin Exatecanmesylat (Daiichi)Inhibitors Epirubicin Exatecan Mesylate (Daiichi)
Etoposid Quinamed (ChemGenex)Etoposide Quinamed (ChemGenex)
Teniposid oder Gimatecan (Sigma- Tau)Teniposide or Gimatecan (Sigma-Tau)
Mitoxantron Diflomotecan (Beaufour- lrinotecan (CPT-11) Ipsen)Mitoxantrone diflomotecan (Beaufourrinotecan (CPT-11) Ipsen)
7-Ethyl-10- TAS-103 (Taiho) hydroxycamptothecin Elsamitrucin (Spectrum)7-Ethyl-10-TAS-103 (Taiho) hydroxycamptothecin Elsamitrucine (Spectrum)
Topotecan J-107088 (Merck & Co)Topotecan J-107088 (Merck & Co)
Dexrazoxanet BNP-1350 (BioNumerik)Dexrazoxanet BNP-1350 (BioNumerik)
(TopoTarget) CKD-602 (Chong Kun(TopoTarget) CKD-602 (Chong Kun
Pixantron (Novuspharrna) Dang)Pixantron (Novuspharrna) Dang)
Rebeccamycin-Analogon KW-2170 (Kyowa Hakko)Rebeccamycin analog KW-2170 (Kyowa Hakko)
(Exelixis)(Exelixis)
BBR-3576 (Novuspharrna)BBR-3576 (Novuspharrna)
Antitumor- Dactinomycin (Actinomycin AmonafidAntitumor Dactinomycin (Actinomycin Amonafide
Antibiotika D) AzonafidAntibiotics D) Azonafide
Doxorubicin (Adriamycin) AnthrapyrazolDoxorubicin (adriamycin) anthrapyrazole
Deoxyrubicin OxantrazolDeoxyrubicin Oxantrazole
Valrubicin LosoxantronValrubicin losoxantrone
Daunorubicin BleomycinsulfatDaunorubicin bleomycin sulfate
(Daunomycin) (Blenoxan)(Daunomycin) (Blenoxan)
Epirubicin BleomycinsäureEpirubicin bleomycinic acid
Therarubicin Bleomycin ATherarubicin Bleomycin A
Idarubicin Bleomycin BIdarubicin bleomycin B
Rubidazon Mitomycin CRubidazone mitomycin C
Plicamycinp MEN-10755 (Menarini)Plicamycin p MEN-10755 (Menarini)
Porfiromycin GPX-100 (GemPorfiromycin GPX-100 (gem
Cyanomorpholinodoxorubi Pharmaceuticals) ein Mitoxantron (Novantron)Cyanomorpholinodoxorubi Pharmaceuticals) Mitoxantrone (Novantrone)
Antimitotische Paclitaxel SB 408075Antimitotic Paclitaxel SB 408075
Mittel Docetaxel (GlaxoSmithKline)Agent Docetaxel (GlaxoSmithKline)
Colchicin E7010 (Abbott)Colchicine E7010 (Abbott)
Vinblastin PG-TXL (CellVinblastine PG-TXL (Cell
Vincristin Therapeutics)Vincristin Therapeutics)
Vinorelbin IDN 5109 (Bayer)Vinorelbine IDN 5109 (Bayer)
Vindesin A 105972 (Abbott)Vindesin A 105972 (Abbott)
Dolastatin 10 (NCI) A 204197 (Abbott)Dolastatin 10 (NCI) A 204197 (Abbott)
Rhizoxin (Fujisawa) LU 223651 (BASF)Rhizoxin (Fujisawa) LU 223651 (BASF)
Mivobulin (Warner- D 24851 (ASTA Medica)Mivobulin (Warner-D 24851 (ASTA Medica)
Lambert) ER-86526 (Eisai)Lambert) ER-86526 (Eisai)
Cemadotin (BASF) Combretastatin A4 (BMS)Cemadotin (BASF) Combretastatin A4 (BMS)
RPR 109881A (Aventis) Isohomohalichondrin-BRPR 109881A (Aventis) isohomohalichondrin-B
TXD 258 (Aventis) (PharmaMar)TXD 258 (Aventis) (PharmaMar)
Epothilon B (Novartis) ZD 6126 (AstraZeneca)Epothilone B (Novartis) ZD 6126 (AstraZeneca)
T 900607 (Tularik) PEG-Paclitaxel (Enzon)T 900607 (Tularik) PEG paclitaxel (Enzon)
T 138067 (Tularik) AZ10992 (Asahi)T 138067 (Tularik) AZ10992 (Asahi)
Cryptophycin 52 (EIi Lilly) !DN-5109 (lndena)Cryptophycin 52 (Eli Lilly)! DN-5109 (lndena)
Vinflunin (Fabre) AVLB (PrescientVinflunin (Fabre) AVLB (Prescient
Auristatin PE (Teikoku NeuroPharma)Auristatin PE (Teikoku NeuroPharma)
Hormone) Azaepothilon B (BMS)Hormones) azaepothilone B (BMS)
BMS 247550 (BMS) BNP- 7787 (BioNumerik)BMS 247550 (BMS) BNP-7787 (BioNumerik)
BMS 184476 (BMS) CA-4-Prodrug (OXiGENE)BMS 184476 (BMS) CA-4 prodrug (OXiGENE)
BMS 188797 (BMS) Dolastatin-10 (NrH)BMS 188797 (BMS) Dolastatin-10 (NrH)
Taxoprexin (Protarga) CA-4 (OXiGENE)Taxoprexin (Protarga) CA-4 (OXiGENE)
Aromatase- Aminoglutethimid ExemestanAromatase-aminoglutethimide exemestane
Inhibitoren Letrozol Atamestan (BioMedicines)Inhibitors Letrozole Atamestane (BioMedicines)
Anastrazol YM-511 (Yamanouchi)Anastrazole YM-511 (Yamanouchi)
Formestanformestane
Thymidylatsyntha Pemetrexed (EIi Lilly) Nolatrexed (Eximias) se-lnhibitoren ZD-9331 (BTG) CoFactor™ (BioKeys)Thymidylate Syntha Pemetrexed (EIi Lilly) Nolatrexed (Eximias) se Inhibitors ZD-9331 (BTG) CoFactor ™ (BioKeys)
DNA- Trabectedin (PharmaMar) Mafosfamid (BaxterDNA Trabectedin (PharmaMar) Mafosfamide (Baxter
Antagonisten Glufosfamid (Baxter International)Antagonists glufosfamide (Baxter International)
International) Apaziquon (SpectrumInternational) Apaziquon (Spectrum
Albumin + 32P (Isotope Pharmaceuticals)Albumin + 32P (Isotope Pharmaceuticals)
Solutions) O6-BenzylguaninSolutions) O6-Benzylguanine
Thymectacin (NewBiotics) (Paligent)Thymectacin (NewBiotics) (Paligent)
Edotreotid (Novartis)Edotreotide (Novartis)
Famesyltransfera Arglabin (NuOncology Tipifarnib (Johnson & se-lnhibitoren Labs) Johnson) lonafamib (Schering- Perillylalkohol (DOR Plough) BioPharma)Famesyltransfera Arglabin (NuOncology Tipifarnib (Johnson & se Inhibitors Labs) Johnson) lonafamib (Schering-Perillyl Alcohol (DOR Plow) BioPharma)
BAY-43-9006 (Bayer)BAY-43-9006 (Bayer)
Pumpen- CBT-1 (CBA Pharma) Zosuquidar-TrihydrochloridPump CBT-1 (CBA Pharma) Zosuquidar trihydrochloride
Inhibitoren Tariquidar (Xenova) (EIi Lilly)Inhibitors Tariquidar (Xenova) (EIi Lilly)
MS-209 (Schering AG) Biricodar-Dicitrat (Vertex)MS-209 (Schering AG) Biricodar dicitrate (vertex)
Histonacetyltransf Tacedinalin (Pfizer) Pivaloyloxymethylbutyrat erase- SAHA (Aton Pharma) (Titan)Histone acetyl trans Tacedinalin (Pfizer) pivaloyloxymethyl butyrate erase SAHA (Aton Pharma) (titanium)
Inhibitoren MS-275 (Schering AG) Depsipeptid (Fujisawa)Inhibitors MS-275 (Schering AG) Depsipeptide (Fujisawa)
Metalloproteinase- Neovastat (Aeterna CMT -3 (CollaGenex)Metalloproteinase neovastate (Aeterna CMT -3 (CollaGenex)
Inhibitoren Laboratories) BMS-275291 (Celltech)Inhibitors Laboratories) BMS-275291 (Celltech)
Ribonucleosidred Marimastat (British Tezacitabin (Aventis) uktase- Biotech) Didox (Molecules forRibonucleosidred Marimastat (British Tezacitabine (Aventis) uktase-Biotech) Didox (Molecules for
Inhibitoren Galliummaltolat (Titan) Health)Inhibitors gallium maltolate (titanium) Health)
Triapin (Vion)Triapin (Vion)
TNF-alpha- Virulizin (Lorus Revimid (Celgene)TNF-alpha-virulizine (Lorus Revimid (Celgene)
Agonisten/Antago Therapeutics) nisten CDC-394 (Celgene)Agonists / Antago Therapeutics) nest CDC-394 (Celgene)
Endothelin-A- Atrasentan (Abbot) YM-598 (Yamanouchi)Endothelin A Atrasentan (Abbot) YM-598 (Yamanouchi)
Rezeptor- ZD-4054 (AstraZeneca)Receptor ZD-4054 (AstraZeneca)
Antagonistenantagonists
Retinsäurerezepto Fenretinid (Johnson & Alitretinoin (Ligand) r-Agonisten Johnson)Retinoic Acid Fenretinide (Johnson & Alitretinoin (Ligand) R-agonist Johnson)
LGD-1550 (Ligand)LGD-1550 (ligand)
Immunmodulatore Interferon Dexosom-Therapie n Oncophage (Antigenics) (Anosys)Immunomodulators Interferon Dexosome Therapy n Oncophage (Antigenics) (Anosys)
GMK (Progenics) Pentrix (Australian CancerGMK (Progenics) Pentrix (Australian Cancer
Adenokarzinom-Impfstoff Technology)Adenocarcinoma Vaccine Technology)
(Biomira) JSF-154 (Tragen)(Biomira) JSF-154 (Carrying)
CTP-37 (AVI BioPharma) Krebsimpfstoff (Intercell)CTP-37 (AVI BioPharma) cancer vaccine (Intercell)
JRX-2 (Immuno-Rx) Norelin (Biostar)JRX-2 (Immuno-Rx) Norelin (Biostar)
PEP-005 (Peplin Biotech) BLP-25 (Biomira)PEP-005 (Peplin Biotech) BLP-25 (Biomira)
Synchrovax-Impfstoffe MGV (Progenics)Synchrovax vaccines MGV (Progenics)
(CTL Immuno) !3-Alethin (Dovetail)(CTL Immuno)! 3-Alethine (Dovetail)
Melanom-Impfstoff (CTL CLL-Thera (Vasogen)Melanoma vaccine (CTL CLL-Thera (Vasogen)
Immuno) p21-RAS-lmpfstoffImmuno) p21 RAS vaccine
(GemVax)(GemVax)
Hormonelle und Östrogene Prednison antihormonelle konjugierte Östrogene Methylprednisolon Mittel Ethinylestradiol PrednisolonHormonal and estrogenic prednisone antihormonal conjugated estrogens methylprednisolone Agent ethinyl estradiol prednisolone
Chlortrianisen AminoglutethimidChlorotrienes Aminoglutethimide
Idenestrol LeuprolidIdenestrol Leuprolide
Hydroxyprogesteroncaproa Goserelin t LeuporelinHydroxyprogesterone caproa Goserelin t Leuporelin
Medroxyprogesteron BicalutamidMedroxyprogesterone Bicalutamide
Testosteron FlutamidTestosterone Flutamide
Testosteronpropionat OctreotidTestosterone Propionate Octreotide
Fluoxymesteron NilutamidFluoxymesterone nilutamide
Methyltestosteron MitotanMethyltestosterone mitotane
Diethylstilbestrol P-04 (Novogen)Diethylstilbestrol P-04 (Novogen)
Megestrol 2-MethoxyöstradiolMegestrol 2-Methoxyestradiol
Tamoxifen (EntreMed)Tamoxifen (EntreMed)
Toremofin Arzoxifen (EIi Lilly)Toremofin Arzoxifen (EIi Lilly)
Dexamethasondexamethasone
Photodynamische Talaporfin (Light Sciences) Pd-BacteriopheophorbidPhotodynamic Talaporfin (Light Sciences) Pd-Bacteriopheophorbide
Mittel Theralux (Yeda)Central Theralux (Yeda)
(Theratechnologies) Lutetium-Texaphyrin(Theratechnologies) Lutetium Texaphyrin
Motexafin-Gadolinium (Pharmacyclics)Motexafin Gadolinium (Pharmacyclics)
(Pharmacyclics) Hypericin(Pharmacyclics) Hypericin
Tyrosinkinase- Imatinib (Novartis) Kahalid F (PharmaMar)Tyrosine kinase imatinib (Novartis) Kahalid F (PharmaMar)
Inhibitoren Leflunomid CEP- 701 (Cephalon)Inhibitors Leflunomide CEP-701 (Cephalon)
(Sugen/Pharmacia) CEP-751 (Cephalon)(Sugen / Pharmacia) CEP-751 (Cephalon)
ZDI839 (AstraZeneca) MLN518 (Millenium)ZDI839 (AstraZeneca) MLN518 (Millenium)
Erlotinib (Oncogene PKC412 (Novartis)Erlotinib (Oncogene PKC412 (Novartis)
Science) Phenoxodiol OScience) phenoxodiol O
Canertjnib (Pfizer) Trastuzumab (Genentech)Canertjnib (Pfizer) Trastuzumab (Genentech)
Squalamin (Genaera) C225 (ImCIone)Squalamine (Genaera) C225 (ImCIone)
SU5416 (Pharmacia) rhu-Mab (Genentech)SU5416 (Pharmacia) rhu-Mab (Genentech)
SU6668 (Pharmacia) MDX-H210 (Medarex)SU6668 (Pharmacia) MDX-H210 (Medarex)
ZD4190 (AstraZeneca) 2C4 (Genentech)ZD4190 (AstraZeneca) 2C4 (Genentech)
ZD6474 (AstraZeneca) MDX-447 (Medarex)ZD6474 (AstraZeneca) MDX-447 (Medarex)
Vatalanib (Novartis) ABX-EGF (Abgenix)Vatalanib (Novartis) ABX-EGF (Abgenix)
PK1166 (Novartis) IMC-1C11 (ImCIone)PK1166 (Novartis) IMC-1C11 (ImCIone)
GW2016GW2016
(GlaxoSmithKline)(GlaxoSmithKline)
EKB-509 (Wyeth)EKB-509 (Wyeth)
EKB-569 (Wyeth)EKB-569 (Wyeth)
Verschiedene SR-27897 (CCK-A- BCX-1777 (PNP-lnhibitor,Various SR-27897 (CCK-A-BCX-1777 (PNP inhibitor,
Mittel Inhibitor, Sanofi- BioCryst)Medium Inhibitor, Sanofi-BioCryst)
Synthelabo) RanpirnaseSynthelabo) Ranpirnase
Tocladesin (cyclisches- (Ribonuclease-Stimulans,Tocladesin (cyclic (ribonuclease stimulant,
AMP-Agonist, Ribapharm) Alfacell)AMP agonist, Ribapharm) Alfacell)
Alvocidib (CDK-Inhibitor, Galarubicin (RNA-Alvocidib (CDK inhibitor, galarubicin (RNA
Aventis) Synthese-Inhibitor, Dong-Aventis) Synthesis Inhibitor, Dong-
CV-247 (COX-2-lnhibitor, A) Ivy Medical) TirapazaminCV-247 (COX-2 inhibitor, A) Ivy Medical) Tirapazamine
P54 (COX-2-lnhibitor, (Reduktionsmittel, SRIP54 (COX-2 inhibitor, (reducing agent, SRI
Phytopharm) International)Phytopharm) International)
CapCell™ (CYP450- N-AcetylcysteinCapCell ™ (CYP450-N-acetylcysteine
Stimulans, Bavarian (Reduktionsmittel,Stimulant, Bavarian (reducing agent,
Nordic) Zambon)Nordic) Zambon)
GCS-IOO (gal3- R-Flurbiprofen (NF-GCS-IOO (gal3-R-flurbiprofen (NF-
Antagonist, kappaB-lnhibitor, Encore)Antagonist, kappaB inhibitor, Encore)
GlycoGenesys) 3CPA (NF-kappaB-GlycoGenesys) 3CPA (NF-kappaB-
G17DT-Immunogen Inhibitor, Active Biotech)G17DT immunogen inhibitor, Active Biotech)
(Gastrin-Inhibitor, Aphton) Seocalcitol (Vitamin-D-(Gastrin inhibitor, Aphton) seocalcitol (vitamin D
Efaproxiral (Oxygenator, Rezeptor-Agonist, Leo)Efaproxiral (oxygenator, receptor agonist, Leo)
Allos Therapeutics) 131-I-TM-601 (DNA-Allos Therapeutics) 131-I-TM-601 (DNA
PI-88 (Heparanase- Antagonist,PI-88 (heparanase antagonist,
10 Inhibitor, Progen) TransMolecular)10 inhibitor, Progen) TransMolecular)
Tesmilifen (Histamin- Eflomithin (ODC-Inhibitor,Tesmilifen (histamine eflomithine (ODC inhibitor,
Antagonist, YM ILEX Oncology)Antagonist, YM ILEX Oncology)
BioSciences) MinodronsäureBioSciences) Minodronic acid
Histamin (Histamin-H2- (Osteoclasten-Inhibitor,Histamine (histamine H2 (osteoclast inhibitor,
Rezeptor- Agonist, Maxim) Yamanouchi)Receptor agonist, Maxim) Yamanouchi)
Tiazofurin (IMPDH- Indisulam (p53-Stimulans,Tiazofurin (IMPDH-indisulam (p53 stimulant,
15 Inhibitor, Ribapharm) Eisai)15 inhibitor, Ribapharm) Eisai)
Cilengitid (Integrin- Aplidin (PPT-Inhibitor,Cilengitide (Integrin Aplidine (PPT inhibitor,
Antagonist, Merck KGaA) PharmaMar)Antagonist, Merck KGaA) PharmaMar)
SR-31747 (IL-1- Rituximab (CD20-SR-31747 (IL-1 rituximab (CD20-
Antagonist, Sanofi- Antikörper, Genentech)Antagonist, Sanofi antibody, Genentech)
Synthelabo) Gemtuzumab (CD33-Synthelabo) gemtuzumab (CD33-
CCI-779 (mTOR-Kinase- Antikörper, Wyeth Ayerst)CCI-779 (mTOR kinase antibody, Wyeth Ayerst)
Inhibitor, Wyeth) PG2 (Hämatopoese-Inhibitor, Wyeth) PG2 (hematopoietic
20 Exisuiind (PDE-V-Inhibitor, Verstärker,20 Exisuiind (PDE-V inhibitor, enhancer,
Cell Pathways) Pharmagenesis)Cell Pathways) Pharmagenesis)
CP-461 (PDE-V-Inhibitor, Immunol™ (Triclosan-CP-461 (PDE-V inhibitor, Immunol ™ (triclosan)
Cell Pathways) Oralspülung, Endo)Cell Pathways) Oral Irrigation, Endo)
AG-2037 (GART-Inhibitor, Triacetyluridin (Uridin-AG-2037 (GART inhibitor, triacetyluridine (uridine)
Pfizer) Prodrug, Wellstat)Pfizer) prodrug, Wellstat)
WX-UK1 SN-4071 (Sarkom-Mittel,WX-UK1 SN-4071 (sarcoma agent,
25 (Plasminogenaktivator- Signature BioScience)25 (plasminogen activator Signature BioScience)
Inhibitor, Wilex) TransMID-107™Inhibitor, Wilex) TransMID-107 ™
PBI-1402 (PMN-Stimulans, (Immunotoxin, KSPBI-1402 (PMN stimulant, (immunotoxin, KS
ProMetic LifeSciences) Biomedix)ProMetic LifeSciences) Biomedix)
Bortezomib (Proteasom- PCK-3145 (Apoptose-Bortezomib (proteasome PCK-3145 (apoptosis)
Inhibitor, Millennium) Förderer, Procyon)Inhibitor, Millennium) promoter, Procyon)
SRL-172 (T-ZeII- Doranidazol (Apoptose-SRL-172 (T-cell doranidazole (apoptosis
Stimulans, SR Pharma) Förderer, PoIa)Stimulant, SR Pharma) promoter, PoIa)
30 TLK-286 (Glutathion-S- CHS-828 (cytotoxisches30 TLK-286 (glutathione-S-CHS-828 (cytotoxic
Transferase-Inhibitor, Mittel, Leo)Transferase inhibitor, agent, Leo)
Telik) trans-RetinsäureTelik) trans-retinoic acid
PT- 100 (Wachstumsfaktor- (Differentiator, NIH) Agonist, Point MX6 (Apoptose-Förderer,PT-100 (growth factor (differentiator, NIH) Agonist, Point MX6 (apoptosis promoter,
Therapeutics) MAXIA)Therapeutics) MAXIA)
Midostaurin (PKC-Inhibitor, Apomin (Apoptose-Midostaurin (PKC inhibitor, apomin (apoptosis
Novartis) Förderer, ILEX Oncology)Novartis) Sponsors, ILEX Oncology)
Bryostatin-1 (PKC- Urocidin (Apoptose-Bryostatin-1 (PKC-urocidin (apoptosis)
Stimulans, GPC Biotech) Förderer, Bioniche)Stimulant, GPC Biotech) promoter, Bioniche)
CDA-II (Apoptose- Ro-31-7453 (Apoptose-CDA-II (apoptosis-Ro-31-7453 (apoptosis
Förderer, Everlife) Förderer, La Roche)Conveyor, Everlife) conveyor, La Roche)
SDX-101 (Apoptose- Brostallicin (Apoptose-SDX-101 (apoptosis-brostallicin (apoptosis)
Förderer, Salmedix) Förderer, Pharmacia)Promoter, Salmedix) promoter, Pharmacia)
Ceflatonin (Apoptose-Ceflatonin (apoptosis
Förderer, ChemGenex)Conveyor, ChemGenex)
Bevorzugt werden die Verbindungen der Formel I mit bekannten Antikrebsmitteln kombiniert.Preferably, the compounds of the formula I are combined with known anticancer agents.
Zu diesen bekannten Antikrebsmitteln zählen die folgenden: östrogenrezeptormodulatoren, Androgenrezeptormodulatoren, Retinoid- rezeptormodulatoren, Zytotoxika, antiproliferative Mittel, Prenyl- Proteintransferasehemmer, HMG-CoA-Reduktase-Hemmer, HlV-Protease- Hemmer, Reverse-Transkriptase-Hemmer sowie weitere Angiogenese- hemmer. Die vorliegenden Verbindungen eignen sich insbesondere zur gemeinsamen Anwendung mit Radiotherapie. Die synergistischen Wirkungen der Hemmung des VEGF in Kombination mit Radiotherapie sind in der Fachwelt beschrieben worden (siehe WO 00/61186). „Östrogenrezeptormodulatoren" bezieht sich auf Verbindungen, die die Bindung von Östrogen an den Rezeptor stören oder diese hemmen, und zwar unabhängig davon, wie dies geschieht. Zu den Östrogenrezeptormodulatoren zählen zum Beispiel Tamoxifen, Raloxifen, Idoxifen, LY353381 , LY 117081 , Toremifen, Fulvestrant, 4-[7-(2,2-Dimethyl-1-oxopropoxy-4- methyl-2-[4-[2-(1 - piperidinyl)ethoxy]phenyl]-2H-1 -benzopyran-3-yl]phenyl- 2,2-dimethylpropanoat, 4,4'-Dihydroxybenzophenon-2,4- dinitrophenylhydrazon und SH646, was jedoch keine Einschränkung darstellen soll.These known anticancer agents include the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors and other angiogenesis inhibitors. The present compounds are particularly suitable for co-administration with radiotherapy. The synergistic effects of inhibiting VEGF in combination with radiotherapy have been described in the art (see WO 00/61186). "Estrogen receptor modulators" refers to compounds that interfere with or inhibit the binding of estrogen to the receptor, regardless of how this occurs: Estrogen receptor modulators include, for example, tamoxifen, raloxifene, idoxifen, LY353381, LY 117081, toremifene, fulvestrant , 4- [7- (2,2-Dimethyl-1-oxopropoxy-4-methyl-2- [4- [2- (1-piperidinyl) ethoxy] phenyl] -2H-1-benzopyran-3-yl] phenyl - 2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and SH646, but this is not intended to be limiting.
„Androgenrezeptormodulatoren" bezieht sich auf Verbindungen, die die Bindung von Androgenen an den Rezeptor stören oder diese hemmen, und zwar unabhängig davon, wie dies geschieht. Zu den Androgenrezeptormodulatoren zählen zum Beispiel Finasterid und andere 5α-Reduktase-Hemmer, Nilutamid, Flutamid, Bicalutamid, Liarozol und Abirateron-acetat. „Retinoidrezeptormodulatoren" bezieht sich auf Verbindungen, die die Bindung von Retinoiden an den Rezeptor stören oder diese hemmen, und zwar unabhängig davon, wie dies geschieht. Zu solchen Retinoidrezeptormodulatoren zählen zum Beispiel Bexaroten, Tretinoin, 13-cis-Retinsäure, 9-cis- Retinsäure, α-Difluormethylornithin, ILX23-7553, trans-N-(4'-Hydroxy- phenyl)retinamid und N-4-Carboxyphenylretinamid."Androgen receptor modulators" refers to compounds that interfere with or inhibit the binding of androgens to the receptor, and regardless of how this happens. The androgen receptor modulators include, for example, finasteride and other 5α-reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate. "Retinoid receptor modulators" refers to compounds that interfere with or inhibit the binding of retinoids to the receptor, regardless of how this occurs Such retinoid receptor modulators include, for example, bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis Retinoic acid, α-difluoromethylornithine, ILX23-7553, trans-N- (4'-hydroxyphenyl) -retinamide and N-4-carboxyphenylretinamide.
„Zytotoxika" bezieht sich auf Verbindungen, die in erster Linie durch direkte Einwirkung auf die Zellfunktion zum Zelltod führen oder die die Zellmyose hemmen oder diese stören, darunter Alkylierungsmittel, Tumornekrosefaktoren, interkaliernde Mittel, Mikrotubulin-Hemmer und Topoisomerase- Hemmer."Cytotoxic agents" refers to compounds that cause cell death or interfere with cell myosis, primarily through direct action on cell function, including alkylating agents, tumor necrosis factors, intercalators, microtubulin inhibitors, and topoisomerase inhibitors.
Zu den Zytotoxika zählen zum Beispiel Tirapazimin, Sertenef, Cachectin, Ifosfamid, Tasonermin, Lonidamin, Carboplatin, Altretamin, Prednimustin, Dibromdulcit, Ranimustin, Fotemustin, Nedaplatin, Oxaliplatin, Temozolomid, Heptaplatin, Estramustin, Improsulfan-tosylat, Trofosfamid, Nimustin, Dibros- pidium-chlorid, Pumitepa, Lobaplatin, Satraplatin, Profiromycin, Cisplatin, Iro- fulven, Dexifosfamid, cis-Amindichlor(2-methylpyridin)platin, Benzylguanin, Glufosfamid, GPX100, (trans,trans,trans)-bis-mu-(hexan-1,6-diamin)-mu- [diamin-platin(ll)]bis[diamin(chlor)platin(ll)]-tetrachlorid, Diarizidinylspermin, Arsentrioxid, 1-(11-Dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthin, Zorubicin, Idarubicin, Daunorubicin, Bisantren, Mitoxantron, Pirarubicin,The cytotoxic agents include, for example, tirapazimine, Sertenef, cachectin, ifosfamide, tasonermine, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcite, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improvisulfan-tosylate, trofosfamide, nimustine, dibrosylamine. pidium chloride, Pumitepa, Lobaplatin, Satraplatin, Profiromycin, Cisplatin, Irofulvene, Dexifosfamide, cis-Amine dichloro (2-methylpyridine) platinum, Benzylguanine, Glufosfamide, GPX100, (trans, trans, trans) -bis-mu (hexane -1,6-diamine) -mu- [diamine-platinum (II)] bis [diamine (chloro) -platinum (II)] - tetrachloride, diarizidinylspermine, arsenic trioxide, 1- (11-dodecylamino-10-hydroxyundecyl) -3, 7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin,
Pinafid, Valrubicin, Amrubicin, Antineoplaston, 3'-Desamino-3'-morpholino- 13-desoxo-10-hydroxycarminomycin, Annamycin, Galarubicin, Elinafid, MEN 10755 und 4-Desmethoxy-3-desamino-3-aziridinyl-4-methylsulfonyl- daunorubicin (siehe WO 00/50032), was jedoch keine Einschränkung darstellen soll.Pinafid, valrubicin, amrubicin, antineoplaston, 3'-desamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN 10755 and 4-desmethoxy-3-desamino-3-aziridinyl-4-methylsulfonyl - daunorubicin (see WO 00/50032), but this is not intended to be limiting.
Zu den Mikrotubulin-Hemmem zählen zum Beispiel Paclitaxel, Vindesin- sulfat, S'^'-Dideshydro^'-desoxy-δ'-norvincaleukoblastin, Docetaxol, Rhizoxin, Dolastatin, Mivobulin-isethionat, Auristatin, Cemadotin, RPR109881 , BMS184476, Vinflunin, Cryptophycin, 2,3,4,5,6-pentafluor-N- (3-fluor-4-methoxyphenyl)benzolsulfonamid, Anhydrovinblastin, N1N- dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-prolin-t-butylamid, TDX258 und BMS188797.The microtubulin inhibitors include, for example, paclitaxel, vindesine sulfate, S '''-dideshidro''-deoxy-δ'-norvincaleukoblastin, docetaxol, Rhizoxin, dolastatin, mivobulinisethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N- (3-fluoro-4-methoxyphenyl) benzenesulfonamide, anhydrovinblastine, N 1 N - dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline t-butylamide, TDX258 and BMS188797.
Topoisomerase-Hemmer sind zum Beispiel Topotecan, Hycaptamin, Irinotecan, Rubitecan, 6-Ethoxypropionyl-3',4'-O-exo-benzyliden-chartreusin, 9-Methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridin-2-(6H)propanamin, 1-Amino-9-ethyl-5-fluor-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]- Lurtotecan, 7-[2- (N-lsopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPM 100, BN80915, BN80942, Etoposid-phosphat, Teniposid, Sobuzoxan, 2'- Dimethylamino-2'-desoxy-etoposid, GL331 , N-[2-(Dimethylamino)ethyl]-9- hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazol-1-carboxamid, Asulacrin, (5a,5aB,8aa,9b)-9-[2-[N-[2-(Dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4- hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9- hexohydrofuro(3I,4l:6,7)naphtho(2,3-d)-1 I3-dioxol-6-on) 2,3-(Methylendioxy)- 5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium, 6,9-Bis[(2- aminoethyl)amino]benzo[g]isochinolin-5,10-dion, 5-(3-Aminopropylamino)- 7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin- 6-on, N-[1-[2(Diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4- ylmethyl]formamid, N-(2-(Dimethyl-amino)-ethyl)acridin-4-carboxamid, 6-[[2- (Dimethylamino)-ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]chinolin-7-on und Dimesna. Zu den „antiproliferativen Mitteln" zählen Antisense-RNA- und -DNA-Topoisomerase inhibitors are, for example, topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3 ', 4'-O-exo-benzylidene-chartreusine, 9-methoxy-N, N-dimethyl-5-nitropyrazolo [3,4, 5-kl] acridine-2- (6H) propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [en] - Lurtotecan, 7- [2- (N-isopropylamino) ethyl] - (20S) camptothecin, BNP1350, BNPM 100, BN80915, BN80942, etoposide-phosphate, teniposide, sobuzoxan, 2'-dimethylamino-2'-deoxy-etoposide, GL331 , N- [2- (dimethylamino) ethyl] -9-hydroxy-5,6-dimethyl-6H-pyrido [4,3-b] carbazole-1-carboxamide, asulacrine, (5a, 5aB, 8aa, 9b) - 9- [2- [N- [2- (dimethylamino) ethyl] -N-methylamino] ethyl] -5- [4-hydroxy-3,5-dimethoxyphenyl] -5,5a, 6,8,8a, 9- hexohydrofuro (3 l, 4 l: 6,7) naphtho (2,3-d) -1 I 3-dioxol-6-one) 2,3- (methylenedioxy) - 5-methyl-7-hydroxy-8-methoxybenzo [c] phenanthridinium, 6,9-bis [(2-aminoethyl) amino] benzo [g] isoquinoline-5,10-dione, 5- (3-aminopropylamino) -7,10-dihydroxy-2- (2-hydroxyethylaminomethyl ) -6H-pyrazolo [4,5,1-de] acridin-6-one, N- [1- [2 (diethylamino) ethylamino] -7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl] formamide , N- (2- (dimethylamino) ethyl) acridine-4-carboxamide, 6 - [[2- (dimethylamino) ethyl] amino] -3-hydroxy-7H-indeno [2,1-c] quinoline -7-on and Dimesna. Antiproliferative agents include antisense RNA and DNA
Oligonucleotide wie G3139, ODN698, RVASKRAS, GEM231 und INX3001 , sowie Antimetaboliten wie Enocitabin, Carmofur, Tegafur, Pentostatin, Doxifluridin, Trimetrexat, Fludarabin, Capecitabin, Galocitabin, Cytarabin- ocfosfat, Fosteabin-Natriumhydrat, Raltitrexed, Paltitrexid, Emitefur, Tiazo- furin, Decitabin, Nolatrexed, Pemetrexed, Nelzarabin, 2'-Desoxy-2'- methylidencytidin, 2'-Fluormethylen-2'-desoxycytidin, N-[5-(2,3- DihydrobenzofuryOsulfonylJ-N'-CS^-dichlorphenyOharnstoff, N6-[4-Desoxy-4- [N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-hepto- pyranosyl]adenin, Aplidin, Ecteinascidin, Troxacitabine, 4-[2-Amino-4-oxo- 4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b][1 ,4]thiazin-6-yl-(S)-ethyl]-2,5- thienoyl-L-glutaminsäure, Aminopterin, 5-Flurouracil, Alanosin, 11 -Acetyl-8- (carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1 ,11-diazatetracyclo-Oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabic sodium hydrate, raltitrexed, paltitrexide, emitefur, tiazo- furin , Decitabine, Nolatrexed, Pemetrexed, Nelzarabin, 2'-Deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N- [5- (2,3-DihydrobenzofuryOsulfonyl) J-N'-CS-dichlorophenyl urea, N6 - [4-deoxy-4- [N2- [2 (E), 4 (E) -tetradecadienoyl] glycylamino] -L-glycero-BL-manno-heptopyranosyl] adenine, aplidine, ecteinascidin, troxacitabine, 4- [2-amino-4-oxo] 4,6,7,8-tetrahydro-3H-pyrimidino [5,4-b] [1, 4] thiazine-6-yl- (S) -ethyl] -2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8- (carbamoyloxymethyl) -4-formyl-6-methoxy-14-oxa-1,11-diazatetracycyl
(7.4.1.0.0)-tetradeca-2,4,6-trien-9-ylessigsäureester, Swainsonin, Lometrexol, Dexrazoxan, Methioninase, 2'-cyan-2'-desoxy-N4-palmitoyl-1-B- D-Arabinofuranosylcytosin und 3-Aminopyridin-2-carboxaldehyd-thiosemi- carbazon. Die „antiproliferativen Mittel" beinhalten auch andere monoklonale Antikörper gegen Wachstumsfaktoren als bereits unter den „Angiogenese- Hemmern" angeführt wurden, wie Trastuzumab, sowie Tυmorsuppressorgene, wie p53, die über rekombinanten virusvermittelten Gentransfer abgegeben werden können (siehe z.B. US-Patent Nr. 6,069,134).(7.4.1.0.0) -tetradeca-2,4,6-trien-9-ylacetic acid ester, swainsonine, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B- D- Arabinofuranosylcytosine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. The "antiproliferative agents" also include other monoclonal antibodies to growth factors already mentioned among the "angiogenesis inhibitors", such as trastuzumab, as well as tumor suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see, eg, US Patent No. 6,069,134 ).
Insbesondere bevorzugt ist die Verwendung der erfindungsgemäßen Verbindung zur Behandlung und Prophylaxe von Tumorerkrankungen.Particularly preferred is the use of the compound according to the invention for the treatment and prophylaxis of tumor diseases.
Der Tumor ist vorzugsweise ausgewählt aus der Gruppe der Tumoren des Plattenepithel, der Blasen, des Magens, der Nieren, von Kopf und Hals, des Ösophagus, des Gebärmutterhals, der Schilddrüse, des Darm, der Leber, des Gehirns, der Prostata, des Urogenitaltrakts, des lymphatischen Systems, des Magens, des Kehlkopft und/oder der Lunge.The tumor is preferably selected from the group of squamous cell tumors, bladder, stomach, kidney, head and neck, esophagus, cervix, thyroid, intestine, liver, brain, prostate, genitourinary tract , the lymphatic system, the stomach, the larynx and / or the lungs.
Der Tumor ist weiterhin vorzugsweise ausgewählt aus der GruppeThe tumor is furthermore preferably selected from the group
Lungenadenokarzinom, kleinzellige Lungenkarzinome, Bauchspeicheldrüsenkrebs, Glioblastome, Kolonkarzinom und Brustkarzinom.Lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma, colon carcinoma and breast carcinoma.
Weiterhin bevorzugt ist die Verwendung zur Behandlung eines Tumors des Blut- und Immunsystems, vorzugsweise zur Behandlung eines Tumors ausgewählt aus der Gruppe der akuten myeloischen Leukämie, der chronischen myelotischen Leukämie, akuten lymphatischen Leukämie und/oder chronischen lymphatischen Leukämie.Further preferred is the use for the treatment of a tumor of the blood and immune system, preferably for the treatment of a tumor selected from the group of acute myeloid leukemia, the chronic myeloid leukemia, acute lymphoblastic leukemia and / or chronic lymphocytic leukemia.
Die Erfindung umfasst auch ein Verfahren zur Behandlung eines Patienten, der ein Neoplasma, wie einen Krebs, hat, durch VerabreichungThe invention also includes a method of treating a patient having a neoplasm, such as a cancer, by administration
a) einer oder mehrerer der Verbindungen der Formel I:a) one or more of the compounds of the formula I:
b) und einer oder mehrerer der Verbindungen der Formel V oder deren Säure-Additionssalze, insbesondere Hydrochloride:b) and one or more of the compounds of the formula V or their acid addition salts, in particular hydrochlorides:
worin Y' und Z' jeweils unabhängig voneinander O oder N bedeuten, R6 und R7 jeweils unabhängig voneinander H, OH, Halogen, OC1-10-Alkyl, OCF3, NO2 oder NH2 bedeuten, S eine ganze Zahl zwischen 2 und 6, jeweils einschließlich, bedeutet und R8 und R9 jeweils unabhängig voneinander vorzugsweise an der meta- oder para-Position stehen und aus der Gruppe:wherein Y 'and Z' are each independently O or N, R 6 and R 7 are each independently H, OH, halogen, OC 1-10 alkyl, OCF 3 , NO 2 or NH 2 , S is an integer between 2 and 6, each inclusive, and R 8 and R 9 are each independently preferably at the meta or para position and selected from the group:
ausgewählt sind, wobei die erste und die zweite Verbindung gleichzeitig oder innerhalb von 14 Tagen voneinander in Mengen verabreicht werden, die ausreichen, um das Wachstum des Neoplasmas zu hemmen. wherein the first and second compounds are administered simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.
Die Kombination der Verbindungen der Formel I mit den Verbindungen der Formeis V und anderer Pentamedin-Analoga führt zu einer synergistischen Wirkung bei der Hemmung von Neoplasien. Kombinationen enthaltend die Verbindungen der Formel V sind z.B. in WO 02058684 erwähnt.The combination of the compounds of the formula I with the compounds of the formula V and other pentamedin analogues leads to a synergistic effect in the inhibition of neoplasms. Combinations containing the compounds of formula V are e.g. mentioned in WO 02058684.
Der Wirkungsmechanismus von Pentamidin oder seiner Derivate ist derzeit nicht eindeutig geklärt: Pentamidin oder seine Derivate hat offenbar pleiotrope Wirkungen, da es zu einer Abnahme von DNA-, RNA- und Protein-Synthese führt. Vor kurzem wurde beschrieben, dass Pentamidin ein leistungsfähiger Hemmstoff von PRL1-, -2- und 3-Phosphatasen (Pathak et al., 2002) und Tyrosinphosphatasen ist, und ihre Überexpression geht mit neoplastischen bösartigen Tumoren beim Menschen einher. Andererseits wurde beschrieben, dass Pentamidin ein Arzneimittel ist, das an die kleine DNA-Furche bindet (Puckowska et al., 2004) und das seine Wirkung über die Störung der Genexpression und/oder DNA-Synthese ausüben kann.The mechanism of action of pentamidine or its derivatives is currently unclear: pentamidine or its derivatives appear to have pleiotropic effects as it leads to a decrease in DNA, RNA and protein synthesis. Pentamidine has recently been described as a potent inhibitor of PRL1, -2 and 3 phosphatases (Pathak et al., 2002) and tyrosine phosphatases, and its overexpression is associated with human neoplastic malignant tumors. On the other hand, it has been described that pentamidine is a drug that binds to the small DNA groove (Puckowska et al., 2004) and that can exert its effect via the disruption of gene expression and / or DNA synthesis.
Andere geeignete Pentamidin-Analoga umfassen Stilbamidin (G-1) und Hydroxystilbamidin (G-2) und ihre Indolanaloga (z.B. G-3):Other suitable pentamidine analogs include stilbamidine (G-1) and hydroxystilbamidine (G-2) and their indole analogs (e.g., G-3):
(G-3)(G-3)
Jede Amidineinheit kann unabhängig voneinander durch eine der Einheiten ersetzt werden, die vorstehend für R8 und R11 definiert sind. Wie im Fall der Benzimidazole und Pentamidine, eignen sich auch Salze von Stilbamidin, Hydroxystilbamidin und ihren Indolderivaten für das erfindungsgemäße Verfahren. Bevorzugte Salze umfassen zum Beispiel Dihydrochlorid- und Methansulfonatsalze.Each amidine unit can be independently replaced by one of the units defined above for R 8 and R 11 . As in the case of benzimidazoles and pentamidines, salts of stilbamidine, hydroxystilbamidine and their indole derivatives are also suitable for the process according to the invention. Preferred salts include, for example, dihydrochloride and methanesulfonate salts.
Noch andere Analoga sind diejenigen, die unter eine Formel fallen, die in einem der U.S.-Patente Nr. 5,428,051 , 5,521 ,189, 5,602,172, 5,643,935, 5,723,495, 5,843,980, 6,172,104 und 6,326,395 oder der U.S.Patentanmeldung mit der Veröffentlichungsnr. US 2002/0019437 A1 bereitgestellt werden, die jeweils in ihrer Gesamtheit durch Bezugname aufgenommen sind. Beispielhafte Analoga umfassen 1 ,5-Bis-(4'-(N- hydroxyamidino)phenoxy)pentan, 1 ,3-Bis-(4'-(N-hydroxyamidino)- phenoxy)propan, 1 ,3-Bis-(2'-methoxy-4'-(N-hydroxyamidino)-phenoxy)- propan, 1 ,4-Bis-(4'-(N-hydroxyamidino)phenoxy)butan, 1 ,5-Bis-(4'-(N- hydroxyamidino)phenoxy)pentan, 1,4-Bis-(4'-(N-hydroxyamidino)- phenoxy)butan, 1 ,3-Bis-(4'-(4-hydroxyamidino)phenoxy)propan, 1 ,3-Bis-(2'- methoxy-4'-(N-hydroxyamidino)phenoxy)propan, 2,5-Bis-[4- amidinophenyl]furan, 2,5-Bis-[4-amidinophenyl]furan-bis-amidoxim, 2,5-Bis- [4-amidinophenyl]furan-bis-O-methylamidoxim, 2,5-Bis-[4- amidinophenyl]furan-bis-O-ethylamidoxim, 2,8-Diamidinodibenzothiophen, 2,8-Bis-(N-isopropylamidino)carbazol, 2,8-Bis-(N-hydroxyamidino)carbazol,Still other analogs are those falling within a formula disclosed in any of U.S. Patent Nos. 5,428,051, 5,521,189, 5,602,172, 5,643,935, 5,723,495, 5,843,980, 6,172,104 and 6,326,395, or US Patent Application Publ. US 2002/0019437 A1, each of which is incorporated by reference in its entirety. Exemplary analogs include 1, 5-bis (4 '- (N-hydroxyamidino) phenoxy) pentane, 1, 3-bis (4' - (N-hydroxyamidino) phenoxy) propane, 1, 3-bis (2 '-methoxy-4' - (N-hydroxyamidino) phenoxy) propane, 1,4-bis (4 '- (N-hydroxyamidino) phenoxy) butane, 1, 5-bis- (4' - (N-) hydroxyamidino) phenoxy) pentane, 1,4-bis (4 '- (N-hydroxyamidino) phenoxy) butane, 1, 3-bis- (4' - (4-hydroxyamidino) phenoxy) propane, 1, 3-bis - (2 ' methoxy-4 '- (N-hydroxyamidino) phenoxy) propane, 2,5-bis [4-amidinophenyl] furan, 2,5-bis- [4-amidinophenyl] furan-bis-amidoxime, 2,5-bis- [4-amidinophenyl] furan-bis-O-methylamidoxime, 2,5-bis [4-amidinophenyl] furan-bis-O-ethylamidoxime, 2,8-diamidinodibenzothiophene, 2,8-bis (N-isopropylamidino) carbazole , 2,8-bis (N-hydroxyamidino) carbazole,
2,8-Bis-(2-imidazolinyl)dibenzothiophen, 2,8-Bis-(2-imidazolinyl)-5,5- dioxodibenzothiophen, 3,7-Diamidinodibenzothiophen, 3,7-BiS-(N- isopropylamidino)dibenzothiophen, 3,7-Bis-(N-hydroxyamidino)-dibenzothio- phen, 3,7-Diaminodibenzothiophen, 3,7-Dibromdibenzothiophen, 3,7- Dicyanodibenzothiophen, 2,8-Diamidinodibenzofuran, 2,8-Di-(2-imidazolinyl)- dibenzofuran, 2,8-Di-(N-isopropylamidino)dibenzofuran, 2, 8-Di-(N- hydroxylamidino)dibenzofuran, 3,7-Di-(2-imidazolinyl)dibenzofuran, 3,7-Di- (isopropylamidino)dibenzofuran, 3,7-Di-(A-hydroxylamidino)dibenzofuran, 2,8-Dicyanodibenzofuran, 4,4'-Dibrom-2,2l-dinitrobiphenyl, 2-Methoxy-2'- nitro-4,4'-dibrombiphenyl, 2-Methoxy-2'-amino-4,4'-dibrombiphenyl, 3,7- Dibromdibenzofuran, 3,7-Dicyanodibenzofuran, 2,5-Bis-(5-amidino-2- benzimidazolyl)pyrrol, 2,5-Bis-[5-(2-imidazolinyl)-2-benzimidazolyl]pyrrol, 2,6- Bis-[5-(2-imidazolinyl)-2-benzimidazolyl]pyridin, 1-Methyl-2,5-bis-(5-amidino- 2-benzimidazolyl)pyrrol, 1-Methyl-2,5-bis-[5-(2-imidazolyl)-2- benzimidazolyl]pyrrol, 1-Methyl-2,5-bis-[5-(1 ,4,5,6-tetrahydro-2-pyrimidinyl)- 2-benzimidazolyl]pyrrol, 2,6-Bis-(5-amidino-2-benzimidazoyl)pyridin, 2,6-Bis- [5-(1 ,4,5,6-tetrahydro-2-pyrimidinyl)-2-benzimidazolyl]pyridin, 2,5-Bis-(5- amidino-2-benzimidazolyl)furan, 2,5-Bis-[5-(2-imidazolinyl)-2- benzimidazolyl]furan, 2,5-Bis-(5-N-isopropylamidino-2-benzimidazolyl)furan, 2,5-Bis-(4-guanylphenyl)furan, 2,5-Bis(4-guanylphenyl)-3,4-dimethylfuran, 2,5-Di-p-[2-(3,4,5,6-tetrahydropyrimidyl)phenyl]furan, 2,5-Bis-[4-(2- imidazolinyl)phenyl]furan, 2,5-[Bis-{4-(2-tetrahydropyrimidinyl)}phenyl]-p- (tolyloxy)furan, 2,5-[Bis-{4-(2-imidazolinyl)}-phenyl]-3-p-(tolyloxy)furan, 2,5- Bis-{4-[5-(N-2-aminoethylamido)benzimidazol-2-yl]phenyl}furan, 2,5-Bis-[4- (3a,4, 5,6,7, 7a-hexahydro-1 H-benzimidazol-2-yl)phenyl]furan, 2,5-Bis-[4- (4,5,6,7-tetrahydro-1 H-1 ,3-diazepin-2-yl)phenyl]furan, 2,5-Bis-(4-N,N- dimethylcarboxhydrazidphenyl)furan, 2,5-Bis-{4-[2-(N-2- hydroxyethyl)imidazolinyl]phenyl}furan, 2,5-Bis-[4-(N-isopropyl- amidino)phenyl]furan, 2,5-Bis-{4-[3-(dimethylaminopropyl)amidino]phenyl}- furan, 2,5-Bis-{4-[N-(3-aminopropyl)amidino]phenyl}furan, 2,5-Bis-[2- (imidzaolinyl)phenyl]-3,4-bis-(methoxymethyl)furan, 2,5-Bis-[4-N-(dimethyl- aminoethyl)guanyl]-phenylfuran, 2,5-Bis-{4-[(N-2-hydroxyethyl)guanyl]- phenyl}furan, 2,5-Bis-[4-N-(cyclopropylguanyl)phenyl]furan, 2,5-Bis-[4-(N,N- diethylaminopropyl)-guanyl]phenylfuran, 2,5-Bis-{4-[2-(N-ethylimidazolinyl)]- phenyl}furan, 2,5-Bis-{4-[N-(3-pentylguanyl)]}phenylfuran, 2,5-Bis-[4-(2- imidazolinyl)phenyl]-3-methoxyfuran, 2,5-Bis-[4-(N-isopropylamidino)phenyl]- 3-methylfuran, Bis-[5-amidino-2-benzimidazolyl]methan, Bis-[5-(2-imidazolyl)- 2-benzimidazolyl]methan, 1 ,2-Bis-[5-amidino-2-benzimidazolyl]ethan, 1 ,2- Bis-[5-(2-imidazolyl)-2-benzimidazolyl]ethan, 1 ,3-Bis-[5-amidino-2- benzimidazolyl]propan, 1 ,3-Bis-[5-(2-imidazolyl)-2-benzimidazolyl]propan, 1 ,4-Bis-[5-amidino-2-benzimidazolyl]propan, 1 ,4-Bis-[5-(2-imidazolyl)-2- benzimidazolyljbutan, 1 ,8-Bis-[5-amidino-2-benzimidazolyl]octan, trans-1 ,2- Bis-[5-amidino-2-benzimidazolyl]ethen, 1 ,4-Bis-[5-(2-imidazolyl)-2- benzimidazolyl]-1 -buten, 1 ,4-Bis-[5-(2-imidazolyl)-2-benzimidazolyl]-2-buten, 1 ,4-Bis-[5-(2-imidazolyl)-2-benzimidazolyl]-1-methylbutan, 1 ,4-Bis-[5-(2- imidazolyl)-2-benzimidazolyl]-2-ethylbutan, 1 ,4-Bis-[5-(2-imidazolyl)-2- benzimidazolyl]-1-methyl-1 -buten, 1 ,4-Bis-[5-(2-imidazolyl)-2-benzimidazolyl]- 2,3-diethyl-2-buten, 1 ,4-Bis-[5-(2-imidazolyl)-2-benzimidazolyl]-1 ,3-butadien, 1 ,4-Bis-[5-(2-imidazolyl)-2-benzimidazolyl]-2-methyl-1 ,3-butadien, Bis-[5-(2- pyrimidyl)-2-benzimidazolyl]methan, 1 ,2-Bis-[5-(2-pyrimidyl)-2- benzimidazolyl]ethan, 1 ,3-Bis-[5-amidino-2-benzimidazolyl]propan, 1 ,3-Bis- [5-(2-pyrimidyl)-2-benzimidazolyl]propan, 1 ,4-Bis-[5-(2-pyrimidyl)-2- benzimidazolyl]butan, 1 )4-Bis-[5-(2-pyrimidyl)-2-benzimidazolyl]-1 -buten, 1 ,4- Bis-[5-(2-pyrimidyl)-2-benzimidazolyl]-2-buten, 1 ,4-Bis-[5-(2-pyhmidyl)-2- benzimidazolyl]-1 -methylbutan , 1 ,4-Bis-[5-(2-pyrimidyl)-2-benzimidazolyl]-2- ethylbutan, 1 ,4-Bis-[5-(2-pyrimidyl)-2-benzimidazolyl]-1-methyl-1 -buten, 1 ,4- Bis-[5-(2-pyrimidyl)-2-benzimidazolyl]-2,3-diethyl-2-buten, 1 ,4-Bis-[5-(2- pyrimidyl)-2-benzimidazolyi]-1 ,3-butadien und 1 ,4-Bis-[5-(2-pyrimidyl)-2- benzimidazolyl]-2-methyl-1 ,3-butadien, 2,4-Bis-(4-guanylphenyl)pyrimidin, 2,4-Bis-(4-imidazolin-2-yl)pyrimidin, 2,4-Bis-[(tetrahydropyrimidinyl-2- yl)phenyl]pyrimidin, 2-(4-[N-i-Propylguanyl]phenyl)-4-(2-methoxy-4-[N-i- propylguanyl]phenyl)pyrimidin, 4-(N-Cyclopentylamidino)-1 ,2- phenylendiamin, 2,5-Bis-[2-(5-amidino)benzimidazoyl]furan, 2,5-Bis-[2-{5-(2- imidazolino)}benzimidazoyl]furan, 2,5-Bis-[2-(5-N-isopropylamidino)- benzimidazoyl]furan, 2,5-Bis-[2-(5-N-cyclopentylamidino)-benzimida- zoyl]furan, 2,5-Bis[2-(5-amidino)benzimidazoyl]pyrrol, 2,5-Bis-[2-{5-(2- imidazolino)}benzimidazoyl]pyrrol, 2,5-Bis-[2-(5-N-isopropylamidino)- benzimidazoyljpyrrol, 2,5-Bis-[2-(5-N-cyclopentylamidino)- benzimidazoyl]pyrrol, 1-Methy!-2,5-bis-[2-(5-amidino)benzimidazoyl]pyrrol, 2,5-Bis-[2-{5-(2-imidazolino)}benzimidazoyl]-1-methylpyrroll 2,5-Bis-[2-(5-N- cyclopentylamidino)benzimidazoyl]-1-methylpyrrol, 2,5-Bis-[2-(5-N- isopropylamidino)benzimidazoyl]thiophen, 2,6-Bis-[2-{5-(2- imidazolinojjbenzimidazoyljpyridin, 2,6-Bis-[2-(5-amidino)benzimidazoyl]- pyridin, 4,4'-Bis-[2-(5-N-isopropylamidino)benzimidazoyl]-1 ,2-diphenylethan, 4,41-Bis-[2-(5-N-cyclopentylamidino)benzimidazoyl]-2,5-diphenylfuran, 2,5- Bis-[2-(5-amidino)benzimidazoyl]benzo-[b]-furan, 2,5-Bis-[2-(5-N- cyclopentylamidino)benzimidazoyl]benzo-[b]-furan, 2,7-Bis-[2-(5-N-isopropyl- amidino)benzimidazoyl]fluor, 2,5-Bis-[4-(3-(N-morpholinopropyl)carbamoyl)- phenyl]furan, 2,5-Bis-[4-(2-N,N-dimethylaminoethylcarbamoyl)phenyl]furan, 2,5-Bis-[4-(3-N,N-dimethylaminopropylcarbamoyl)phenyl]furan, 2,5-Bis-[4-(3- N-methyl-3-N-phenylaminopropylcarbamoyl)phenyl]furan, 2,5-Bis-[4-(3- N,N8,N11-trimethylaminopropylcarbamoyl)phenyl]furan, 2,5-Bis-[3- amidinophenyl]furan, 2)5-Bis-[3-(N-isopropylamidino)amidinophenyl]furan, 2,5-Bis-[3-[(N-(2-dimethylaminoethyl)amidino]phenylfuran, 2,5-Bis-[4-(N- 2,2,2-trichlorethoxycarbonyl)amidinophenyl]furan, 2,5-Bis-[4-(N- thioethylcarbonyl)amidinophenyl]furan, 2,5-Bis-[4-(N- benzyloxycarbonyl)amidinophenyl]furan, 2,5-Bis[4-(N-phenoxycarbonyl)- amidinophenyl]furan, 2,5-Bis-[4-(N-(4-fluor)-phenoxycarbonyl)amidino- phenyl]furan, 2,5-Bis-[4-(N-(4- methoxy)phenoxycarbonyl)amidinophenyl]furan, 2,5-Bis-[4-(1- acetoxyethoxycarbonyl)amidinophenyl]furan und 2,5-Bis-[4-(N-(3- fluor)phenoxycarbonyl)amidinophenyl]furan. Verfahren zur Herstellung einer der vorstehenden Verbindungen sind in den U.S.-Patenten Nr. 5,428,051 , 5,521 ,189, 5,602,172, 5,643,935, 5,723,495, 5,843,980, 6,172,104 und 6,326,395 oder der US-Patentanmeldung mit der Veröffentlichungsnr. US 2002/0019437 A1 beschrieben.2,8-bis (2-imidazolinyl) dibenzothiophene, 2,8-bis (2-imidazolinyl) -5,5-dioxodibenzothiophene, 3,7-diamidinodibenzothiophene, 3,7-BiS- (N-isopropylamidino) dibenzothiophene, 3,7-bis (N-hydroxyamidino) -dibenzothiophene, 3,7-diaminodibenzothiophene, 3,7-dibromodibenzothiophene, 3,7-dicyanodibenzothiophene, 2,8-diamidinodibenzofuran, 2,8-di- (2-imidazolinyl ) - dibenzofuran, 2,8-di (N-isopropylamidino) dibenzofuran, 2, 8-di (N-hydroxylamidino) dibenzofuran, 3,7-di- (2-imidazolinyl) dibenzofuran, 3,7-di- ( isopropylamidino) dibenzofuran, 3,7-di- (A-hydroxylamidino) dibenzofuran, 2,8-Dicyanodibenzofuran, 4,4'-dibromo-2,2 l -dinitrobiphenyl, 2-methoxy-2'-nitro-4,4 ' dibromobiphenyl, 2-methoxy-2'-amino-4,4'-dibromobiphenyl, 3,7-dibromodibenzofuran, 3,7-dicyanodibenzofuran, 2,5-bis (5-amidino-2-benzimidazolyl) pyrrole, 2, 5-Bis- [5- (2-imidazolinyl) -2-benzimidazolyl] pyrrole, 2,6-bis [5- (2-imidazolinyl) -2-benzimidazolyl] pyridine, 1-methyl-2,5-bis- (5-amidino-2-benzimidazolyl) pyrrole, 1-methyl-2,5-bis [5- (2-imidazolyl) -2 - benzimidazolyl] pyrrole, 1-methyl-2,5-bis- [5- (1, 4,5,6-tetrahydro-2-pyrimidinyl) -2-benzimidazolyl] pyrrole, 2,6-bis (5-amidino 2-benzimidazoyl) pyridine, 2,6-bis [5- (1, 4,5,6-tetrahydro-2-pyrimidinyl) -2-benzimidazolyl] pyridine, 2,5-bis (5-amidino-2 benzimidazolyl) furan, 2,5-bis [5- (2-imidazolinyl) -2-benzimidazolyl] furan, 2,5-bis- (5-N-isopropylamidino-2-benzimidazolyl) furan, 2,5-bis - (4-guanylphenyl) furan, 2,5-bis (4-guanylphenyl) -3,4-dimethylfuran, 2,5-di-p- [2- (3,4,5,6-tetrahydropyrimidyl) phenyl] furan , 2,5-Bis- [4- (2-imidazolinyl) phenyl] furan, 2,5- [bis {4- (2-tetrahydropyrimidinyl)} phenyl] -p- (tolyloxy) furan, 2,5- [ Bis {4- (2-imidazolinyl)} - phenyl] -3-p- (tolyloxy) furan, 2,5-bis {4- [5- (N-2-aminoethylamido) benzimidazol-2-yl] phenyl } furan, 2,5-bis- [4- (3a, 4, 5, 6, 7, 7a-hexahydro-1H-benzimidazol-2-yl) phenyl] furan, 2,5-bis- [4- (2-bis) 4,5,6,7-tetrahydro-1H-1,3-diazepin-2-yl) phenyl] furan, 2,5-bis- (4-N, N-dimethylcarboxhydrazidophenyl) furan, 2,5-bis- {4- [2- (N-2- hydroxyethyl) imidazolinyl] phenyl} furan, 2,5-bis [4- (N-isopropylamidino) phenyl] furan, 2,5-bis {4- [3- (dimethylaminopropyl) amidino] phenyl} furan, 2,5-Bis {4- [N- (3-aminopropyl) amidino] phenyl} furan, 2,5-bis [2- (imidazolinyl) phenyl] -3,4-bis (methoxymethyl) furan, 2 , 5-Bis- [4-N- (dimethylaminoethyl) guanyl] phenylfuran, 2,5-bis {4 - [(N-2-hydroxyethyl) guanyl] phenyl} furan, 2,5-bis- [4-N- (cyclopropylguanyl) phenyl] furan, 2,5-bis [4- (N, N-diethylaminopropyl) guanyl] phenylfuran, 2,5-bis {4- [2- (N-ethylimidazolinyl) ] - phenyl} furan, 2,5-bis {4- [N- (3-pentylguanyl)]} phenylfuran, 2,5-bis [4- (2-imidazolinyl) phenyl] -3-methoxyfuran, 2, 5-Bis- [4- (N-isopropylamidino) phenyl] -3-methylfuran, bis [5-amidino-2-benzimidazolyl] methane, bis [5- (2-imidazolyl) -2-benzimidazolyl] methane, 1 , 2-Bis- [5-amidino-2-benzimidazolyl] ethane, 1, 2-bis [5- (2-imidazolyl) -2-benzimidazolyl] ethane, 1, 3-bis- [5-amidino-2-one benzimidazolyl] propane, 1, 3-bis [5- (2-imidazolyl) -2-benzimidazolyl] propane, 1,4-bis [5-amidino-2-benzimidazolyl] prop 1,1,4-bis [5- (2-imidazolyl) -2-benzimidazolylbutano, 1,8-bis- [5-amidino-2-benzimidazolyl] octane, trans-1,2-bis- [5-amidino -2-benzimidazolyl] ethene, 1,4-Bis- [5- (2-imidazolyl) -2-benzimidazolyl] -1-butene, 1,4-bis [5- (2-imidazolyl) -2-benzimidazolyl] -2-butene, 1,4-bis [5- (2-imidazolyl) -2-benzimidazolyl] -1-methylbutane, 1,4-bis [5- (2-imidazolyl) -2-benzimidazolyl] -2 ethylbutane, 1,4-bis [5- (2-imidazolyl) -2-benzimidazolyl] -1-methyl-1-butene, 1,4-bis [5- (2-imidazolyl) -2-benzimidazolyl] - 2,3-diethyl-2-butene, 1,4-bis [5- (2-imidazolyl) -2-benzimidazolyl] -1,3-butadiene, 1,4-bis [5- (2-imidazolyl ) -2-benzimidazolyl] -2-methyl-1,3-butadiene, bis [5- (2-pyrimidyl) -2-benzimidazolyl] methane, 1,2-bis [5- (2-pyrimidyl) -2 benzimidazolyl] ethane, 1,3-bis [5-amidino-2-benzimidazolyl] propane, 1, 3-bis [5- (2-pyrimidyl) -2-benzimidazolyl] propane, 1, 4-bis- 5- (2-pyrimidyl) -2-benzimidazolyl] butane, 1 ) 4-bis- [5- (2-pyrimidyl) -2-benzimidazolyl] -1-butene, 1,4-bis- [5- (2- pyrimidyl) -2-benzimidazolyl] -2-butene, 1, 4-Bis- [5- (2-pymidyl) -2-benzimidazolyl] -1-methylbutane, 1,4-bis [5- (2-pyrimidyl) -2-benzimidazolyl] -2-ethylbutane, 1, 4- Bis- [5- (2-pyrimidyl) -2-benzimidazolyl] -1-methyl-1-butene, 1,4-bis [5- (2-pyrimidyl) -2-benzimidazolyl] -2,3-diethyl 2-butene, 1,4-bis [5- (2-pyrimidyl) -2-benzimidazolyi] -1,3-butadiene and 1,4-bis [5- (2-pyrimidyl) -2-benzimidazolyl] - 2-methyl-1,3-butadiene, 2,4-bis (4-guanylphenyl) pyrimidine, 2,4-Bis- (4-imidazolin-2-yl) pyrimidine, 2,4-bis - [(tetrahydropyrimidinyl-2-yl) phenyl] pyrimidine, 2- (4- [Ni-propylguanyl] phenyl) -4- (2-methoxy-4- [propylguanyl] phenyl) pyrimidine, 4- (N-cyclopentylamidino) -1, 2-phenylenediamine, 2,5-bis- [2- (5-amidino) benzimidazoyl] furan, 2, 5-Bis- [2- {5- (2-imidazolino)} benzimidazoyl] furan, 2,5-bis [2- (5-N-isopropylamidino) benzimidazoyl] furan, 2,5-bis- [2- (5-N-cyclopentylamidino) benzimidazoyl] furan, 2,5-bis [2- (5-amidino) benzimidazoyl] pyrrole, 2,5-bis [2- {5- (2-imidazolino)} benzimidazoyl ] pyrrole, 2,5-bis- [2- (5-N-isopropylamidino) benzimidazoyl pyrrole, 2,5-bis [2- (5-N-cyclopentylamidino) benzimidazoyl] pyrrole, 1-methyl-2, 5-bis- [2- (5-amidino) benzimidazoyl] pyrrole, 2,5-bis- [2- {5- (2-imidazolino)} benzimidazoyl] -1-methylpyrrole l 2,5-bis- [2- (5-N-cyclopentylamidino) benzimidazoyl] -1-methylpyrrole, 2,5-bis [2- (5-N-isopropylamidino) benzimidazoyl] thiophene, 2,6-bis [2- {5- (2-imidazolino} benzimidazoyl pyridine , 2,6-bis- [2- (5-amidino) benzimidazoyl] pyridine, 4,4'-bis- [2- (5- N-isopropylamidino) benzimidazoyl] -1, 2-diphenylethane, 4,4-bis- 1 [2- (5-N-cyclopentylamidino) benzimidazoyl] -2,5-diphenylfuran, 2,5-bis [2- (5 -amidino) benzimidazoyl] benzo [b] furan, 2,5-bis [2- (5-N-cyclopentylamidino) benzimidazoyl] benzo [b] furan, 2,7-bis- [2- (5 -N-isopropylamidino) benzimidazoyl] fluoro, 2,5-bis [4- (3- (N-morpholinopropyl) carbamoyl) phenyl] furan, 2,5-bis- [4- (2-N, N -dimethylaminoethylcarbamoyl) phenyl] furan, 2,5-bis [4- (3-N, N-dimethylaminopropylcarbamoyl) phenyl] furan, 2,5-bis [4- (3-N-methyl-3-N-phenylaminopropylcarbamoyl ) phenyl] furan, 2,5-bis- [4- (3-N, N8, N11-trimethylaminopropylcarbamoyl) phenyl] furan, 2,5-bis [3-amidinophenyl] furan, 2 ) 5-bis- [3 - (N-isopropylamidino) amidinophenyl] furan, 2,5-bis [3 - [(N- (2-dimethylaminoethyl) amidino] phenylfuran, 2,5-bis- [4- (N-2,2,2-) trichloroethoxycarbonyl) amidinophenyl] furan, 2,5-bis [4- (N-thioethylcarbonyl) amidinophenyl] furan, 2,5-bis [4- (N-benzyloxycarbonyl) amidinophenyl] furan, 2,5-bis [4- (N-phenoxycarbonyl) amidinophenyl] furan, 2,5-bis- [ 4- (N- (4-fluoro) phenoxycarbonyl) amidinophenyl] furan, 2,5-bis [4- (N- (4-methoxy) phenoxycarbonyl) amidinophenyl] furan, 2,5-bis- [4 - (1-acetoxyethoxycarbonyl) amidinophenyl] furan and 2,5-bis- [4- (N- (3- fluoro) phenoxycarbonyl) amidinophenyl] furan. Methods for preparing any of the above compounds are described in U.S. Patent Nos. 5,428,051, 5,521,189, 5,602,172, 5,643,935, 5,723,495, 5,843,980, 6,172,104 and 6,326,395, or U.S. Patent Application Publication no. US 2002/0019437 A1.
Pentamidin-Metabolite eignen sich ebenfalls in der erfindungsgemäßen antiproliferativen Kombination. Pentamidin wird im Körper schnell zu mindestens sieben primären Metaboliten metabolisiert. Einige dieser Metabolite haben eine oder mehrere Wirkungen mit Pentamidin gemeinsam Pentamidin- Metabolite weisenh antiproliferative Wirkung auf, wenn sie mit einem Benzimidazol oder einem Analogon davon kombiniert werden. Pentamidine metabolites are also useful in the antiproliferative combination of this invention. Pentamidine is rapidly metabolized in the body to at least seven primary metabolites. Some of these metabolites have one or more effects in common with pentamidine. Pentamidine metabolites exhibit antiproliferative activity when combined with a benzimidazole or an analog thereof.
Sieben Pentamidin-Analoga sind nachstehend gezeigt.Seven pentamidine analogs are shown below.
Die erfindungsgemäßen Kombinationen von Verbindungen der Formel I und Formel V oder deren Analoga und seiner Metaboliten eignen sich zur Behandlung von Neoplasmen. Eine Kombinationstherapie kann allein oder in Verbindung mit einer anderen Therapie (z.B. Operation, Bestrahlung, Chemotherapie, biologische Therapie) durchgeführt werden. Zusätzlich kann eine Person, deren Risiko, ein Neoplasma zu entwickeln, größer ist, (z.B. jemand, der genetisch prädisponiert ist, oder jemand, der zuvor ein Neoplasma hatte) eine prophylaktische Behandlung erhalten, um die Neoplasmabildung zu hemmen oder zu verzögern. Die Kombination der kinesin-ATPase Eg5/KSP mit den Verbindungen der Formel V, Pentamidin, seine Analoga und /der seiner Metaboliten ist ebenfalls Gegenstand der Erfindung.The combinations of compounds of the formula I and formula V or their analogues and their metabolites according to the invention are suitable for the treatment of neoplasms. Combination therapy may be performed alone or in conjunction with another therapy (eg surgery, radiation, chemotherapy, biological therapy). In addition, a person whose risk of developing a neoplasm is greater (eg, someone who is genetically predisposed or someone who previously had a neoplasm) may be given prophylactic treatment to inhibit or delay neoplasm formation. The combination of kinesin ATPase Eg5 / KSP with the compounds of formula V, pentamidine, its analogues and / or its metabolites is also an object of the invention.
Die Dosierung und Häufigkeit der Verabreichung jeder Verbindung der Kombination kann unabhängig gesteuert werden. Zum Beispiel kann eine Verbindung dreimal täglich oral verabreicht werden, während die zweite Verbindung einmal pro Tag intramuskulär verabreicht werden kann. Die Verbindungen können auch zusammen formuliert werden, so dass eine Verabreichung beiden Verbindungen zuführt.The dosage and frequency of administration of each compound of the combination can be independently controlled. For example, a compound may be administered orally three times a day while the second compound may be administered intramuscularly once a day. The compounds may also be formulated together so that administration will deliver to both compounds.
Die erfindungsgemäßen antiproliferativen Kombinationen können auch als Komponenten eines pharmazeutischen Pakets bereitgestellt werden. Die zwei Arzneimittel können zusammen oder getrennt und in einzelnen Dosierungsmengen formuliert werden.The antiproliferative combinations of the invention may also be provided as components of a pharmaceutical package. The two drugs may be formulated together or separately and in single dosage amounts.
Unter einem anderen Aspekt umfasst die Erfindung ein zur Behandlung eines Patienten, der ein Neoplasma, wie einen Krebs, hat, durch Verabreichung einer Verbindung der Formel (I) und (V) in Kombination mit einem antiproliferativen Mittel. Geeignete antiproliferative Mittel umfassen die in Tabelle 1 bereitgestellten.In another aspect, the invention includes a treatment of a patient having a neoplasm such as a cancer by administering a compound of the formula (I) and (V) in combination with an antiproliferative agent. Suitable antiproliferative agents include those provided in Table 1.
Vor- und nachstehend sina alle Temperaturen in 0C angegeben. In den nachfolgenden Beispielen bedeutet „übliche Aufarbeitung": Man gibt, falls erforderlich, Wasser hinzu, stellt, falls erforderlich, je nach Konstitution des Endprodukts auf pH-Werte zwischen 2 und 10 ein, extrahiert mit Ethylacetet oder Dichlormethan, trennt ab, trocknet die organische Phase über Natriumsulfat, dampft ein und reinigt duch Chromatographie an Kieselgel und/oder durch Kristallisation. Rf-Werte an Kieselgel; Laufmittel: Ethylacetat/Methanol 9: 1.Above and below all temperatures are given in 0 C. In the following examples, "usual workup" means adding water if necessary, adjusting to pH values between 2 and 10, if necessary, depending on the constitution of the final product, extracted with ethyl acetate or dichloromethane, separating, drying organic phase over sodium sulfate, evaporated and purified by chromatography on silica gel and / or by crystallization Rf values on silica gel, mobile phase: ethyl acetate / methanol 9: 1.
Massenspektrometrie (MS): El (Eletronenstoß-Ionisation) M+ Mass spectrometry (MS): El (electron impact ionization) M +
FAB (Fast Atom Bombardment) (M+H)+ ESI (Electrospray lonization) (M+H)+ FAB (Fast Atom Bombardment) (M + H) + ESI (electrospray ionisation) (M + H) +
APCI-MS (atmospheric pressure chemical ionization - mass spectrometry) (M+H)+ APCI-MS (atmospheric pressure chemical ionization - mass spectrometry) (M + H) +
Beispiel 1example 1
Synthese von 4,5,6, 7-Tetrahydro-benzo[d]isoxazol-3-carbonsäure-3-hydroxy- benzylamidSynthesis of 4,5,6,7-tetrahydrobenzo [d] isoxazole-3-carboxylic acid 3-hydroxybenzylamide
Die kommerziell verfügbare Säure 1 (100 mg, 0.60 mmol), das Amin 2 (73.6 mg, 0.60 mmol) und Λ/-Methylmorpholin (0.07 mL, 0.60 mmol) wurden in DMF (5 mL) gelöst und sukzessive /V-(3-Dimethylaminopropyl)-/V- ethylcarbodiimid Hydrochlorid (115 mg, 0.06 mmol) und 1- Hydroxybenzotriazol (80.0 mg, 0.06 mmol) zugefügt. Es wurde bei RT 15 h gerührt und mit Wasser gefällt. Der Rückstand wurde abfiltriert und säulenchromatographisch (Ethylacetat/Cyclohexan) aufgereinigt. Man erhielt das Anid 3 als farblosen Feststoff.The commercially available acid 1 (100 mg, 0.60 mmol), the amine 2 (73.6 mg, 0.60 mmol) and Λ / -methylmorpholine (0.07 mL, 0.60 mmol) were dissolved in DMF (5 mL) and successive / V- (3 Dimethylaminopropyl) - / V-ethylcarbodiimide hydrochloride (115 mg, 0.06 mmol) and 1-hydroxybenzotriazole (80.0 mg, 0.06 mmol). The mixture was stirred at RT for 15 h and precipitated with water. The residue was filtered off and purified by column chromatography (ethyl acetate / cyclohexane). Anid 3 was obtained as a colorless solid.
Beispiel 2Example 2
Synthese von 4,5,6, 7-Tetrahydro-benzo[d]isoxazol-3-carbonsäure-[2-(2- dimethylamino-ethylcarbamoyl)-1-(3-hydroxy-phenyl)-ethyl]-amid Synthesis of 4,5,6,7-Tetrahydro-benzo [d] isoxazole-3-carboxylic acid [2- (2-dimethylamino-ethylcarbamoyl) -1- (3-hydroxy-phenyl) -ethyl] -amide
b. Verbindung 4 wurde analog zur Vorschrift a. aus der Säure 1 und 3- Amino-3-(3-hydroxyphenyl)-propionsäuremethylester erhalten.b. Compound 4 was analogous to the procedure a. obtained from the acid 1 and 3-amino-3- (3-hydroxyphenyl) -propionic acid methyl ester.
Verbindung 4 (40 mg, 0.12 mmol) und Λ/,Λ/-Dimethylethylendiamin (0.5 ml_) wurden in einem Druckkolben bei 100°C 12 h gerührt. Die abgekühlte Lösung wurde mit Ethylacetat versetzt, mit Wasser gewaschen, getrocknet, filtriert und zum Rückstand eingedampft. Dieser wurde aus EtOH/Wasser umkristallisiert. Man erhielt einen farblosen Feststoff, welcher als Verbindung 5 identifiziert wurde.Compound 4 (40 mg, 0.12 mmol) and Λ /, Λ / -dimethylethylenediamine (0.5 mL) were stirred in a pressure flask at 100 ° C for 12 h. The cooled solution was combined with ethyl acetate, washed with water, dried, filtered and evaporated to dryness. This was recrystallized from EtOH / water. A colorless solid was obtained which was identified as Compound 5.
Beispiel 3Example 3
Synthese von 4,5,6,7-Tetrahydro-benzo[d]isoxazol-3-carbonsäure-((1 S,2S)- 2-methylamino-indan-1 -yl)-amidSynthesis of 4,5,6,7-tetrahydro-benzo [d] isoxazole-3-carboxylic acid - ((1S, 2S) -2-methylamino-indan-1-yl) -amide
c. Verbindung 6 wurde analog zur Vorschrift a. aus der Säure 1 und cis-1- Amino-2-indanol erhalten. Verbindung 6 (158 mg, 0.53 mmol) wurde in Dichlormethan (5 ml_) vorgelegt, Triethylamin (0.06 mL, 0.80 mmol) zugegeben und Methansulfonylchlorid (0.15 ml_, 10.06 mmol, gelöst in 1 mL DCM) bei 00C zugetropft. Anschließend wurde 12 h bei RT gerührt. Es wurde zur Trockne eingedampft, der Rückstand in Ethylacetat aufgenommen und mit Wasser gewaschen. Die org. Phase wurde getrocknet, filtriert und zum Rückstand eingedampft. Dieser (ca. 140 mg Rohsubstanz) wurde ohne weitere Aufreinigung in die nächste Reaktion eingesetzt.c. Compound 6 was analogously to the procedure a. obtained from the acid 1 and cis-1-amino-2-indanol. Compound 6 (158 mg, 0:53 mmol) was dissolved in dichloromethane (5 mL) were charged, triethylamine (0.06 mL, 0.80 mmol) and methanesulfonyl chloride (0.15 mL, 6.10 mmol, dissolved in 1 mL DCM) at 0 0 C was added dropwise. The mixture was then stirred at RT for 12 h. It was evaporated to dryness, the residue taken up in ethyl acetate and washed with water. The org. Phase was dried, filtered and evaporated to dryness. This (about 140 mg of crude substance) was used without further purification in the next reaction.
Die Hälfte der Rohsubstanz (70 mg) wurde in Methylamin (33%ige Lösung in EtOH, 1 mL) aufgenommen und im Druckkolben bei 1000C 8 h gerührt. Die Lösung wurde zur Trockne eingedampft und direkt säulenchromatograhisch aufgereinigt (Ethylacetat/Cyclohexan). Man erhielt 42 mg einen farblosen Feststoff (7).Half of the crude substance (70 mg) was taken up in methylamine (33% solution in EtOH, 1 mL) and stirred in the pressure flask at 100 0 C for 8 h. The solution was evaporated to dryness and purified directly by column chromatography (ethyl acetate / cyclohexane). 42 mg of a colorless solid (7) were obtained.
Beispiel 4Example 4
Synthese von 3-(4-Phenyl-4,5-dihydro-oxazol-2-yl)-4,5,6,7-tetrahydro- benzo[d]isoxazolSynthesis of 3- (4-phenyl-4,5-dihydrooxazol-2-yl) -4,5,6,7-tetrahydrobenzo [d] isoxazole
d. Verbindung 8 wurde analog zur Vorschrift a. aus der Säure 1 und 2- Penylglycinol erhalten. Verbindung 8 (106 mg, 0.37 mmol) wurde in Dichlormethan (5 ml_) gelöst, Thionylchlorid (0.06 ml_, 0.89 mmol) zugegeben und 2 h bei 7O0C im Druckkolben gerührt. Man ließ den Ansatz abkühlen und versetzte das Gemisch mit ges. NaHCO3-Lösung. Die org. Phase wurde abgetrennt, über Na2SO4 getrocknet, filtriert und zur Trockne eingedampft. Dieser Rückstand wurde in MeOH (5 ml_) gelöst, das NaOH (ca. 15 mg, 0.37 mmol) zugegeben und nochmals 2h bei 7O0C im Druckkolben rühren gelassen. Man ließ den Ansatz abkühlen und dampfte zur Trockene ein. Der Rückstand wurde in DCM (5 ml_) aufgenommen und 2 mal mit ges. NaHCO3-Lösing extrahiert. Die org. Phase wurde über Na2SO4 getrocknet, filtriert und zur Trockne eingedampft. Anschließend wurde aus Ethylacetat/Cyclohexan kristallisiert. Man erhielt die Verbindung 9 als farblosen Feststoff.d. Compound 8 was analogously to the procedure a. obtained from the acid 1 and 2-penylglycinol. Compound 8 (106 mg, 0:37 mmol) was dissolved in dichloromethane (5 mL), added thionyl chloride (0.06 mL, 0.89 mmol) was added and stirred for 2 hours at 7O 0 C in a pressure flask. The reaction was allowed to cool and the mixture was treated with sat. NaHCO 3 solution. The org. Phase was separated, dried over Na 2 SO 4 , filtered and evaporated to dryness. This residue was dissolved in MeOH (5 ml_), the NaOH (approximately 15 mg, 0:37 mmol) was added and again for 2 hours at 7O 0 C in a pressure flask left to stir. The batch was allowed to cool and evaporated to dryness. The residue was taken up in DCM (5 ml) and washed twice with sat. Extracted NaHCO 3 solution. The org. Phase was dried over Na 2 SO 4 , filtered and evaporated to dryness. It was then crystallized from ethyl acetate / cyclohexane. Compound 9 was obtained as a colorless solid.
Beispiel 5Example 5
Analog a. können auch Hydrazine mit der Säure 1 in die entsprechenden Carbonsäurehydrazide überführt werden.Analog a. Hydrazines with the acid 1 can also be converted into the corresponding carboxylic acid hydrazides.
Beispiel 6Example 6
Synthese von 4,5,6,7-Tetrahydro-1 H-indazole-3-carbonsäure-2-methyl-benzyl- amidSynthesis of 4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid 2-methylbenzylamide
10 1110 11
e. Analog zu a. wurde die Kaufware 10 (50 mg, 0.28 mmol) mit 2- Methylbenzylamin (34 L, 0.28 mmol) unter Verwendung von Λ/-Methylmorpholin (1 eq), Λ/-(3-Dimethylaminopropyl)-Λ/'-ethylcarbodiimid Hydrochlorid (1 eq) und 1-Hydroxybenzotriazol (1 eq) umgesetzt. Das Produkt kristallisierte nach Zugabe von Wasser sauber aus der Reaktionslösung aus. Man erhielt das Amid 11 als farblosen Feststoff.e. Analogous to a. the purchased product was 10 (50 mg, 0.28 mmol) with 2-methylbenzylamine (34 L, 0.28 mmol) using Λ / -methylmorpholine (1 eq), Λ / - (3-dimethylaminopropyl) -Λ / '- ethylcarbodiimide hydrochloride (1 eq) and 1-hydroxybenzotriazole (1 eq). The product crystallized cleanly from the reaction solution after addition of water. The amide 11 was obtained as a colorless solid.
Beispiel 7Example 7
Synthese 5-Ethyl-4,5,6,7-tetrahydro-benzo[c]isoxazole-3-carbonsäureSynthesis 5-Ethyl-4,5,6,7-tetrahydro-benzo [c] isoxazole-3-carboxylic acid
12 13 14 1512 13 14 15
f. Natriumethylat (14 ml_ einer 20%igen Lösung in EtOH) wurde unter Eiskühlung vorgelegt und eine Lösung aus dem 4-Ethylcyclohexanon (5.00 mL, 36.3 mmol) und Diethyloxalat (4.91 mL, 36.3 mmol) langsam unter Rühren bei Eiskühlung zugetropft. Während des Zutropfens wurde die Temperatur unter 5°C gehalten. Anschließend wurde das Reaktionsgemisch langsam auf RT kommen gelassen und 15 h weiter gerührt. Die Reaktionsmischung wurde zu einer Mischung aus Eis und 10ml konz.H2SO4 geschüttet und zweimal mit DCM extrahiert. Die org. Phase wurde noch einmal mit ges.NaHCO3-Lsg. gewaschen, getrocknet, filtriert und zur Trockne eingedampft. Die Rohsubstanz wurde ohne weitere Aufreinigung weiter umgesetzt (siehe g.).f. Sodium ethylate (14 ml of a 20% solution in EtOH) was placed under ice-cooling and a solution of 4-ethylcyclohexanone (5.00 ml, 36.3 mmol) and diethyl oxalate (4.91 ml, 36.3 mmol) was slowly added dropwise with stirring with ice cooling. During the dropping, the temperature was kept below 5 ° C. The reaction mixture was then allowed to slowly rise to RT and stirring was continued for 15 h. The reaction mixture was poured into a mixture of ice and 10 ml conc. H 2 SO 4 and extracted twice with DCM. The org. Phase was repeated with sat. NaHCO 3 solution. washed, dried, filtered and evaporated to dryness. The crude substance was further reacted without further purification (see g.).
g. Die Rohsubstanz 14 (6.8 g, 30.1 mmol) wurde in Essigsäure (10 mL) gelöst, unter Eiskühlung wurde Hydroxylammoniumchlorid (2.09 g, 30.1 mmol), gelöst in 5 ml Wasser, langsam zugetropft. Anschließend wurde über Nacht unter Rückfluss gerührt. Nach dem Abkühlen auf RT wurde das Reaktionsgemisch auf Eis/Wasser gegossen und mit ges. NaHCO3-Lsg. neutralisiert. Dann wurde 2mal mit Dichlormethan und 1 mal mit Ethylacetat extrahiert. Die vereinigten org. Phasen wurden über Na2SO4 getrocknet, filtriert und zur Trockne eingedampft. Der Rückstand bestand aus einer geringen Menge aus der gewünschten Säure und dem entsprechenden Ethylester; er wurde verworfen.G. The crude substance 14 (6.8 g, 30.1 mmol) was dissolved in acetic acid (10 mL), while cooling with ice, hydroxylammonium chloride (2.09 g, 30.1 mmol), dissolved in 5 ml of water, was slowly added dropwise. The mixture was then stirred at reflux overnight. After cooling to RT, the reaction mixture was poured onto ice / water and washed with sat. NaHCO 3 sol. neutralized. It was then extracted twice with dichloromethane and once with ethyl acetate. The united org. Phases were dried over Na 2 SO 4 , filtered and evaporated to dryness. The residue was a small one Amount of the desired acid and the corresponding ethyl ester; he was rejected.
Die wässrige Phase wurde wieder mit 2 N HCl angesäuert, mehrmals mit Ethylacetat extrahiert. Die vereinigten org. Phasen wurden über ^SO4 getrocknet, filtriert und eingeengt. Man erhielt die Verbindung 15 als gelblichen Feststoff.The aqueous phase was acidified again with 2N HCl, extracted several times with ethyl acetate. The united org. Phases were dried over SO 4 , filtered and concentrated. Compound 15 was obtained as a yellowish solid.
Beispiel 8Example 8
Analog f. und g. wurde Cyclohexanon in 4,5,6,7-tetrahydro-benzo[c]isoxazole-3- carbonsäure überführt. Beide Säuren wurden analog a., b., c. und d. weiter umgesetzt.Analog f. and G. cyclohexanone was converted to 4,5,6,7-tetrahydro-benzo [c] isoxazole-3-carboxylic acid. Both acids were analogously a., B., C. and d. implemented further.
Beispiel 9Example 9
Synthese von 1-(4,5,6,7-Tetrahydro-benzo[d]isoxazol-3-yl)-3-o-tolyl-harnstoff und N-(4,5,6,7-Tetrahydro-benzo[d]isoxazol-3-yl)-2-o-tolyl-acetamidSynthesis of 1- (4,5,6,7-tetrahydrobenzo [d] isoxazol-3-yl) -3-o-tolylurea and N- (4,5,6,7-tetrahydrobenzo [d ] isoxazol-3-yl) -2-o-tolyl-acetamide
h. 2-Oxocyclohexancarbonitril 16 (1.00 g, 8.12 mmol) und Hydroxylammoniumchlorid (0.56 g, 8.12 mmol) wurde in Essigsäure (1 ml_) aufgenommen und 15 h bei 600C im Druckkolben gerührt. Die Mischung wurde zur Trockne eingedampft und direkt säulenchromatographisch aufgereinigt (Ethylacetat/Cyclohexan). Die Verbindung 17 konnte als farbloser Feststoff isoliert werden.H. 2-Oxocyclohexanecarbonitrile 16 (1.00 g, 8.12 mmol) and hydroxylammonium chloride (0.56 g, 8.12 mmol) was dissolved in acetic acid (1 mL). taken up and stirred for 15 h at 60 0 C in a pressure flask. The mixture was evaporated to dryness and purified directly by column chromatography (ethyl acetate / cyclohexane). Compound 17 could be isolated as a colorless solid.
i. Verbindung 17 (130 mg, 0.94 mmol) wurde in DCM (2 mL) gelöst und bei RT mit o-Tolylisocyanat (138 mg, 1.04 mmol) versetzt. Nach 12 h bei RT wurde zur Trockne eingedampft und säulenchromatographisch aufgereinigt, wodurch die Verbindung 18 erhalten werden konnte.i. Compound 17 (130 mg, 0.94 mmol) was dissolved in DCM (2 mL) and o-tolyl isocyanate (138 mg, 1.04 mmol) was added at RT. After 12 h at RT, it was evaporated to dryness and purified by column chromatography, whereby the compound 18 could be obtained.
j. Das Amin 17 (130 mg, 0.94 mmol) wurde in DCM (2 mL) aufgenommen, Triethylamin bei RT (0.16 mL, 1.13 mmol) zugefügt und auf 00C abgekühlt. Zu dieser Mischung wurde o-Tolyl-acetylchlorid (166 mg, 0.99 mmol), gelöst in DCM (1mL), zugetropft und 12 h bei RT weitergerührt. Die Reaktionsmischung wurde 2x mit Wasser gewaschen, getrocknet, filtriert und zur Trockne eingedampft. Nach säulenchromatographischer Aufarbeitung (Ethylacetat/ Cyclohexan) erhielt man das Amid 19 als farblosen Feststoff.j. The amine 17 (130 mg, 0.94 mmol) was taken up in DCM (2 mL), triethylamine added at RT (0.16 mL, 1.13 mmol) and cooled to 0 ° C. To this mixture, o-tolyl-acetyl chloride (166 mg, 0.99 mmol) dissolved in DCM (1 mL) was added dropwise and stirring was continued at RT for 12 h. The reaction mixture was washed twice with water, dried, filtered and evaporated to dryness. After work-up by column chromatography (ethyl acetate / cyclohexane), the amide 19 was obtained as a colorless solid.
Analog werden unter Verwendung oder entsprechenden Vorstufen die folgenden erfindungsgemäßen Verbindungen erhalten. Analogously, the following compounds according to the invention are obtained using or corresponding precursors.
MOLSTRUCTURE MOLSTRUCTURE
1010
ChiräChirä
1111
1414
30 30
18 18
20 20
26 26
2929
3030
3131
30 30
3333
30 36 30 36
3737
3838
4040
4141
30 30
4242
4444
4646
30 Chiral30 chiral
4747
4848
20 4920 49
5050
30 30
5252
5454
55 55
5656
5757
5858
6060
6262
65 65
6666
71 71
7272
7373
7474
25 7525 75
76 76
7777
7878
8080
30 30
8181
8282
8383
8484
30 30
8585
8888
9191
30 93 30 93
9494
9797
Chiral chiral
98 98
99 10099 100
10 10110 101
106 106
107107
Chiralchiral
108 108
109 110 109 110
111 111
113 113
115 115
15 11715 117
OO
2020
< CH,<CH,
118 118
122 122
123 123
124124
30 30
126 126
128128
30 H3CN 30 H 3 C N
129 W // 129 W //
134134
30 137 30 1 37
Die nachfolgenden Beispiele betreffen Arzneimittel:The following examples relate to drugs:
Beispiel C: InjektionsgläserExample C: Injection glasses
Eine Lösung von 100 g eines Wirkstoffes der Formel I und 5 g Dinatrium- hydrogenphosphat wird in 3 I zweifach destilliertem Wasser mit 2 n Salzsäure auf pH 6,5 eingestellt, steril filtriert, in Injektionsgläser abgefüllt, unter sterilen Bedingungen lyophilisiert und steril verschlossen. Jedes Injektions- glas enthält 5 mg Wirkstoff.A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 2 l of bidistilled water with 2N hydrochloric acid, filtered sterile, filled into injection jars, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg active substance.
Beispiel D: SuppositorienExample D: Suppositories
Man schmilzt ein Gemisch von 20 g eines Wirkstoffes der Formel I mit 100 gA mixture of 20 g of an active compound of the formula I is melted with 100 g
Sojalecithin und 1400 g Kakaobutter, gießt in Formen und läßt erkalten.Soya lecithin and 1400 g cocoa butter, pour into molds and let cool.
Jedes Suppositorium enthält 20 mg Wirkstoff. Beispiel E: LösungEach suppository contains 20 mg of active ingredient. Example E: Solution
Man bereitet eine Lösung aus 1 g eines Wirkstoffes der Formel I1 9,38 g NaH2PO4 • 2 H2O, 28,48 g Na2HPO4 • 12 H2O und 0,1 g Benzalkoniumchlorid in 940 ml zweifach destilliertem Wasser. Man stellt auf pH 6,8 ein, füllt auf 1 I auf und sterilisiert durch Bestrahlung. Diese Lösung kann in Form von Augentropfen verwendet werden.A solution of 1 g of an active ingredient of the formula I 1 9.38 g of NaH 2 PO 4 • 2H 2 O, 28.48 g Na 2 HPO 4 • 12 H 2 O and 0.1 g of benzalkonium chloride in 940 ml of double-one prepares distilled water. Adjust to pH 6.8, make up to 1 liter and sterilize by irradiation. This solution can be used in the form of eye drops.
Beispiel F: SalbeExample F: ointment
Man mischt 500 mg eines Wirkstoffes der Formel I mit 99,5 g Vaseline unter aseptischen Bedingungen.500 mg of an active compound of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions.
Beispiel G: TablettenExample G: Tablets
Ein Gemisch von 1 kg Wirkstoff der Formel I, 4 kg Lactose, 1 ,2 kg Kartoffelstärke, 0,2 kg Talk und 0,1 kg Magnesiumstearat wird in üblicher weise zu Tabletten verpreßt, derart, daß jede Tablette 10 mg Wirkstoff enthält.A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed in the usual way into tablets, such that each tablet contains 10 mg of active ingredient.
Beispiel H: DrageesExample H: dragees
Analog Beispiel E werden Tabletten gepreßt, die anschließend in üblicher Weise mit einem Überzug aus Saccharose, Kartoffelstärke, Talk, Tragant und Farbstoff überzogen werden.Tablets are pressed analogously to Example E, which are then coated in the usual way with a coating of sucrose, potato starch, talc, tragacanth and dye.
Beispiel I: KapselnExample I: Capsules
2 kg Wirkstoff der Formel I werden in üblicher Weise in Hartgelatinekapseln gefüllt, so daß jede Kapsel 20 mg des Wirkstoffs enthält.2 kg of active compound of the formula I are filled in the usual way in hard gelatin capsules, so that each capsule contains 20 mg of the active ingredient.
Beispiel J: Ampullen Eine Lösung von 1 kg Wirkstoff der Formel I in 60 I zweifach destilliertem Wasser wird steril filtriert, in Ampullen abgefüllt, unter sterilen Bedingungen lyophilisiert und steril verschlossen. Jede Ampulle enthält 10 mg Wirkstoff. Example J: Ampoules A solution of 1 kg of active compound of the formula I in 60 l of bidistilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each vial contains 10 mg of active ingredient.

Claims

Patentansprüche claims
1. Verbindungen der Formel I1. Compounds of the formula I
worin wherein
A1, A2 unabhängig voneinander N, O oder S,A 1 , A 2 independently of one another N, O or S,
X1 , X2, X3 unabhängig voneinander einer Einfachbindung, NR3-NR3, NR3, O, S, oder eine der folgenden Gruppen:X 1 , X 2 , X 3 are each independently a single bond, NR 3 -NR 3 , NR 3 , O, S, or one of the following groups:
Cy H, ein carbocyclischer oder heberocyclischer gesättigter, ungesättigter oder aromatischer Rest, der unsubstituiert oder ein- oder mehrfach durch Alkyl, HaI, CN, OH; OR, OCF3, CF3, COOR oder durch eine Gruppe (CR1 2)n-Y-X1- (CR1 2)n-Q substituiert sein kann,Cy H, a carbocyclic or heberocyclic saturated, unsaturated or aromatic radical which is unsubstituted or mono- or polysubstituted by alkyl, Hal, CN, OH; OR, OCF 3 , CF 3 , COOR or may be substituted by a group (CR 1 2 ) n -YX 1 - (CR 1 2 ) n -Q,
Q H, Alkyl, Cycloalkyl, Aryl oder Heteroaryl R, R1, R2, R3 H, Alkyl, HaI, Alkoxy, OH, Alkenyl, Alkoxyalkyl,Q is H, alkyl, cycloalkyl, aryl or heteroaryl R, R 1 , R 2 , R 3 H, alkyl, Hal, alkoxy, OH, alkenyl, alkoxyalkyl,
Hydroxyalkyl, (CH2)n-Q, (CH2)n-Cy oder (CH2)nNR2,Hydroxyalkyl, (CH 2 ) n -Q, (CH 2 ) n -Cy or (CH 2 ) n NR 2 ,
HaI F, Br oder ClHaI F, Br or Cl
n 0, 1 , 2, 3, 4, 5, 6, 7, oder 8,n 0, 1, 2, 3, 4, 5, 6, 7, or 8,
m 1 oder 2 undm 1 or 2 and
P 0, 1 oder 2P 0, 1 or 2
bedeuten,mean,
sowie ihre pharmazeutisch verwendbaren Derivate, Solvate, Tautomere, Salze und Stereoisomere, einschließlich deren Mischungen in allen Verhältnissen.and their pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers, including mixtures thereof in all ratios.
2. Verbindungen nach Anspruch 1 , worin A1, A2 O und/oder N bedeuten.2. Compounds according to claim 1, wherein A 1 , A 2 O and / or N mean.
3. Verbindungen nach Anspruch 1 oder 2, worin R1 und R2 H, Alkyl, CF3, OCF3, OCOH, HaI oder SCF3 bedeutet.3. Compounds according to claim 1 or 2, wherein R 1 and R 2 is H, alkyl, CF 3 , OCF 3 , OCOH, Hal or SCF 3 .
4. Verbindungen nach einem oder mehreren der Ansprüche 1-3, worin R3, H, Alkyl, Hydroxyalkyl, Alkoxyalkyl, (CH2Jn Q oder (CH2)n NR2 bedeutet, worin Q, R1 und n die in Anspruch 1 angegebene Bedeutung aufweisen.4. Compounds according to one or more of claims 1-3, wherein R 3 , H, alkyl, hydroxyalkyl, alkoxyalkyl, (CH 2 J n Q or (CH 2 ) n NR 2 , wherein Q, R 1 and n are the in Claim 1 given meaning.
5. Verbindungen nach einem oder mehreren der Ansprüche 1-4, worin X1,5. Compounds according to one or more of claims 1-4, wherein X 1 ,
X2, NR3, O oder die folgende Gruppe bedeutet: N NX 2 , NR 3 , O or the following group means: NN
und R3, m und p die in Anspruch 1 angegebene Bedeutung aufweisen.and R 3 , m and p have the meaning given in claim 1.
6. Verbindungen nach einem oder mehreren der Ansprüche 1-5, worin X3 eine Einfachbindung oder (CH2)n bedeutet und n die in Anspruch 1 angegebene Bedeutung aufweist.6. Compounds according to one or more of claims 1-5, wherein X 3 is a single bond or (CH 2 ) n and n has the meaning given in claim 1.
7. Verbindungen nach einem oder mehreren der Ansprüche 1-6, worin7. Compounds according to one or more of claims 1-6, wherein
8. Verbindungen nach einem oder mehreren der Ansprüche 1-7, worin Cy substituiertes oder unstubstituiertes Cyclopentyl Cyclohexyl, Aryl oder Heteroaryl bedeutet.8. Compounds according to one or more of claims 1-7, wherein Cy represents substituted or unsubstituted cyclopentyl cyclohexyl, aryl or heteroaryl.
9. Verbindungen nach einem oder mehreren der Ansprüche 1-8, worin Q9. Compounds according to one or more of claims 1-8, wherein Q
Aryl oder Heteroaryl bedeutet.Aryl or heteroaryl means.
10. Verbindungen nach einem oder mehreren der Ansprüche 1-9, worin die Gruppe Y-X2-(CR2 2)n-X eine Einfachbindung bedeutet.10. Compounds according to one or more of claims 1-9, wherein the group YX 2 - (CR 2 2 ) n -X represents a single bond.
11. Verbindungen der Teilformeln IA bis IC: -X2-(CR2 2)n-X3-Cy 11. Compounds of sub-formulas IA to IC: -X 2 - (CR 2 2 ) n -X 3 -Cy
IAIA
IBIB
ICIC
worin R1, X1, X2, X3, Y, R2 und Cy die in Anspruch 1 angegebene Bedeutung aufweisen.wherein R 1 , X 1 , X 2 , X 3 , Y, R 2 and Cy have the meaning given in claim 1.
12. Verfahren zur Herstellung von Verbindungen der Formel I nach den Ansprüchen 1-11 sowie ihrer pharmazeutisch verwendbaren Derivate, Salze, Solvate, Tautomeren und Stereoisomeren, dadurch gekennzeichnet, daß man eine Verbindung der Formel Il12. A process for the preparation of compounds of the formula I according to claims 1-11 and their pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers, characterized in that a compound of the formula II
worin A1, A2 und X1 die in Anspruch 1 angegebenen Bedeutungen haben, mit einer Verbindung der Formel IIIwherein A 1 , A 2 and X 1 have the meanings given in claim 1, with a compound of formula III
H-Y-X2-(CR2 2)n-X3-CyHYX 2 - (CR 2 2 ) n -X 3 -Cy
worinwherein
Y, X2, R2, X3 und Cy die in Anspruch 1 angegebene Bedeutung aufweisen,Y, X 2 , R 2 , X 3 and Cy have the meaning given in claim 1,
und/oder gegebenenfalls eine Base oder Säure der Formel I in eines ihrer Salze umwandelt.and / or optionally converts a base or acid of the formula I into one of its salts.
13. Arzneimittel, enthaltend mindestens eine Verbindung der Formel I nach Anspruch 1 bis 11 und/oder ihre pharmazeutisch verwendbaren Derivate, Salze, Solvate, Tautomere und Stereoisomeren, einschließlich deren Mischungen in allen Verhältnissen, sowie gegebenenfalls Träger- und/oder Hilfsstoffe.13. Medicaments containing at least one compound of the formula I according to claim 1 to 11 and / or pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios, and optionally excipients and / or adjuvants.
14. Mischung enthalten eine oder mehrere Verbindungen der Formel I sowie Menge einer oder mehrerer Verbindungen der Formel V, deren14. Mixture contain one or more compounds of the formula I and the amount of one or more compounds of the formula V, the
Analoga und/oder seiner Metaboliten,Analogues and / or its metabolites,
worinwherein
Y' und Z' jeweils unabhängig voneinander O oder N bedeuten, R9 und R10 jeweils unabhängig voneineander H, OH, Halogen, OC1-10-Alkyl,Y 'and Z' each independently represent O or N, R 9 and R 10 each independently of another of H, OH, halogen, OC 1-10 alkyl,
OCF3, NO2 oder NH2 bedeuten, s eine ganze Zahl zwischen 2 und 6, jeweils einschließlich, bedeutet und R8 und R11 jeweils unabhängig voneinander an der meta- oder para-Position stehen und aus der Gruppe:OCF 3 , NO 2 or NH 2 , s is an integer between 2 and 6 inclusive, and R 8 and R 11 are each independently from each other at the meta or para position and from the group:
ausgewählt sind.are selected.
15. Verwendung nach Anspruch 14, wobei als Verbindung der Formel V Pentamidin oder seine Salze verwendet werden.15. Use according to claim 14, wherein as the compound of formula V pentamidine or its salts are used.
16. Verwendung von Verbindungen nach Anspruch 1 bis 11 sowie ihrer pharmazeutisch verwendbaren Derivate, Salze, Solvate, Tautomeren und Stereoisomeren, einschließlich deren Mischungen in allen Verhältnissen oder der Mischung nach Anspruch 14, zur Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die durch die Hemmung, Regulierung und/oder Modulation der mitotischen Motor- Proteins Eg5 beeinflusst werden können.16. Use of compounds according to claim 1 to 11 and their pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers, including mixtures thereof in all proportions or the mixture according to claim 14, for the preparation of a medicament for the treatment of diseases caused by the inhibition , Regulation and / or modulation of the mitotic motor protein Eg5.
17. Verwendung von Verbindung nach Anspruch 1 bis 11 oder der17. Use of compound according to claim 1 to 11 or the
Mischung nach Anspruch 14, zur Herstellung eines Arzneimittels zur Behandlung und Prophylaxe von Krebskrankheiten.A mixture according to claim 14 for the preparation of a medicament for the treatment and prophylaxis of cancerous diseases.
18. Verwendung nach Anspruch 17, wobei die Krebskrankheiten mit einem Tumor aus der Gruppe der Tumoren des Plattenepithel, der Blasen, des Magens, der Nieren, von Kopf und Hals, des Ösophagus, des Gebärmutterhals, der Schilddrüse, des Darm, der Leber, des Gehirns, der Prostata, des Urogenitaltrakts, des lymphatischen Systems, des Magens, des Kehlkopf und/oder der Lunge einhergehen.18. Use according to claim 17, wherein the cancerous diseases with a tumor from the group of tumors of the squamous epithelium, the bladder, the stomach, the kidneys, the head and neck, the esophagus, the cervix, the thyroid, the intestine, the liver, of the brain, of the prostate, genitourinary tract, lymphatic system, stomach, larynx and / or lungs.
19. Verwendung nach Anspruch 18, wobei der Tumor aus der Gruppe Monozytenleukämie, Lungenadenokarzinom, kleinzellige19. Use according to claim 18, wherein the tumor is selected from the group monocytic leukemia, lung adenocarcinoma, small cell
Lungenkarzinome, Bauchspeicheldrüsenkrebs, Glioblastome und Brustkarzinom und Kolokarzinom stammt.Lung cancer, pancreatic cancer, glioblastoma and breast carcinoma and colorectal carcinoma.
20. Verwendung nach Anspruch 19, wobei die zu behandelnde Krebs- Krankheit ein Tumor des Blut- und Immunsystems ist.20. Use according to claim 19, wherein the cancer to be treated is a tumor of the blood and immune system.
21. Verwendung nach Anspruch 20, wobei der Tumor aus der Gruppe der akuten myelotischen Leukämie, der chronischen myelotischen Leukämie, akuten lymphatischen Leukämie und/oder chronischen lymphatischen Leukämie stammt.The use of claim 20, wherein the tumor is from the group of acute myeloid leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia and / or chronic lymphocytic leukemia.
22. Verwendung von Verbindungen der Formel I gemäß Anspruch 1 bis 11 und/oder ihrer physiologisch unbedenklichen Salze und Solvate zur Herstellung eines Arzneimittels zur Behandlung von Tumoren in Kombination mit einer therapeutisch wirksamen Menge einer oder mehrerer Verbindungen der Formel V, deren Analoga und/oder seiner Metaboliten,22. Use of compounds of the formula I according to claim 1 to 11 and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment of tumors in combination with a therapeutically effective amount of one or more compounds of formula V, their analogs and / or its metabolites,
worin Y' und Z' jeweils unabhängig voneinander O oder N bedeuten, R9 undwherein Y 'and Z' are each independently O or N, R 9 and
R10 jeweils unabhängig voneineander H, OH, Halogen, OC1-10-Alkyl, OCF3, NO2 oder NH2 bedeuten, s eine ganze Zahl zwischen 2 und 6, jeweils einschließlich, bedeutet und R8 und R11 jeweils unabhängig voneinander an der meta- oder para-Position stehen und aus der Gruppe:R 10 are each independently of another H, OH, halogen, OC 1-10 alkyl, OCF 3 , NO 2 or NH 2 , s is an integer between 2 and 6, each inclusive, and R 8 and R 11 are each independently at the meta or para position and from the group:
ausgewählt sind, wobei die Verbindungen der Formel I und die Verbindungen der Formel V, ihre Analoga und/oder ihre Metaboliten gleichzeitig oder innerhalb vonwherein the compounds of the formula I and the compounds of the formula V, their analogs and / or their metabolites are used simultaneously or within
14 Tagen voneinander in Mengen verabreicht werden, die ausreichen, um das Wachstum eines Tumors oder von anderen hyperproliferativen Zellen zu hemmen.14 days of each other in amounts sufficient to inhibit the growth of a tumor or other hyperproliferative cells.
23. Verwendung nach Anspruch 22, wobei als Verbindung der Formel V Pentamidin oder seine Salze verwendet werden.23. Use according to claim 22, wherein as the compound of formula V pentamidine or its salts are used.
24. Verwendung von Verbindungen der Formel I gemäß Anspruch 1 bis 11 und/oder ihrer physiologisch unbedenklichen Salze und Solvate zur Herstellung eines Arzneimittels zur Behandlung von Tumoren wobei eine therapeutisch wirksame Menge einer Verbindung der Formel I in Kombination mit Radiotherapie und einer Verbindung aus der Gruppe 1) Östrogenrezeptormodulator, 2) Androgenrezeptormodulator, 3) Retinoidrezeptormodulator, 4) Zytotoxikum, 5) antiproliferatives Mittel, 6) Prenyl-Proteintransferasehemmer, 7) HMG-CoA-Reduktase-24. Use of compounds of the formula I according to claim 1 to 11 and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment of tumors wherein a therapeutically effective amount of a compound of formula I in combination with radiotherapy and a compound from the group 1) estrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-proteintransferase inhibitor, 7) HMG-CoA reductase
Hemmer, 8) HIV-Protease-Hemmer, 9) Reverse-Transkriptase-Hemmer sowie 10) weiterer Angiogenese-Hemmer verabreicht wird. Inhibitors, 8) HIV protease inhibitors, 9) reverse transcriptase inhibitors, and 10) other angiogenesis inhibitors.
EP07856223A 2006-12-21 2007-11-22 Tetrahydrobenzoisoxazole - and tetrahydroindazole derivatives as modulators of the mitotic motor protein Withdrawn EP2104664A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006060598A DE102006060598A1 (en) 2006-12-21 2006-12-21 New tetrahydrobenzoisoxazole compounds are mitotic motor protein Eg5 modulators useful to treat and prevent cancer, and to treat e.g. monocyte leukemia, glioblastoma, colon carcinoma, myelotic leukemia and lymphatic leukemia
PCT/EP2007/010122 WO2008080455A1 (en) 2006-12-21 2007-11-22 Tetrahydrobenzoisoxazole - and tetrahydroindazole derivatives as modulators of the mitotic motor protein

Publications (1)

Publication Number Publication Date
EP2104664A1 true EP2104664A1 (en) 2009-09-30

Family

ID=39048886

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07856223A Withdrawn EP2104664A1 (en) 2006-12-21 2007-11-22 Tetrahydrobenzoisoxazole - and tetrahydroindazole derivatives as modulators of the mitotic motor protein

Country Status (7)

Country Link
US (1) US20100022530A1 (en)
EP (1) EP2104664A1 (en)
JP (1) JP2010513335A (en)
AU (1) AU2007341749A1 (en)
CA (1) CA2673428A1 (en)
DE (1) DE102006060598A1 (en)
WO (1) WO2008080455A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2142529T3 (en) 2007-04-27 2014-02-10 Purdue Pharma Lp TRPV1 ANTAGONISTS AND APPLICATIONS THEREOF
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
MX340488B (en) 2010-11-05 2016-07-08 Senomyx Inc Compounds useful as modulators of trpm8.
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
CA2837178C (en) 2011-06-22 2016-09-20 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
AU2013355220B2 (en) * 2012-12-06 2018-08-02 Baruch S. Blumberg Institute Functionalized benzamide derivatives as antiviral agents against HBV infection
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014138812A1 (en) * 2013-03-15 2014-09-18 Bionomics Limited Salts, co-crystals, and polymorphs of an anxiolytic compound
PE20161035A1 (en) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc COMPOUNDS AND USES OF THESE FOR THE MODULATION OF HEMOGLOBIN
JPWO2014174745A1 (en) * 2013-04-26 2017-02-23 国立大学法人京都大学 Eg5 inhibitor
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
DK3137168T3 (en) 2014-04-30 2022-03-21 Univ Columbia SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
CA2998647A1 (en) * 2014-10-03 2016-04-07 The Royal Institution For The Advancement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
CN108473484B (en) 2015-10-01 2021-06-29 弗门尼舍公司 Compounds useful as TRPM8 modulators
US10245259B2 (en) 2017-06-15 2019-04-02 Belite Bio, Inc Methods of treating RBP4 related diseases with triazolopyridines
US11389444B2 (en) * 2017-06-15 2022-07-19 Belite Bio, Inc Methods of treating metabolic diseases with fused bicyclic pyrazoles
AU2018289303B2 (en) 2017-06-20 2023-12-21 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
AU2020310120A1 (en) 2019-07-08 2022-03-03 Belite Bio, Llc Formulations of RBP4 inhibitors and methods of use
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
CN114524776A (en) * 2022-02-25 2022-05-24 中国科学院广州生物医药与健康研究院 Tetrazole compound and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3073840A (en) * 1960-08-24 1963-01-15 Shionogi & Co Benz[d]soxazole derivatives
US3457269A (en) * 1967-02-24 1969-07-22 Sterling Drug Inc N-substituted phenyl and n-substituted phenylalkyl 3 - indazolecarboxamides and preparation thereof
CH516578A (en) * 1967-11-02 1971-12-15 Bayer Ag Process for the preparation of arylsulfonylureas containing heterocyclic acylamino groups and having an antihypertensive effect
DE1795344B2 (en) * 1968-09-17 1976-05-06 Bayer Ag, 5090 Leverkusen PROCESS FOR THE PREPARATION OF 3-AMINOISOTHIAZOLS
JPS5031039A (en) * 1973-07-27 1975-03-27
JPH06306053A (en) * 1993-01-29 1994-11-01 Sagami Chem Res Center Production of 3-azole-carboxylic acid derivative and intermediate thereof
US6187774B1 (en) * 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
GB9911053D0 (en) * 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
AU2002334217B2 (en) * 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
JP2003231687A (en) * 2002-02-04 2003-08-19 Japan Tobacco Inc Pyrazolyl condensed ring compound and pharmaceutical use thereof
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
CA2480856A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
US20040110802A1 (en) * 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
US20050256159A1 (en) * 2002-10-11 2005-11-17 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
RU2361862C2 (en) * 2003-12-29 2009-07-20 Сепракор Инк. Pyrrole and pyrazole daao inhibitors
WO2005094805A1 (en) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. Imine derivative and amide derivative
SE0401969D0 (en) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
DE102005027168A1 (en) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydroquinolines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008080455A1 *

Also Published As

Publication number Publication date
WO2008080455A1 (en) 2008-07-10
AU2007341749A1 (en) 2008-07-10
DE102006060598A1 (en) 2008-06-26
CA2673428A1 (en) 2008-07-10
US20100022530A1 (en) 2010-01-28
JP2010513335A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
EP2193118B1 (en) Piperidine and piperazine derivatives for treating tumours
WO2008080455A1 (en) Tetrahydrobenzoisoxazole - and tetrahydroindazole derivatives as modulators of the mitotic motor protein
EP2193122B1 (en) Imidazole derivatives
EP2033959B1 (en) Tetrahydropyranoquinoline derivatives
EP1885702A2 (en) Quinazolinones
WO2010060532A1 (en) Benzonaphtyridine compounds used as inhibitors of autotaxin
DE102007047735A1 (en) thiazole
EP1891011B1 (en) Tetrahydroquinolines used in the form of modulators of mitotic motor-proteins eg5
EP1891076B1 (en) Substituted tetrahydroquinolines
EP2121700B1 (en) Substituted tetrahydroquinolines
EP1891013B1 (en) Tetrahydroquinoline derivatives
WO2008113456A1 (en) Tetrahydroquinoline derivatives and use of same for treating cancer
WO2006002726A1 (en) Tetrahydroquinolines
WO2006097176A1 (en) Phthalazinones
WO2006094602A1 (en) Indane
EP2121684A1 (en) Substituted tetrahydropyrroloquinolines
WO2005108355A2 (en) Dihydrobenzothiophenes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090409

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100517

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120626